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Abstract 
Photoactive platinum compounds have the potential to reduce some of the 
debilitating side-effects associated with conventional chemotherapeutics, such as 
cisplatin. Stable, inert platinum(IV) compounds which are reduced to active 
platinum(II) species only upon irradiation, could provide a site-specific treatment. 
The Pt's' azide complexes, cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] and cis, trans-
[Pt(en)(N3)2(OH)2], have previously been shown to be stable in the dark but reduced 
to Pt" upon irradiation. The synthesis and characterisation of new platinum azide 
compounds, designed to improve important properties such as solubility and 
wavelength of absorbance are described here. Complexes which have azide ligands 
in a trans position were synthesised, the general formula is trans, trans, trans-
[Pt(N3)2(OH)2(NH3)R] where R is NH3, pyridine, methylamine, ethylamine, thiazole, 
2-picoline, 3-picoline, 4-picoline or cyclohexylamine. Several Pt1V  diazido 
compounds containing chelating aromatic ligands, such as 2,2'-bipyridine and 1,10-
phenanthroline were also prepared. Many of the novel compounds synthesised were 
characterised by X-ray structure determination. The complexes with trans azides 
generally showed improved water solubility as well as a shift of the main absorbance 
band towards the visible region, compared to their cis analogues. 
The photochemistry of these Pt's' azide compounds was investigated by UV-visible 
spectroscopy, NMR spectroscopy and mass spectrometry. Several compounds were 
synthesised with '5N-labels which allowed the reactions to be followed by 2D 
['H,'5N] HSQC NMR spectroscopy. Photoreactions in the presence of nucleotides 
such as 5'-GMP and d(GpG) were also studied. Reduction and binding to 5'-GMP 
was observed after only 1 min of irradiation for some complexes. 
A transcription mapping study of a fragment of pSP73KB plasmid DNA treated with 
cis, trans-[Pt(en)(N3)2(OH)2] and visible light, has shown that platination mainly 
occurs at consecutive guanine bases. The major binding sites were similar to those of 
cisplatin. No platination was seen in an identical sample which was not irradiated. 
Two-photon excitation (TPE) involves the simultaneous absorption of two photons to 
produce an excited state which corresponds to absorption of a single photon of 
approximately twice the energy (half the wavelength). This technique could 
potentially enable the use of red light to activate compounds which mainly absorb in 
the blue / UV region. The two-photon photochemistry of an azo-dye was investigated 
to determine the optimum experimental conditions. The trans to cis 
photo isomerisation was followed by 'H NMR spectroscopy. The rate constants for 
the one- and two-photon reactions are of a similar magnitude, which suggests that the 
two-photon induced reaction closely mimics the one-photon process. Attempts were 
made to apply TPE to photoactive platinum compounds. 
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Chapter 1 Introduction 
This thesis is concerned with platinum(IV) azide complexes as potential 
photoactivated anticancer drugs. An introduction to the coordination chemistry of 
platinum, platinum anticancer drugs and platinum photochemistry is given in this 
chapter. 
1.1 Platinum 
Platinum is in group 10 of the periodic table, it has atomic number 78 and is found in 
six naturally occurring isotopes (Table 1.1). "'Pt has a nuclear spin quantum number 
½ and is therefore NMR active. 
Table 1.1 Atomic and physical properties of platinum. 
Atomic Number 78 
Isotopes 190Pt (0.01 %) 
192Pt  (0.78 %) 
'94 t (32.9 %) 
'95rt (33.8 %) 
196 Pt (25.3 %) 
'98Pt (7.21%) 
Atomic Weight 195.078(2) 
Electronic Configuration [Xe] 414 5d9 6s' 
Electronegativity 2.2 
Effective Ionic Radius (Oxidation State) 0.57 A (V) 
0.63 A (IV) 
0.80 A (II) 
The abundance of platinum in the earth's crust is approximately 0.01 ppm. Platinum 
is usually recovered from nickel or copper sulphide ores, and then has to be 
selectively extracted from other "Platinum Group" metals (ruthenium, rhodium, 
palladium, osmium and iridium). Although these metals occur together, the cost of 
the individual metals varies widely, as their consumption is not proportional to their 
abundance. The world's major deposits are found in Bushveld in South Africa, 
Sudbury in Canada and Noril'sk Talnakh in Russia. 
2 
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Platinum compounds in the +2 and +4 oxidation states are by far the most common, 
although complexes in the 0, +1, +3, +5 and +6 states are also known. Compounds in 
the 0 oxidation state often contain I-acceptor ligands, such as PR3 or CO. The higher 
oxidation states (+5 and +6) have only been found in a few fluoro and oxyfluoro 
compounds.W 
1.1.1 Coordination Chemistry of Platinum 
Platinum(II) complexes are d8, diamagnetic and virtually always square-planar due to 
the strong splitting of the d-orbitals (Figure 1.1). All eight electrons can be placed in 
the four lower energy orbitals which leaves the uppermost orbital (d 22) empty. As a 
third row transition metal, the d-orbital splitting is sufficient to offset the energy 
required to pair-up two electrons (Figure 1.1). Pt1' shows class-b / soft characteristics 





dX 2-Y 2' d, 	f dxy 
fitflt4k 	1 d, 
"itHtfld,d yz 
Tetrahedral 	Free ion' Octahedral Tetragonal Square- 
distortion planar 
Figure 1.1 Splitting of the d-orbitals in crystal fields of different symmetries, and the 
resulting electronic configurations of a d8 ion. 
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An important feature of coordination chemistry, which is widely used in the 
synthesis of square-planar complexes is the trans effect. The trans effect is defined 
as the effect of the ligand on the rate of substitution of the group trans to it. [21  By 
comparison with a large number of reactions, it is possible to set up a trans-directing 
series. The ordering of ligands in this series is as follows: [31 
CO, CN, C2H4 > PR3, H > CH3 > C6H5 , NO2 , 1, SC> Br, cr> py, NH3, 0H, H20 
This order roughly correlates with the degree of increasing overlap of the ligand 
orbitals with either a cy or a it Pt 6p orbital, therefore the greater the overlap the 
stronger the trans effect. 141 The trans effect is kinetically controlled as the 
thermodynamically most stable isomer is not always produced. Synthetic use of the 
trans effect is illustrated later in the preparation of square-planar Pt" starting 
materials (Chapter 3). 
Another important phenomenon is the thermodynamic trans influence. This effect is 
greatest for ligands which are strong a-donors and the ordering of the ligands in the 
series is as follows: 
H> PR3 > SCN> r, CH3 , CO, CN> B( > cr> NH3 > 0H 
The trans influence is the extent to which a ligand weakens the bond trans to itself, 
and can affect properties such as metal-ligand bond lengths and NMR coupling 
constants. 
Pt IV  complexes are octahedral, diamagnetic and have a low-spin t2g6 electron 
configuration. They generally display class-a or hard characteristics, and compounds 
containing halides, pseudohalides and N-donors are particularly abundant. Compared 
to pt", p\J  complexes are generally more thermodynamically stable and kinetically 
inert. 
4 
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1.2 	Platinum Anticancer Drugs 
1.2.1 Cisplatin 
Cis-[Pt"C12(NH3)2] (Figure 1.2), now better known as cisplatin, was first synthesised 
in 1845, but its biological activity was not discovered until the 1960'sJ51 It was 
approved for clinical use in 1978 and has gone on to be one of the most widely used 
and effective anticancer drugs in the world. Cisplatin is used to treat various types of 
cancer, including testicular, ovarian, cervical, bladder and head and neck cancers. [6]  
Its use against testicular cancer has turned this disease from one which killed about 
80 % of patients, to one which is now more than 90 % curable. [71 
H3 N, C I 
Pt 
H3N"  CI 
Figure 1.2 Structure of cisplatin. 
There are, however, some serous drawbacks associated with cisplatin chemotherapy, 
these include (i) severe toxicity (e.g. nausea, ear damage, vomiting, loss of sensation 
in hands and kidney toxicity), (ii) poor solubility in saline and (iii) resistance to the 
drug, either intrinsic or acquired. Cisplatin is also only effective in quite a narrow 
range of tumours. The design of new platinum drugs to circumvent some of these 
problems has been the subject of a great deal of research (Section 1.2.2). 
Cisplatin is administered by injection or infusion, and while it is transported in the 
blood stream hydrolysis is inhibited due to the relatively high chloride concentration 
in blood (ca. 100 mM). The precise mechanism of cellular uptake still remains 
unclear. There are some data to suggest that cisplatin enters the cell via passive 
diffusion, 81 although there is also evidence for an additional pathway involving 
active transport, and an altered expression of some membrane proteins has been 
reported for cisplatin-resistant cellsJ9"01 Upon entering the cell the chloride 
concentration drops to 4 - 25 mM, and cisplatin is hydrolysed to cis-
[PtC1(NH3)2(H20)] and cis-[Pt(NH3)2(H2O)2]2 , which are more active forms of the 
5 
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drug.1111 These aqua species go on to react with DNA mainly at the N7 position of 
consecutive guanine bases to form 1 ,2-intrastrand cross-links.112' It is now generally 
accepted that cisplatin exerts it cytotoxic effect by forming these bifunctional DNA-
adducts. These adducts are capable of blocking replication and inhibiting 
transcription. The cis-{Pt(NH3)2}2 moiety can also bind to proteins. '21 Some of the 
important events relating to the mechanism of action of cisplatin and cellular 
resistance are summarised in Figure 1.3. 
shield from 	/ 
f101 
repair (H MG) \ repaired 
Pt 
A&V 
I Pt drug complex r 
1V DNAadduct 
[Cr] 	 /QEi~ 1 	
activation 
(100 MM)  (e.g.. hydrolysis) excision 
[CI] = 4 mM  repair 
Figure 1.3 Schematic representation of the reactions of cisplatin in the cell. Based 
on reference 13. 
Hydrolysis is known to be the rate limiting step in the binding of cisplatin to 
DNA.1141 A summary of the hydrolysis reactions, including half lives of aquation,1151 
and pKa values 1161 is given in Figure 1.4. 
Platinum in cells  
I apoptosis 
,". cell deathPt SG 	Resistance 	




cellular thiols I Pt uptake 
detoxification 
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PKa 7.21 




Figure 1.4 Hydrolysis of cisplatin in aqueous solution with half-lives for hydrolysis 
(3 10 K)'5' and pKa values (3 00 K)'6' of its aqua adducts. 
There are a large number of potential biological targets for platinum compounds. The 
hard-soft acid-base principle indicates S-donor ligands in proteins would bind 
strongly and give very stable bonds, however binding to nitrogen lone pairs would 
also be expected to be strong. Such bonds could be formed with the amino acid side 
chains of cysteine, methionine, histidine, and also the solvent-exposed N7 atoms of 
adenine and guanine in double-stranded DNA. The N3 atoms of cytosine and Ni of 
adenine would be additionally accessible in single-stranded DNA and RNA. '71  
Approximately 1 % of intracellular cisplatin reacts with genomic DNA and produces 
a variety of mono-adducts and intra- and interstrand cross-links. The most 
nucleophilic site in duplex DNA is the N7 position of a guanine residue located 
adjacent to a second guanine residue. 181 It has been shown that binding at N7 of two 
adjacent guanines to form intrastrand d(GpG) cross-links is the preferred binding site 
of cisplatin. 191 Besides GG intrastrand cross-links (70 %), the other major DNA 
adducts of cisplatin are intrastrand AG (but not GA) cross-links (15 %). Minor 
':1 
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adducts include 1 ,3-intrastrand and interstrand cross-links involving two non-
neighbouring guanines. [191 
Many structural studies have been carried out to determine the nature of this 1,2-
intrastrand cisplatin adduct on double and single-stranded DNA fragments, both by 
X-ray crystallography, 2022  and NMR spectroscopy. 23251  The X-ray structure of the 
Pt adduct of a double-stranded dodecamer has been determined and is shown in 
Figure 1.5. The basic structure is kinked with a significant bend towards the major 
groove (ca. 45 0),  and the dihedral angle between the guanine bases is 30 
0•  A 
consequence of the platinum binding is a widened shallow minor groove, a feature 
which may be important for protein recognition and anticancer activity. 
* 
e 
.3.' 	.•.1 ,  






'.-.. 	'. 	.4• 	-.. 
Figure 1.5 X-ray crystal structure of a dodecamer platinated with {Pt(NH3)2}2 . The 
sequence of the duplex is d(CCTCTG*G*TCTCC), d(GGAGACCAGAGG); where 
G* indicates the G residue is platinated at N7J21' 
The discovery of a protein that preferentially binds to cisplatin-damaged DNA, the 
high mobility group (HMG) protein, 1261  has led to the identification of many more 
such proteins which have similar binding affinities towards cisplatin-modified 
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DNA. '21 An X-ray crystal structure of HMG  protein domain A bound to a 16-mer 
strand of duplex DNA containing a cis-GG adduct has been determined. 271 It is 
thought that the HMG protein specifically recognises locally bent and unwound 
DNA, and that this protein binding could shield DNA repair and ultimately lead to 
cell apoptosis. 
Drug resistance is a major complication in cancer chemotherapy. Cisplatin resistance 
exists in two forms: acquired resistance, in which a drug is initially beneficial but 
becomes ineffective over time, and intrinsic resistance, in which the drug is 
ineffective from the outset. Drug resistance can operate by a number of mechanisms, 
none of which is fully understood. Suggested mechanisms of cisplatin drug 
resistance include decreased intracellular accumulation of cisplatin, increased 
intracellular levels of certain sulfur-containing macromolecules, and increased DNA 
repair. 2829' 
1.2.2 Development of New Platinum Anticancer Drugs 
The design of new platinum drugs to circumvent some of the problems associated 
with cisplatin, such as toxic side effects, resistance and poor solubility in saline, has 
been the subject of a great deal of research. Indeed over 3000 platinum compounds 
have been synthesised and tested for antitumour activity, 21 but of these only a few 
have made it into clinical trials, [301  and there are currently six platinum drugs 
approved (in at least one country) for clinical use. [31] 
1.2.2.1 Cisplatin Derivatives 
Carboplatin (Figure 1.6a), like cisplatin, has achieved routine clinical use. It is more 
stable towards biomolecules because of the chelating 1,1-cyclobutanedicarboxylato 
ligand, and this stability is believed to be the reason carboplatin can be tolerated in 
higher doses than cisplatin (2000 mg / dose compared to 100 mg / dose for 
cisplatin))1 '71 Carboplatin shows an identical spectrum of activity to that of cisplatin, 
but lacks nephrotoxicity in standard doses; neurotoxicity, ototoxicity and 
gastrointestinal effects are also less pronounced. 
9 
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Oxaliplatin (Figure 1.6b), was approved for clinical use in major European countries 
in 1999.[3h] It has shown some potency in tumours that are resistant to cisplatin and 
carboplatin, and is now the standard first line treatment for metastatic colorectal 
cancer. 321 The dose-limiting toxicity of oxaliplatin is neurotoxicity. 
Nedaplatin (Figure 1.6c) has been approved for clinical use in Japan, and like 
carboplatin myleosuppression is the dose-limiting toxicity. Unlike oxaliplatin, 
nedaplatin shows cross-resistance with cisplatin and carboplatin. 331 This can be 
attributed to the fact that these drugs all form the same type of DNA adducts. 
Loboplatin (Figure 1.6d) and heptaplatin (Figure 1.6e) have been approved in China 
and South Korea, respectively. 311 Loboplatin is used against small cell lung cancer, 
breast tumours and chronic myelogenous leukaemia. Heptaplatin is used to treat 
gastric cancer, but nephrotoxicity is a major dose-limiting factor. 

















e),O//,,,,,."~NH2 0 0 
Pt 
0NH2 0 
Figure 1.6 Structures of platinum drugs approved for clinical use. [311 a) Carboplatin, 





\ 0 :1 
10 
Chapter 1 Introduction 
NX473 (formerly AMD473, ZD0473, Figure 1.7a) is currently in Phase I / II clinical 
trials, and has shown promising activity against a range of tumour types, including 
ovarian, lung and breast. Interestingly it has also shown significantly reduced cross 
resistance with cisplatin. The steric hindrance caused by the methyl group is believed 
to destabilize the trigonal bipyrarnidal transition state formed during substitution 
reactions. This reduces the rate of deactivation by biological thiols, [34,351  and is also 
believed to result in the formation of DNA-adducts which are recognised differently 
from those of cisplatin by the excision repair system. [361 





-000 N /OCOC13H27 
Pt 000C13H27 
H2 










Figure 1.7 Structures of some platinum(II) complexes currently in clinical trials, a) 
NX473, b) SM-i 1355, c) aroplatin (L-NDDP) and d) AP5280. 
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Several other platinum(II) compounds are currently in clinical trials, including three 
which are based on a targeted therapy approach, where the aim is for the platinum to 
be selectively accumulated in the tumour. These compounds are SM1 1355, aroplatin 
(L-NDDP) and AP5280, and their structures are shown in Figure 1.7. For a 
comprehensive review of the current state of preclinical platinum anticancer 
complexes see reference 31. 
1.2.2.2 Pta' Complexes 
Platinum(IV) complexes, such as cis-[PtC14(NH3)2] (Figure 1.8a), have been known 
to have anticancer activity since the early studies by Rosenberg and co-workers. [37,381 
It is generally accepted that reduction of Pt IV  complexes to their Pt 11  counterparts is 
required for activity, this has been discussed in detail in a recent reviewJ391 pt' 
complexes offer several advantages over their Pt" analogues, these include (i) the 
possibility of oral administration, (ii) reduced side-effects, (iii) reduced reactivity, 
(iv) more possibilities of structural variations and (v) reduction to more reactive 
platinum(II) compounds. It is therefore surprising that only three Pt IV  anticancer 
complexes have entered clinical trials; satraplatin (JM2 16), tetraplatin (ormaplatin) 
and iproplatin (Figure 1.8). Trials of tetraplatin and iproplatin were abandoned due to 
severe neurotoxicity and lack of superior performance, respectively. 40' Satraplatin 
entered clinical trials in 1992; it is a lipophilic complex which can be administered 
orally. Oral administration opens the possibility for an outpatient treatment, which is 
also beneficial in terms of cost. In vitro, satraplatin is capable of circumventing both 
intrinsic and acquired cisplatin resistance; interestingly this has been shown to occur 
by a mechanism not related to the initial extent of DNA piatination. 4 The lipophilic 
nature of satraplatin could help overcome resistance caused by reduced platinum 
accumulation. [311  Phase III studies comparing satraplatin plus prednisone (a 
corticosteroid), with prednisone alone are underway. Phase I / II trials combining 
satraplatin with radiation therapy have also begun. [3 
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CI 	 H3N,, 	\\CI  H3N, 	\\CI  
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Figure 1.8 Structures of antiturnour active Pt1" complexes. a) cis-[PtC14(NH3)2], b) 
satraplatin (JM2 16), c) tetraplatin (ormaplatin) and d) iproplatin. 
Pt IV  complexes are much more inert to ligand substitution than Pt" complexes. [42]  
This kinetic inertness means that loss of the drug through deactivating reactions with 
biomolecules could be reduced, and unwanted side reactions which lead to toxic 
side-effects could potentially be avoided. It is not yet known whether Pt'"' complexes 
are reduced extra- or intra-cellularly in vivo. Upon reduction the axial ligands are lost 
and the resulting Pt" complex will be less lipophilic (decreased cell uptake) and 
much more reactive (increased toxicity). Therefore the in vivo anticancer activity of 
Pt IV  complexes is difficult to predict from in vitro studies. 
Pt "' 5'-GMP adducts have been reported in the literature, but only as minor 
products. E431  Evidence was found of an intermediate 5'-GMP adduct of tetraplatin 
which was then rapidly reduced to a Pt" adduct by 5'-GMP. More recently, Galanski 
et al. described the formation of a Pt"-5'-GMP adduct from the reaction of 
[Pt(en)(OAc)4] with 5'-GMP, this adduct was reported to be stable over several 
weeks without reduction. [44]  
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If reduction is necessary for activity, it seems logical that the ease of reduction of a 
Pt" complex influences its biological behaviour. The reduction potentials of many 
Pt"' compounds have been compared, 391 and a general trend established. Complexes 
containing chlorides in the axial position are easily reduced, whereas if these are 
replaced by hydroxides the analogous complex becomes significantly harder to 
reduce. The reduction potentials of complexes with axial carboxylato ligands fall 
somewhere in between those of chloride and hydroxide. Changing these ligands also 
affects the lipophilicity of the complexes. Cyclic voltammetry (CV) is generally used 
to measure reduction potentials (Er) of platinum (IV) complexes, but reduction 
results in loss of ligands and so the process is irreversible, and the E values obtained 
by CV are not thermodynamic. However, a correlation between E and reduction 
rates has been established. 391  
Biomolecules in blood and cells are numerous and diverse, in both structure and 
chemical activity. Many of these small molecules, proteins and enzymes have the 
potential to react with Pt"' complexes and reduce them. Glutathione (GSH) is a 
tripeptide found in cells at concentrations of up to 10 MMJ451  GSH is one of the 
primary defenses against toxins and oxidants in cells, and can deactivate 
chemotherapeutic drugs such as cisplatin by coordinating to them and thereby 
reducing the amount of active species that arrives at the target site (DNA). It is 
therefore important to understand the kinetics and mechanisms of reduction of PtR 
complexes by thiols (e.g. GSH) and other biomolecules; several such studies have 
been publishedJ46501  
1.2.2.3 Trans Platinum Complexes 
All the complexes approved for clinical use so far, adhere to a set of structure-
activity relationships which were derived by Cleare and Hoeschele over 30 years 
ago. 51' These relationships were formulated from early systematic studies, and state 
that for a platinum complex to show antitumour activity it has to have the following 
features. 
1. Cis geometry of the form PtX2(amine)2 for Pt", and PtX2(amine)2Y2 for Pt'v, (with 
Y ligands trans). 
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The X ligand (leaving group) should be an anion with intermediate binding 
strength such as C1, citrate, oxalate, and other carboxylic acid residues. The Y 
ligands can be Cl-, OH or O(CO)CH2+1. 
The complex should be neutral, as passive transport through the lipophilic cell 
wall is believed to be the mechanism of cell uptake, a pathway which is less 
available to charged compounds. 
The amine should possess at least one NH moiety, necessary for H-bonding 
interactions with DNA. 
These structure-activity relationships dominated platinum drug design for over 20 
years. However, recently so-called "non-classical" platinum complexes have been 
developed which violate and in some cases invert these rules. Such complexes 
include those with trans geometry, charged complexes, complexes with more than 
two coordinated nitrogens, multinuclear complexes, compounds with sulphur ligands 
and platinum complexes with tertiary amine ligands. E311  Some of these are discussed 
below with particular attention paid to trans complexes due to the relevance to this 
work. 
The trans isomer of cisplatin, trans-[PtC12(NH3)2] (transplatin, Figure 1.9a) is 
relatively non-toxic to cancer cells. [521  The first chloride of transplatin is very labile, 
and so monofunctional adducts are quickly formed. However, removal / substitution 
of the second chloride to form bifunctional adducts is much more difficult. The rapid 
formation of monofunctional adducts with biomolecules could lead to deactivation of 
transplatin before it reaches the cell nucleus. The trans geometry also prevents the 
formation of GG intrastrand cross-links of the type formed by cisplatin. 
There are four known classes of antitumour active mononuclear trans compounds. [53]  
These are Pt" complexes with planar aromatic ligands (Figure 1.9b), with 
asymmetric aliphatic amine ligands (Figure 1.9c), iminoether compounds (Figure 
1.9d), and Pt1v mixed amine complexes. 
For the complexes with planar aromatic ligands, three different series of trans- 
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[PtCl2(L)(L')] have been investigated as potential anticancer agents. 54 i) L = L' = 
pyridine, N-rnethylimidazole, or thiazole, ii) L = quinoline and L' = RR'SO (R = Me, 
R' = Me, Benzyl or Phenyl), and iii) L = NH3 and L' = quinoline or thiazole. The 
cytotoxicity of all the trans complexes examined was approximately one-order of 
magnitude larger than that of transpiatin, and was also generally at least as cytotoxic 
as the cis analogues. The trans complexes were generally not cross-resistant with 
cisplatin. The planar ligands are likely to hinder the approach of incoming 
nucleophiles to the axial positions of the platinum centre, which may have some 
effect not only on DNA binding, but also on deactivation by glutathione and other 
sulphur-containing biomolecules. 
a) 	 b) 
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Figure 1.9 Structures of trans-Pt" complexes. a) transplatin, b) trans-[PtCl2(py)2], c) 
trans- [PtCl2(dimethylamine)(amine)] and d) trans- [PtC12(iminoether)2]. 
Trans platinum(II) complexes containing asymmetric aliphatic amines, such as trans-
[PtCl2(amine)(isopropylamine)], have shown cytotoxic activity comparable to that of 
cisplatin. 55'561 In HL-60 leukaemic cells these compounds have IC50 values lower 
than that of cisplatin. 
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The trans iminoether complexes reported by Coluccia and Natile have the general 
formula trans- [PtC12(iminoether)2] or trans- [PtCl2(iminoether)(NH3)J (iminoether, 
HN=C(OR)R'). 57-59' Iminoether ligands are planar, like aromatic amines, but have 
one hydrogen linked to the nitrogen like aliphatic amines. The hydrogen is suitable 
for hydrogen-bond formation. There is also the possibility of isomerisation within the 
ligand, E or Z configurations around the C=N double bond can exist. The trans-
iminoether complexes have shown growth inhibitory activity similar to that of 
cisplatin in various cell lines, and were also active against a cisplatin resistant cell 
line. [601 
TransPtlVmixed amine complexes have also been found to be antitumour active. [611 
An extensive investigation into the activity of over forty complexes with trans 
geometry, half Pt" and half P{", has been carried out. [61]  Many of these compounds 
were found to have an activity comparable to cisplatin against a panel of human cell 
lines, some also overcame cisplatin resistance. Fourteen complexes were also active 
in vivo, all of which were pt', and all except one contained axial hydroxide 
ligands. 6'1 
1.2.2.4 Multinuclear Platinum Complexes 
Dinuclear and trinuclear compounds are a relatively new class of platinum anticancer 
complex. They provide multiple binding sites to DNA, which can be separated by 
linkers of variable lengths. Farrell and co-workers developed BBR3005 (Figure 
1.10a) which contains two monofunctional platinum moieties with a hexane- 1,6-
diamine linker. BBR3005 was found to be active in cisplatin-resistant cell lines, and 
this work led to the synthesis of the trinuclear complex, BBR3464 (Figure 1.10b). 
The third platinum unit is unreactive, but it improves the solubility and electrostatic 
interactions of the drug with DNA. The DNA intrastrand adducts formed by 
BBR3464 do not lead to DNA bending and are not recognised by high mobility 
group (HMG) proteins. This could be a major factor in the ability of multinuclear 
complexes to overcome cisplatin resistance. BBR3464 is approximately 40-fold 
more potent than cisplatin on a molar basis in tumour models, but so far the phase II 
trials have yielded a poor response rate (-j 6 %) and a short time to progression. [311 
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Figure 1.10 Structures of multinuclear Pt" complexes, a) BBR3005 and b) 
1.3 	Photochemistry of Coordination Compounds 
Photochemistry is the branch of chemistry concerned with the chemical effects of 
light. A photochemical reaction is a term generally used to describe a chemical 
reaction caused by the absorption of ultraviolet, visible or infrared radiation. [62] 
This section describes the individual processes which take place during a 
photochemical reaction, with focus on coordination compounds. The formation of 
excited states by photoexcitation, the different types of electronic transitions, and 
photophysical and photochemical deactivation reactions are discussed. This is 
followed by a detailed look at the photochemistry of platinum complexes. 
In most photochemical processes, excitation takes place by interaction of radiation 
with the complex, 631 i.e. by photoexcitation: 
A+hv - A* 
where A is a complex in the ground state and A*  is a complex in an excited state. 
The term photoexcitation describes the electric dipole transition, other types of 
transitions (magnetic dipole or electric quadrupole transitions) are not relevant to 
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photochemistry. Photoexcitation is a resonance process which can occur if the 
difference between the energy of an excited state (EES) and the ground state (EGS) is 
equal to the energy of a photon (hv) interacting with the complex: 
EES - EGS = hv 
The probability of light absorption for a certain transition is expressed by means of 
the oscillator strength f (,u, transition dipole moment; in,, mass of an electron; e, 
charge of an electron; GS/ES,  wavefunction of ground / excited state; R, dipole 
moment operator): 
8zc 2,nv/ 2  
3he 	
11 .NJGSJPESdr 
The transition dipole moment can have a value of zero for certain transitions. 
Transitions for which the transition dipole moment is zero are called forbidden 
transitions. Conditions under which the transition dipole moment adopts a value of 
zero are expressed by selection rules: 
- 	electric dipole transitions between states of different multiplicity are forbidden 
(spin-forbidden transitions). 
- 	electric dipole transitions between states of equal parity (g —* g, u —> u) are 
forbidden (orbitally forbidden transitions). 
- 	electric dipole transitions involving the simultaneous excitation of two or more 
electrons are forbidden. 
The amount of light absorbed in a homogeneous medium is defined by the Beer-
Lambert law: 
1=10 1Oec! 
where To  is the incident light intensity, I is the transmitted light intensity, C is the 
extinction coefficient (M1cm 1), c is the concentration (M) and 1 is the path length of 
the light beam (cm). The absorbance is defined as: 
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A = logio(IIIo) = s c  
and is therefore proportional to the concentration and the path-length. 
The quantum yield or quantum efficiency of a photochemical reaction is normally 
defined as the fraction of photoactivated molecules that undergo some change. This 
is also called the overall quantum yield of products. The quantum yield (0) of any 
stable product X from the photodecomposition of a compound M (M + hv —k X), for 
example, is defined by: 
d[X]/dt 	No. of molecules or ions of X formed / crn3s =  
No. of quanta absorbed by M / ern 3s 
The above quantum yield is measured irrespective of whether X is formed directly in 
a primary process, or in a secondary thermal reaction involving free radicals or 
atoms. [64] 
1.3.1 Types of Electronic Transition 
The excitation process is characterised according to the localisation of the electron 
density transfer. These transfers can occur within a complex, or an electron may be 
exchanged between the complex and its environment. Although electron transfer is 
described as occurring between molecular orbitals, it is important to note that the 
whole electron system of the complex is always changed (i.e. interelectronic 
repulsion, degeneration of levels, energy of orbitals etc.). 
Four fundamental types of electronic transition exist. 
1) Transitions between molecular orbitals (MOs) localised on the central atom. These 
can be divided into: 
- ligand-field (LF) transitions (electron density transfer between d- or f-
orbitals of the same principal quantum number) 
- Rydberg transitions (transfer between orbitals differing in principal 
quantum number) 
- inter-valence charge transfer (IT) transitions (transfer from one to the other 
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central atom in polynuclear bridged complexes) 
Transitions between MOs localised on ligands. These can be either intraligand 
(IL) transitions (electron density transfer between MOs localised on one ligand) or 
ligand-to-ligand (LLCT) transitions (electron transfer from one ligand's HOMO to 
the other ligand's LUMO). 
Transitions between MOs of different localisation. Depending on the direction of 
electron density transfer, there are: 
- metal-to-ligand charge transfer (MLCT) transitions 
- ligand-to-metal charge transfer (LMCT) transitions 
Transfer of an electron between the complex and an environmental particle. Such 













Figure 1.11 Molecular orbital diagram for an octahedral coordination complex and 
the various kinds of electronic transitions that may occur between the orbitals. 
The different types of transitions that can occur in an octahedral coordination 
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complex are shown in Figure 1.11. These transitions are discussed further in the 
following sections. 
1.3.1.1 Ligand Field Transitions 
Transitions between different energy levels corresponding to a redistribution of 
electrons in the partially filled d-orbitals are referred to as ligand field (LF) or d -? d 
transitions. In an octahedral field, the d-orbitals of a metal split into two sets of 
energetically different orbitals; the dxY5 dx, and d 1  orbitals (the t2g Set) decrease in 
energy and the energy of the d22 and d2 orbitals (the eg set) increases (Figure 
1.12a). By absorbing a photon of energy corresponding exactly to the t2g-eg energy 
gap A0, a single electron can, in theory, be promoted from the lower set of orbitals to 
the upper ones (Figure 1.12b). 
a) 	 b) 
e 	 eg 	4= eg 
t2g 	 t2g 	 t29  
Figure 1.12 Energy level splitting for octahedral complexes. a) The two sets of 
orbitals (eg and t2g) are split by energy A0. b) Promotion of an electron from the t2g 
orbital set to the eg orbitals requires the absorption of light of energy A0 
Selection rules determine which transitions are formally allowed. The Laporte or 
parity selection rule forbids transitions between energy levels with the same 
symmetry with respect to the centre of inversion, therefore all d - d transitions in Oh 
complexes are Laporte forbidden. The Laporte rule can be relaxed under certain 
circumstances, either the molecule is not totally symmetric due to the presence of 
different ligands, or as the molecule vibrates the centre of symmetry is temporarily 
removed. Therefore d 4 d transitions for Oh  complexes are observed but are often 
not very intense. 
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1.3.1.2 Charge-Transfer Transitions 
Charge transfer transitions are formally allowed by the selection rules, and are 
therefore much more intense (often by a factor of a thousand or more) compared to 
the forbidden d - d transitions. All ligands possess molecular orbitals which may be 
of -, o- it-, ic- or non-bonding character. If these orbitals are filled, and those on 
the metal are empty, then charge transfer may occur from the ligand-based orbitals to 
the metal d-orbitals (LMCT). If the ligand has low-lying empty orbitals and the metal 
is in a low oxidation state and hence electron rich, then metal-to-ligand charge 
transfer (MLCT) transitions occur. 
Fully allowed electronic transitions have high molar extinction coefficients, whereas 
Laporte and spin-forbidden d-d transitions in centrosymmetric molecules generally 
have relatively weak absorptions. The intensities of the different types of electronic 
transitions of transition metal complexes are summarised in Table 1.2. 
Table 1.2 Intensities of different types of electronic transitions in metal complexes. 
Transition Type 8max (M'cm) 
Spin-forbidden <1 
Laporte-forbidden d-d 20 - 100 
Laporte-allowed d-d 500 
Symmetry-allowed (e.g. CT) 1000 - 50,000 
1.3.1.3 Intraligand and Charge-Transfer to Solvent Transitions 
Intraligand (IL) transitions occur in complexes that contain organic ligands with a 
multiple bond(s), such as pyridine, 2,2'-bipyridine or 1,10-phenanthroline. IL 
transitions are usually orbitally and spin-allowed, and they occur in the spectra as 
intense bands in the visible and UV regions with values of Emax Z  103 - 10 M 1 cm
1 . 
Unlike MLCT and LMCT transitions, with which they frequently overlap, the bands 
of IL transitions depend only slightly on the character of the central atom and on the 
presence of other ligands in the coordination sphere. 
Charge-transfer to solvent (CTTS) transitions can take place if the oxidation number 
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of the complexes central atom is low, if with an increase in the oxidation number of 
the central atom the structure of the coordination sphere is unchanged, and if the 
central atom has a higher oxidation state which is stable. CTTS transitions are 
usually allowed. The CTTS transition bands appear in the UV region of the 
spectrum, and have values of 6max 101 - 103 M'cm* The positions of the bands 
and the values of C1ax are markedly influenced by the solvent reduction potential, 
with the easier the reduction the lower the transition energy. 
1.3.2 Deactivation Processes from Excited States 
Two types of deactivation processes exist - photophysical and photochemical. 
Photophysical processes result in the system returning to the ground state, whereas 
photochemical processes lead to different products. The variety of pathways through 
which an excited system can dissipate the energy gained by absorbing a photon are 
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Figure 1.13 Jablonski diagram summarising the various pathways available to an 
excited molecule or complex, (IC, internal conversion; ISC, intersystem crossing). 
Vibrational relaxation, as shown in Figure 1.13 by the short downward arrows, is the 
process by which most molecules drop back to the lowest vibrational level of the 
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excited electronic state. This is caused by the photoactive species undergoing a rapid 
thermal equilibration with their surroundings, and results in a Boltzman population 
distribution. After vibrational relaxation, the excited molecules can decay back to the 
ground state by luminescent emission or non-radiative decay. Alternatively the 
formation of photoproducts can occur, either directly or via a reactive intermediate. 
Internal conversion (IC) is a transition between two excited states with identical 
multiplicitiy, whereas intersystem crossing (ISC) occurs between excited states of 
different multiplicity. Non-radiative deactivation of an excited state results in the 
energy being released into the environment in the form of heat. The excited state can 
also be deactivated by interacting with a quencher (Q). A quencher is another particle 
in the medium that can absorb the energy difference between the excited and ground 
states. 
1.3.3 Photochemical Reactions of Coordination Compounds 
The photochemical pathways compete with the various photophysical decay 
processes (Section 1.3.2), and this controls the extent to which photochemical 
products are formed. The reactivity of the excited state, which is chemically different 
from the ground state, influences the pathways taken. The following sections discuss 
photoredox, photoisomerisation and photosubstitution reactions with respect to 
coordination compounds. 
1.3.3.1 Photoredox 
Photoredox reactions can be divided into three types: 
reactions producing changes in the constitution of the complex, e.g. elimination 
and addition reactions, 
reactions where an electron is transferred between the complex and particles of 
the environment, the complex constitution and structure are preserved, and 
reactions where the structure is changed but the overall composition of the 
complex is preserved, e.g. inner-complex rearrangements. 
Reactions in group (a) include reductive eliminations and oxidative additions, these 
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are the most important reactions when considering the photochemistry of platinum 
complexes. 
Oxidative addition results in an increase in the oxidation number of the central atom, 
and is usually accompanied by an increase in coordination number. The opposite 
applies to reductive eliminations where a decrease in oxidation state and coordination 
number is generally seen. Charge-transfer from ligands to central atoms, and vice 
versa are involved in these types of reactions. LMCT transitions (Section 1.3.1.2) can 
often lead to reductive elimination of a ligand. Photoinduced reductive elimination 
reactions of Pta' complexes are discussed with specific examples in section 1.3.4. 
Oxidative addition photoreactions of platinum compounds are less common, but have 
been reported, and are also mentioned briefly later. 
1.3.3.2 Photo isomerisation 
Photoisomerisation reactions are light-induced processes where the composition of 
the compound is preserved, but the structure and properties are changed J631 There are 
several different types of photo isomerisation reaction, but only the 
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Figure 1.14 Cis-trans photo isomerisation of a square-planar complex. A and B are 
different ligands, S denotes solvent molecules, or another molecule present in 
solution in excess. I and II represent intermediates, I is tetrahedral, II is trigonal-
planar and III is square-planar. 
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Photoisomerisation of geometrical isomers results in a change in symmetry of the 
complex. Investigations into the mechanism of cis - trans photoisomerisations of 
square-planar [MA2132] and octahedral [MA4132] complexes have been carried out, M 
is the central metal and A and B are the ligands. A proposed mechanism is shown in 
Figure 1.14.[631  The mechanism is believed to be the same for both square-planar and 
octahedral complexes. 
1.3.3.3 Photosubstitution 
Photosubstitution reactions are non-redox photochemical transformations, during 
which a ligand (or ligands) is exchanged between the primary and secondary 
coordination sphere. Photosubstitution reactions are generally different from thermal 
substitutions in their kinetics, products and stereochemistry. Photosubstitutions 
usually take place more rapidly than thermal substitutions (up to 14 orders of 
magnitude) J651  Further examples of these differences can be found in reference 66. 
Photosubstitutions typically take place from ligand-field (Section 1.3.1.1) excited 
states. LF excitation leads to labilisation of the ligands due to population of the c 
orbitals which can subsequently lead to substitution. 
1.3.4 Platinum Photochemistry 
The photochemistry of platinum is extensive and varied, and so is briefly 
summarised here. Several relevant reviews which cover the topic of platinum 
photochemistry have been published. [67-69] 
The nature of photochemical reactions depends to a large extent on the type of 
electronic transition. LF transitions are usually associated with photoisomerization 
and photosubstitution reactions, [681  whereas LMCT generally causes photoreduction 
(i.e., Pt'"  to Pt" and Pt" to Pt). 67' However it should be noted that LF transitions can 
also result in photoredox reactions, [70,711  and LMCT can also cause ligand 
substitutions and isomerisations. The nature of the leaving ligand and the solvent 
play an important role in determining the pathway. The photochemistry of platinum 
complexes is not easy to predict, and the photoproducts must therefore be 
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investigated carefully to establish the pathway(s). 
1.3.4.1 Platinum Halide Photochemistry 
An example of the solvent dependence of reaction pathways can be seen upon 
irradiation (2. = 254 nrn) into the LMCT band of [Pt'(CN)4C12]2 J72' The 
photoreaction in ethanol leads to efficient reduction to [Pt"(CN)4]2 , but in aqueous 
solution the photoredox reactivity is almost negligible, and instead photoaquation is 
observed. Similar photoreactivity was found for the corresponding ammino 
compound [Ptw(NH3)4C12]2t[73]  Often a mixture of photosubstitution I aquation and 
photoreduction products are formed. [671 
Photoredox reactions upon irradiation into ligand field bands have been reported for 
chloro and azido complexes. 70'71 I The photoinduced reduction of [PtC16]2 occurs at 
all wavelengths at which the complex absorbs light. Irradiation at energies as low as 
514 nrn yield platinum metal J701 The photoreactions of platinum azide complexes are 
discussed in Section 1.3.4.2. 
The first photoactivatable Pt"  complexes designed with anticancer applications in 
mind contained iodide ligands. Kratochwil et al. prepared trans, cis-[Pt(en)(OAc)212], 
which has iodide ligands in the cis position and gives rise to a LMCT band at 
relatively long wavelengths (ca. 400 nm). 741 Upon irradiation (> 375 nm) this 
complex was reduced to Pt and bound covalently to DNA. However, in the absence 
of nucleobases, no direct photoreduction of Pt1 " to Pt" was observed, and the 
photoreaction in the presence of nucleobases proved not to be a simple 
photoreductive elimination. [751  These iodo complexes were also found to be easily 
reduced by thiols (e.g. glutathione) to cytotoxic Pt" species, [76]  and so were deemed 
unsuitable for development as photoactive anticancer drugs. 
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The oxidative addition of C12 to [Pt"(bpy)C12] upon irradiation (X = 280 nm) has been 
reported. The mechanism is believed to go via a Pt" species: 
[Pt"(bpy)C]2] + CHCI3 
hv> 
 [Pt 1"(bpy)Cl3] + CHC12 
[Pt"(bpy)C13] + CHC12 	> [Pt'"(bpy)C]3] + CHC12 
[Pt''(bpy)Cl3]+ CHC12 	> [Pt''(bpy)C14] + :CHCI 
[Pt"(bpy)C14} is a stable end-product, but the monochiorocarbene goes on to react 
further with another solvent molecule to give 1,1 ,2,2-tetrachloroethane. 
Photoisomerisation reactions of square-planar Pt" and octahedral Pt1V  complexes can 
be found in the literature. Examples include the cis -* trans isomerisation of 
[PtCl2(PEt3)21, which occurs via intermediate I (Figure 1.14), this mechanism is 
called the intramolecular "twisting" mechanism. [771  The cis ---> trans isomerisation of 
[Pt"C12(py)2] takes place by a solvent-assisted mechanism and involves intermediate 
III (Figure 1.14).[781  A photoinduced isomerisation of trans, trans, trans-
[Pt''C12(0Ac)2NH3(c-HexNH2)] to cis, cis, trans-[Pt IV Cl2(0AC)2NH3(c-HexNH2)1 
has been reported more recently, although no mechanism has been proposed. [791 
1.3.4.2 Platinum Azide Photochemistry 
It has been stated that almost any transition metal azide complex is light sensitive, 
regardless of oxidation state. 801 Metal azides have been found to undergo a variety of 
different photoreactions, which include: (i) photosubstitution of the azide 11gand, 81'821  
(ii) photoreduction of an oxidising meta1, 80'83921 (iii) the generation of metal - 
nitrenes, 93991 and (iv) production of singlet 	 General azide 
photochemistry has also been covered in several reviews. [67,102-1041 
The main focus of this work is the photoredox chemistry of platinum azide 
complexes. The first photoreductive elimination of azide from a platinum centre was 
reported by Vogler et. at. in 1978.[83j  The electronic absorption spectrum of the 
complex trans- [Pt(N3)2 (CN)4
] 2- contains a maximum at 302 nm with an extinction 
coefficient (s) of 18,300 M'cm'. This absorption is assigned as a ligand-to-metal 
29 
Chapter 1 Introduction 
(N3 - Pt) charge-transfer transition. Irradiation of this CT band led to the trans 
elimination of azide, and was found to proceed via the formation of two azide 





[Pt(CN)4]2 + 3N2 
This was also later confirmed by Weber and van Eldik, who found evidence to 
support the theory that the scission of both Pt-N3 bonds occurs simultaneously. [921 
The electronic absorption spectrum of the homoleptic azide complex [Pt(N3)6]2 has a 
maximum at 305 nm (c = 36,300 M'cm') in water. Excitation of this LMCT band 
yields [Pt(N3)4]2 J84'86' Ligand field (LF) transitions of [Pt(N3)6]2 are present above 
400 nm, but irradiation of these bands does not lead to any chemical change. The 
complex [Pt(N3)4]2 has LF absorptions above 300 nm, and LMCT absorptions at 255 
and 211 nm. Charge-transfer excitation again leads to reductive elimination and 
platinum is produced in its zero oxidation state. 
The mechanism for photoactivation of the Pt" azide complex cis-[Pt(N 3)2(PPh3)2] has 
been investigated by many techniques including ESR, luminescence spectroscopy, [851 




[Pt °(PPh3)2] + 3N2 
An interesting feature of the photochemical behaviour of this compound is that it 
undergoes reduction of the metal centre upon irradiation with X > 350 nm. At these 
wavelengths only ligand field transitions are present, and so internal conversion or 
intersystem crossing to a lower lying LMCT state must occur. E1063  Reduction upon 
irradiation into ligand-field transitions has also been reported for the Pt" complex 
[PtC16]2. [70]  
To photoreduce PtnT  to Pt", two azide ligands are required. One possible mechanism 
is that upon irradiation the azides leave in the form of radicals ('N3) (Figure 1.15). 
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Azide radicals are very unstable, and decompose in water rapidly into molecular 
nitrogen (N2), which prevents reoxidation of the platinum centre. This fast 
decomposition is believed to be the reason for the efficiency of photoredox reactions 
involving complexes containing azide ligands. Halogen radicals do not decompose in 







Figure 1.15 Possible mechanism for the photoreduction of a Pt'-diazido complex. 
Two photoactive Pt IV azido complexes based on the structures of cisplatin and its 
ethylenediamine analogue [Pt(en)C12] have previously been synthesised. 
[107,1081 Cis, 
trans, cis-[Pt(N3)2(OH)2(N}13)2] and cis, trans-[Pt(en)(N3)2(OH)2] contain axial 
hydroxo ligands, which enhance aqueous solubility, and stabilize the Pt IV oxidation 
state. 39'471 Changing the am(m)ine ligands does not significantly alter the reduction 
potential of Pt" compounds, so it was thought that these ligands could be varied to 
improve properties such as lipophilicity, without affecting the stability?'] The 
stability, photoreactions and nucleotide / DNA binding of these two compounds were 
investigated using visible light. 107"081 The results were promising; the complexes 
proved to be very stable, even to high concentrations of glutathione, and binding to 
nucleotides and DNA was observed upon irradiation, but not in the dark. This class 
of compounds therefore warranted further investigation as potential photoactivatable 
anticancer drugs (Section 1.5). 
31 
Chapter 1 Introduction 
1.4 	Photoactivated Drugs 
The use of light, in combination with photoactive compounds to treat various 
diseases dates back as far as the Ancient Egyptians, who used sunlight and Bishop's 
Weed or Buliwort, which contain psoralens, to treat vitiligo. Today vitiligo and other 
skin disorders, such as psorisis are still treated in much the same way. Phototherapy 
with synthetic psoralens (e.g. 8-methoxypsoralen), which are applied orally or 
topically is a standard treatment)109' 
Illumination of the skin is clearly not difficult, but applying light to other parts of the 
body is one of the major problems of phototherapy. Recent advances in laser and 
fibre optic technologies have prompted the development of new medical applications 
based on the use of light. It is now possible to irradiate various parts of the body (e.g. 
oesophagus, head and neck, lung, bladder, cervix and colon); this is useful for 
treating cancer, as many solid tumours grow in these areas. The significant advantage 
of treating cancer by locally activating an anticancer agent with light, is the potential 
to avoid the major side-effects associated with chemotherapy. 
The wavelength of light used to activate the compounds once they are inside the 
body is important. Red and near infrared light (Figure 1.16) are preferred, mainly 
because of the increased depth of penetration into tissue. It has been established that 
light in the 600 - 1000 nm spectral region (also known as the "phototherapeutic 
window") possesses the maximum penetration into most human tissues. This is due 
to the low absorbance of the normal cell constituents (e.g. melanin, cytochromes, 
haemoglobin) at these wavelengths, and can also be attributed to inefficient 
scattering of red light by cell organelles. 1101 The penetration depth is defined as the 
depth in the tissue at which the intensity of incident light is reduced to 1 / e, or 37 % 
of its initial intensity. The penetration depth can be as large as 2 cm for lightly 
pigmented tissue with light above 700 nm, and can reach 1.5 cm at 900 nm for 
heavily pigmented tissues. 1101 Further experiments on the penetration of light into 
various tissues can be found in reference 111 and references therein. 
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Figure 1.16 UV, visible and infrared regions of the electromagnetic spectrum. 
Several other important properties, besides wavelength, have to be considered when 
designing photoactive drugs. An ideal compound would also be selective for tumours 
over healthy tissues, produce controllable cell death, and have minimal dark toxicity. 
1.4.1 Photodynamic Therapy 
PDT involves the selective damage of target tissue by using a photosensitizing drug 
and light. PDT is currently used to treat cancers such as lung, superficial gastric, 
cervical and bladder cancer, as well as cancer of the head and neck, and is also 
effective against age-related macular degeneration. The recent availability of 
relatively low-cost, efficient lasers has led to this form of treatment becoming much 
more wide-spread. In turn, the success of PDT has led to the development of new 
non-laser light sources, such as light-emitting diodes and various types of filtered 
lamps especially designed for treating skin lesions. [112] 
The mechanism of action of photosensitizers involves oxygen. The photosensitizer 
absorbs energy from a light source and becomes excited to an energetically higher 
electronic state. Further reactions, which are classed as having type I or type II 
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transfer electrons to biological substrates, this forms radicals and radical ions which 
interact with oxygen to generate products such as the superoxide ion 02.  In type II 
reactions, the energy is transferred to oxygen which converts it from a triplet ground 
state (3 02) to a singlet excited state (102).  The photosensitizer is then regenerated and 
so works catalytically. Singlet oxygen (1 02) is a short-lived but highly reactive 
molecule and reacts rapidly with cellular components. These reactions cause damage 
to the cell that ultimately leads to cell death. The lifetime of singlet oxygen is so 
short ( 0.6 J.ls in a lipid cell membrane)1113 I that it can only diffuse across a single 
cell membrane, and therefore cannot escape into the rest of the body and cause 
damage to healthy tissue. However, the requirement for oxygen is a major drawback 








'Sens sensitiser in singlet electronic ground state 
Sens* sensitiser in singlet electronic excited state 
3Sens* sensitiser in triplet electronic excited state 
02 oxygen in triplet electronic ground state 
102 oxygen in singlet electronic excited state 
ISC intersystem crossing 
Figure 1.17 Photophysical mechanisms involved in photodynamic therapy (PDT) 
based on reference 115. 
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The main advantage of photodynamic therapy over surgery is that it is relatively non-
invasive, and so can often be done in an out-patient or day-case setting (Figure 1.18). 
Repeating the dose is possible as there are no total-dose limitations unlike 
radiotherapy. The treatment is also accurately targeted and so side-effects like those 
associated with chemotherapy can be avoided. 
Figure 1.18 Patients undergoing 
4. 
PDT whilst reading, 
invasive nature of this treatment. Picture courtesy of Dr Sam Eljamel, Consultant 
Neurosurgeon, Ninewells Hospital, Dundee. 
The photosensitizer porfirmer sodium (Photofrin) was approved for clinical use in 
1995. It is a complex mixture of porphyrins, haematoporphyrin derivatives (HpD) 
(Figure 1.1 9a), and is currently used against various cancers, including advanced and 
early-stage lung cancer. [112] Photofrin is one of only two photosensitzers approved 
for systemic administration, the other is temoporfrin (Foscan; Figure 1.19b), which 
entered the clinic in 2001. Foscan is used against palliative head and neck cancer, 
and is a highly active photosensitzer which requires a much lower dose of both drug 
and light compared to Photofrin. 1 161  Aminolevulinic acid (Levulan; Figure 1.19c) 
and methyl aminolevulinate (Metvix; Figure 1.19d) have been approved for topical 
use, and are used for the treatment of actinic keratosis (a precancerous skin 
growth).' 121  These are precursors of protoporphyrin IX (Figure 1.19a) and so the 
porphyrin photosensitizer is generated in situ before light is applied. 
PDT is unable to cure advanced disseminated cancers because it is not possible to 
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patient's quality of life and lengthen survival time. The main side-effect of PDT is 
light sensitivity. Intravenously administered photosensitzers stay in the body for 
some time after treatment (Photofrin 5 - 6 weeks) 131 and patients can sometimes 















Levulan 	 Metvix 
Figure 1.19 Structures of drugs approved for photodynamic therapy. 
A large amount of research is currently devoted to the design of new photosensitizers 
which have (i) a strong absorbance at longer wavelengths, (ii) accumulate selectively 
in tumor tissue, and (iii) are quickly cleared from the body. However due to the 
mechanism of action of PDT the presence of oxygen will still be essential, which is 
not ideal due to the oxygen-deficient nature of many tumors. This is a major 
advantage that photoactivated platinum compounds could have over currently-used 
photosensitizers. 
1.4.2 Phototoxic Metal Compounds 
Recently, there has been a great deal of research into the development of photoactive 
metal complexes with potential medical applications, and a lot of this work has 
involved the platinum group metals. [ 1171 
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The cis and trans isomers of [RuC12(DMSO)4] have recently been reported to be 
phototoxic in human melanoma cell 1ines. 181 Covalent binding of the ruthenium 
complexes to the N7 position of guanines can be induced with UVA light. 
Photoactive rhodium(III) 1,1 0-phenanthroline dichloride complexes have been 
developed which are not only toxic to cancer cells upon irradiation, but have also 
been shown to inactivate an intracellular aiphavirus Sindbis (SINV). 191 Other 
photoactive complexes include the ruthenium(II) bipyridine compound cis- 
[1201 [Ru(bpy)2(NH3)2]2+  which is phototoxic to human skin fibroblasts (Hs-27); 	and 
mixed metal Ru"-Rh" complexes which bind to DNA upon irradiationJ2H  As yet no 
in vitro testing has been reported for these mixed-metal complexes. 
Pt'Lhaematoporphyrin complexes have been designed as dual drugs to take 
advantage of the fact that cancer cells accumulate porphyrins. These complexes are 
technically not photoactivated Pt" complexes, because they are supposed to show 
dark toxicity as well as phototoxicity. The cytotoxic and phototoxic efficacies of 
some of these Pt'Lporphyrin complexes have been reported to exceed the sum of the 
phototoxicity of the corresponding porphyrin ligand and the cytotoxicity of 
cisplatin.'221 These complexes along with others are described in more detail in 
recent reviews. [123,1241 
1.5 	Aims of this Work 
The general aims of this work were to develop new Pt1V  azide complexes, investigate 
the photoactivation mechanism of existing and new pt" azide complexes, and to 
extend the wavelength of absorption towards the red region of the visible spectrum. 
It is important to elucidate the mechanism of photoactivation of these diazido-
complexes to gain further insight into possible in vitro phototoxicity pathways. DNA 
is the major target of Pt" drugs in the body, and so the interaction of PtW  azide 
complexes with nucleobases and DNA upon irradiation is also of interest. It is not yet 
clear if these complexes react in the same way when light of different wavelengths is 
used; higher energy light may open up new activation routes. 
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Ideally a photoactivated drug should absorb between 700 - 1000 nm, this is the 
region where light can penetrate deepest into tissue. PtV  azide complexes typically 
absorb in the UV region due to the high energy N3 - Pt LMCT band. However, by 
careful choice of the other substituents, it may be possible to shift this band far 
enough into the visible region to give sufficient absorbance for photoactivation at 
longer wavelengths. 
Another possible way to overcome the short wavelength of absorbance is to use 
multiphoton techniques. This involves femtosecond pulsed lasers which can activate 
a molecule which absorbs in the UV region (e.g. 350 nm) by irradiation with red 
light (e.g. 700 nm). Two-photons are absorbed almost simultaneously allowing 
access to an excited state which is roughly double the energy of that achieved by 
one-photon absorbance. 
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Chapter 2 Experimental Methods 
2.1 	Nuclear Magnetic Resonance Spectroscopy 
2.1.1 Theory of Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a widely used technique which 
reveals information about the environment of magnetically active nuclei. In the 
absence of a magnetic field the possible orientations of a nucleus are of equal energy. 
However, when a magnetic field is applied the nucleus adopts one of a number of 
allowed orientations of different energy. The nucleus of the hydrogen atom (a 
proton), for example has just two permitted orientations, it can either align itself 
with, or against the field. These two energy levels are separated by an energy AE, 
which depends on the strength of interaction between the nucleus and the field. The 
nuclei can be flipped from the lower energy level to the higher one by applying 
electromagnetic radiation of frequency v, where AE = hv (h is Planck's constant), and 
therefore AE can be measured. This is nuclear magnetic resonance spectroscopy. 4' 
The NMR properties of some commonly studied nuclei are listed in Table 2.1. Due 
to the relevance to this work, the NMR spectroscopy of '5N and 195  Pt nuclei are 
discussed in detail in the following sections. The heteronuclear single-quantum 
correlation (HSQC) NMR technique is also reviewed as it is used extensively in the 
following chapters. 









(107 rad T' s') 
I Frequency at 
11.74 T 
(MHz) 
1H 99.984 1 26.75 1/2 500.00 
0.02 1.5x10 6 4.11 1 76.75 
1.108 1.8x10 4 6.73 V2 36.12 
'5N 0.366 3.9 x 10-6 -2.71 1/2 50.66 
14  N 99.634 1.0 x 10 1.93 1 21.687 
33.80 3.4 x 10 5.77 V2 64.414 
I: Nuclear spin quantum number 
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2.1.1.1 "'Pt NMR Spectroscopy 51  
195Pt is a reasonably sensitive nucleus for NMR detection. It has a natural abundance 
of 33.8 % and nuclear spin quantum number I = V2. Its receptivity relative to 'H is 3.4 
X 10-3 but this can be improved by a factor of three by isotopic enrichment of 195Pt (> 
95%). The spin-lattice relaxation time (Ti ) for 195Pt is usually in the range of 0.3 to 
1.3 s. 
The 195Pt chemical shift range is very large, about 15000 ppm (usually in the range 
from -6000 to 9000 ppm relative to [PtC16]2 ), and often allows easy differentiation 
between Pt" and Pt'", which tend to have chemical shifts at the high-field and low-
fields ends of the range, respectively. The 195Pt chemical shift in monomeric 
complexes is sensitive primarily to the set of bound donor atoms. Some caution is 
required when searching for peaks, as the shifts of Pt1"' halides alone span 12000 
ppm. There are also useful differences in the chemical shifts of geometrical isomers 
and diastereomers (chiral ligands). For '5N-enriched ligands, the splitting pattern in 
the 195Pt spectrum indicates the number of non-equivalent '5N atoms coordinated. 
These characteristics of the 195Pt chemical shift can be utilised in the detection of 
different intermediates formed during the reactions of Pt complexes with 
biomolecules. Sometimes even isotopomers are distinguishable: the 195  Pt isotope 
shift difference for 195Pt-35137C1 is 0.17 ppm and for 195Pt-79181Br is 0.03 ppm. 71 It is 
therefore in principle possible to count the number of Cl and Br ligands bonded to Pt 
via the isotope splitting pattern. In practice it is difficult to resolve because of line 
broadening, which is usually due to either relaxation mechanisms or poor 
temperature control of the sample. The latter is a problem because of the strong 
temperature dependence of 195Pt NMR resonances (0.5 to 1.1 ppm / K). 
The quadrupolar effects of natural abundance 14N (99.6 %, I = 1) from am(m)ines 
which coordinate to Pt can broaden the 195  Pt resonances. Such quadrupolar effects of 
14N have the beneficial effects of shortening the 195  Pt relaxation times and allowing 
rapid pulsing without saturation effects. 195Pt-14N couplings in 195Pt NMR spectra are 
usually better resolved at higher temperature, because of the decreased quadrupolar 
relaxation rate of '4N due to the decrease in correlation time. Even in the absence of 
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'4N ligands, "'Pt resonances can still be very broad owing to chemical shift 
anisotropy (CSA) relaxation, which can be the dominant relaxation mechanism for Pt 
complexes at high magnetic field strength. Similarly, 195  Pt satellites in '5N and 'I-I 
spectra of Pt" complexes are often broadened beyond detection owing to CSA 
relaxation of 195  Pt. The linewidths of 195Pt satellites of 'H NMR resonances are 
dependent on the spin-lattice relaxation time of 195Pt: 
Avy,(H) = 	 + [271T,(Pt)]' 
where [7tT2*(H)]'  is the natural linewidth plus the contribution from magnetic 
inhornogenity broadening (measurable from the linewidth of the centre peak)J51 The 
contribution to 195  Pt T, relaxation from CSA is given by: 
[rtT,(Pt)]' (CSA) = (6/7)X[tT2(Pt)] (CSA) = (2/15) X YPt2X B02 X AY2 X T 
In general, 195Pt satellites (and 195  Pt resonances) are sharper in PtIV  complexes which 
are six coordinate and hence more symmetrical (smaller anisotropy Ac); and are 
broader at higher fields of measurement (B0) and in larger molecules (longer 
correlation time 're ). 
2.1.1.2 '5N NMR Spectroscopy 
'4N NMR spectroscopy can be useful for am(m)ine complexes, but '4N is a 
quadrupolar nucleus, and quadrupolar relaxation is dominant when the environment 
of '4N has a little symmetry. This can lead to very broad lines and a reduction in 
sensitivity. On the other hand, short relaxation times also have the advantage of 
allowing rapid pulsing so that a large number of transients can be acquired. Thus, it 
is possible to follow reactions of cisplatin in blood plasma and cell culture media at 
millimolar drug concentrations, and also to detect ammine release. 81  
By using '5N enriched am(m)ine complexes, the broadening of 195pt  signals caused 
by the quadrupolar effects of '4N can be avoided. Both '5N NMR chemical shifts and 
'J('95 Pt- ' 5N) coupling constants are sensitive to the nature of the trans ligand in Pt 
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am(m)ine complexes, which can provide useful information for identifying the 
ligands in the coordination spheres of both Pt" and Pt"  complexes. Typical 15N and 











H3N-Pt-O 	H3N-Pt-N, CI 
------------------------------------------------------------------------- 
H3N-Pt-N, CI I 	H3N-Pt-S 
------------------------------------------------------------------------- 
H3N-Pt-S 
Pt(IV) 	 Pt(II) 
7.0 	 5.0 	 3.0 
8(1 H) I ppm 
Figure 2.1 Variation in 'H and '5N NMR chemical shifts with the trans ligand in Pt-
NH3 complexes. A similar picture is obtained for amine complexes, but the shifts are 
offset in both dimensions, e.g. for ethylenediamine Pt complexes the 'H resonances 
are shifted to low-field by ca. 2 ppm and the '5N resonances to low-field by Ca. 40 
ppm. 
In general, ligands with a high trans influence give rise to smaller '95Pt-'5N coupling 
constants (S < I < Br < Cl <H20), and cause a low-field shift of the '5N resonance. 
The usefulness of 'J('95Pt-15N) values is limited by the difficulty in determining them 
for larger molecules, especially at high observation frequencies on account of the 
dominance of relaxation via chemical shift anisotropy (CSA). The 'J(195Pt-15N) 
values for Pt's' are smaller than Pt" by a factor of about 1.5 to 1.2 and are 1.4 times 
larger than '.J(195Pt-14N) values. 
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The low receptivity of '5N (3.85 x 106  relative to 'H) limits to some extent its 
usefulness for directly-detected '5N NMR studies of Pt am(m)ine complexes. 
However, the sensitivity of detection can be improved by '5N isotopic enrichment, 
combined with enhancement by polarization transfer from 'H (e.g. '5N-{'H} DEPT 
and INEPT pulse sequences). The maximum enhancement in '5N signal intensity 
achievable via polarization transfer is only 9.8 (7H/7N), which means that inverse 
('H-detected) '5N methods are usually preferred due to the superior enhancement for 
'5N detection. The repetition time of the pulse sequence is governed by the 'H rather 
than the longer '5N spin-lattice relaxation time (T,), which is an additional advantage 
because it allows more rapid pulsing. For example, '5N-{'H} DEPT sequences 
enable the detection of rapidly changing intermediates in the reaction of 15N-cisplatin 
with glutathione, and also ammine release following the reaction of 15N-cisplatin 
with intracellular components in intact red blood cells at concentrations as low as 1 
in M. 
2.1.1.3 Water Suppression 
NMR spectra of biomolecules are usually run in aqueous solutions, such as D20 
(99.9 %) or H20 / D20 (90 % I 10 %, vlv) as this is the most biologically relevant 
medium. However, the Pt-NH 'H NMR resonances for Pt am(m)ine complexes are 
not easily detected in D20 solutions as the half-life for H-D exchange is often only a 
few minutes at ambient temperatures. '°"1 
Two different techniques were used to suppress the large HOD (or H20) signal, 
Presaturation and WATERGATE (WATER suppression by GrAdient Tailored 
Excitation). 121 Presaturation involves irradiation at the frequency of the HOD (1120) 
resonance during the relaxation delay between pulses. The disadvantage is that 
exchangeable NH protons can also be saturated resulting in a loss of intensity. The 
WATERGATE method uses selective 180° pulse field gradients to select different 
coherence pathways, and gives superior water suppression, however this can also 
results in suppression of other signals in close proximity to the water peak. 
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2.1.1.4 Heteronuclear Single-Quantum Coherence Experiments 
The heteronuclear single-quantum coherence (HSQC) experiment is an inverse 
detection method used to enhance the sensitivity of '5N. The sensitivity can be 
improved by a theoretical maximum of 306 with respect to directly detected '5N, this 
means signals in aqueous solutions at concentration of physiological relevance (mM 
or even tM) can be detectedJ51 'H-detected inverse methods are applicable to any 
system which contains a '5N atom with a measurable spin-spin coupling to 'H (i.e. 
in ammine, primary and secondary amines, but not tertiary amines 
although a longer range can sometimes be utilised). In practice the best applications 
are for those systems with large one-bond couplings (e.g. ca 73 Hz for 15NH3). 
Besides the high sensitivity, inverse detection also brings a simplification of 
complicated spectra because it detects only those protons directly attached to the 
labelled '5N atoms in the sample. This is very important for investigations of 'H 
NMR spectra of body fluids or cell culture media which contains thousands of 
overlapping resonances. The basic HSQC pulse sequence is shown in Figure 2.2. 
	
900  1800 900 	1800 900 1800 
1H  Lfl_ _flUA 
1800 900 	 900 1800 
F. t1 	 fl I I JGARP (dec.) 
Figure 2.2 Basic HSQC pulse sequence. The delay A = V2 J(X,H), where J is the 
one-bond HX coupling constant, and one-dimensional 15N-edjted spectra are 
obtained by setting the evolution period t, to zero. Spectra may be recorded with or 
without decoupling of '5N spins (GARP) during the acquisition period. 
A 1D 'H spectrum containing only resonances from pt-15NH species is obtained by 
acquiring only the first increment in a two-dimensional experiment. If '5N 
decoupling is employed during acquisition (e.g. the GARP method), then each 
distinct type of Pt-NH resonance appears as a singlet, sometimes together with the 
broadened 195Pt satellites. In practice the water resonance is so intense that it is 
usually necessary to use additional solvent suppression techniques (e.g. 
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presaturation). The use of pulse sequences in which coherence selection is achieved 
by the use of pulsed field gradients allows greatly improved water suppression. By 
use of the HSQC sequence of Stonehouse et al. ' 31 (Figure 2.2), it is possible to detect 
NH peaks within a few Hz of the water resonance at concentrations as low as about 
10 tM without the need for additional solvent suppression techniques. (5 
The combined detection of 'H and '5N in a 2D inverse NMR experiment is especially 
powerful, since both the '5N NMR chemical shift, and the one-bond coupling 
constant 'J('H-'5N) are diagnostic of the trans ligand (Figure 2.1). As shown in 
Figure 2.3, the 195Pt satellites (when not broadened beyond detection by the effects of 
CSA relaxation) in a 2D ['H,'5N] spectrum appear as diagonal peaks which 
correspond to the 2J('H-195Pt) coupling constant in the F2('H) dimension and to the 
'J(15N-195Pt) coupling in the F,('5N) dimension. Pt" and Pta' am(m)ine complexes 
can be easily distinguished from one another by the combination of 'H and '5N 
chemical shifts (Figure 2.1). 
ö(1 H) 
Figure 2.3 General appearance of a 2D [1H,'5N] HSQC spectrum. The 195Pt satellites 
are usually more intense for symmetrical Pt species (PtIV  rather than Pt"). 
2.1.2 Experimental NMR Spectroscopy 
NMR spectra were recorded at 298 K on a Bruker DMX500 ('H: 500.13 MHz; '5N: 
50.7 MHz; 195Pt: 107.523 MHz) or a Bruker AVA600 ('H: 599.81 MHz) NMR 
spectrometer, using 5 mm NMR tubes. Samples were prepared in d6-acetone, d6- 
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DMSO, or 90 % H20 / 10 % D20 with 'H chemical shifts referenced internally to 
dioxane (6 3.764 ppm). '5N chemical shifts were referenced externally to '5NH4CI (1 
M) in HC1 (1.5 M) (6 0 ppm) and 195Pt to K2[PtCI4] in H20 (6 -1623 ppm). 141 All 
data were processed with XW1N-NMR software (Version 3.6, Bruker, UK Ltd.). For 
'H NMR, typical acquisition conditions for 1D spectra were as follows: 45-60° 
pulses, 16-32 k data points, 1-3 s relaxation delay, collection of 32-128 transients, 
final digital resolution of 0.2-0.5 Hz/point. Water suppression was carried out by 
presaturation. 2D ['H,'5N] HSQC NMR spectra (optimized for 'J(N,H)  72 Hz) were 
recorded using the sequence of Stonehouse et al. 131 The '5N-spins were decoupled by 
irradiation with the GARP-1 sequence during acquisition. Water suppression was 
achieved by presaturation. Typically, 8 scans were acquired for each of 128 
increments of t, and the final resolution was 6 Hz / point for the F2 dimension and 8 
J-Iz /point for the F! dimension. 
2.2 	Ultraviolet and Visible Electronic Absorption Spectroscopy 
Ultraviolet and visible electronic absorption spectroscopy (UV-visible spectroscopy) 
is based on the absorption of light by valence electrons, which are promoted from 
their ground state to an excited state. The energies of the orbitals involved in 
electronic transitions have fixed values, but the spectra produced generally contain 
broad peaks. This is due to the presence of vibrational and rotational energy levels 
which are also available to the absorbing material.' 5"61  
2.2.1 Electronic Transitions 
The absorption bands of metal complexes generally arise from two different types of 
transition: ligand field (d - d) transitions and charge-transfer transitions. Charge-
transfer transitions can be further sub-divided into two categories: ligand-to-metal 
charge-transfer (LMCT) and metal-to-ligand charge-transfer (MLCT). Ligand-
centred transitions which do not involve the metal are also possible, particularly for 
ligands containing it-bonds. These transitions and their selection rules are discussed 
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2.2.2 Experimental UV-visible spectroscopy 
UV-visible electronic absorption spectra were recorded on a Varian Cary 300 UV-
visible spectrophotometer in 1 cm path-length cuvettes. The spectral width was 200 - 
800 nm and the bandwidth was 1.0 nm. Heilma UV quartz cuvettes were used, either 
standard (3.5 mL) or micro (0.5 mL), supplied by Aldrich. All spectra were recorded 
in water and referenced to solvent alone. Data were processed with Origin 5.0. 
2.3 Irradiations 
Two different light sources were used to irradiate the platinum complexes. For UV 
irradiations a UV lamp was used, whereas for visible light irradiations an argon-
krypton ion laser was used. 
2.3.1 Argon-Krypton Ion Laser 
Argon-krypton lasers produce reliable, high power in continuous wave (CW) 
operation on a multitude of lines in the visible region of the electromagnetic 
spectrum. As a result, CW argon-krypton lasers have found applications in fields as 
diverse as retinal surgery, high resolution spectroscopy, and newspaper 
p1atemaking.'71  
Figure 2.4 Irradiation of an NMR sample with the argon-krypton laser (457.9 nm). 
The laser (Coherent Innova 70C Spectrum) used for this work was equipped with a 
fibre optic (FT-600-UMT, 0 = 600 tm; Elliot Scientific) to enable delivery of light 
to a sample within an NMR tube (Figure 2.4). The tip of the fibre optic was always 
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positioned Ca. 2 mm above the solution. The major lines are found at 457.9, 488, 
514.5, 520.8, 530.9, 568.2 and 647.1 tm-i, and the laser output after the fibre optic 
was measured with either a Coherent 210 power meter or a Coherent Fieldmate 
power meter (0P2-VIS head). 
2.3.2 UV Lamp 
The ultraviolet light source was a UV lamp (2 x 15 W tubes, model VL-2 1 5L; Merck 
Eurolab, Poole, UK) which operates at 365 nm and delivers almost pure UVA light. 
UVB and almost all the visible light are blocked with filters (Figure 2.5). 
C 
C 




Figure 2.6 a) Irradiation of samples in quartz cuvettes with the UV lamp. b) The tin 
foil cover ensured any observed changes were not due to external light. 
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Samples were irradiated at a distance of 10 cm from the lamp where the power is ca. 
1.5 mW/cm2, this power delivers a dose of 10 J/cm2 over 2 h. Samples were 
irradiated either in NMR tubes or UV quartz cuvettes (Figure 2.6). The temperature 
under the lamp was recorded as 298-299 K over a 30 min period. 
2.4 	Electrospray lonisation Mass Spectrometry (ESI-MS) 
In electrospray ionisation mass spectrometry (ESI-MS) gaseous ions are produced 
from a liquid solution. 181 ESI-MS is considered a "soft" technique as very little (if 
any) fragmentation occurs during the ionisation process. The ions are generated by 
creating a fine spray of charged molecules in the presence of a strong electric field. 
The charged molecules are sprayed from the tip of a metal nozzle at approximately 
3-4 kV, and then electrostatically directed towards the mass spectrometer inlet. 
Either gas, heat or a combination of both are applied to the droplets to induce 
vaporisation prior to entering the instrument. As the solvent evaporates, the electric 
field density increases, hence the mutual repulsion between individual species 
becomes so great that it exceeds the surface tension and ions leave the droplet. The 
ions then continue along to the mass analyzer of the mass spectrometer. In 
electrospray processes the ions observed are quasimolecular ions, they are ionized by 
the addition of a proton to give [M+H] (M = analyte), negative ions can be 
generated by the removal of a proton. In electrospray multiply charged ions such as 
[M+2H]2 are also often observed. 
Positive ion electrospray mass spectrometry was performed on a Platform II Mass 
Spectrometer (Micromass, Manchester, UK). The samples were infused at 8 iL/min 
and the ions produced in an atmospheric pressure ionisation (API)/ESI ion source. 
The source temperature was 383 K, and the drying gas flow rate was 300 L/h. A 
potential of 3.5 kV was applied to the probe tip, and cone voltage gradients of 10 - 
40 V over 200 - 1000 Da were used. Data acquisition was performed on a Mass 
Lynx (V 2.5) Windows NT PC data system. All samples were prepared in water. 
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2.5 	Inductively Coupled Plasma Atomic Emission Spectroscopy 
ICP-AES analyses were carried out on a Perkin Elmer Optimal Emission 
Spectrometer Optima 5300 DV. The machine was calibrated using freshly prepared 
dilute aqueous solutions of a 980 ppm platinum ICP standard (5 wt. % HCI) supplied 
by Aldrich. The emission wavelength used for platinum detection was 214.423 nm. 
The R.F. power was 1150 W, the nebulizer flow was 30 psi, and the pump rate was 
100 rpm. 
2.6 	CHN Elemental Analysis 
Microanalyses were carried out either at Edinburgh University in the School of 
Chemistry on an Exeter Analytical Elemental Analyser (CE440), or at St. Andrews 
University in the School of Chemistry on a Carlo Erba CHNS Analyser. 
2.7 	pH Measurements 
pH values were measured with an Orion 710A pH meter equipped with a 
microcombination electrode (Aldrich) calibrated with Aldrich standard buffers (pH 
4, 7 and 10), and were adjusted with HC104 (0.1 M) or NaOH (0.1 M). 
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3.1 Introduction 
Platinum(IV) compounds are typically more inert than platinum(II) compounds. It is 
generally accepted that PtIV  prodrugs exert their toxic effects by in situ reduction to 
the reactive Pt" forrnJ l l For this reduction to occur two electrons must be donated to 
the platinum centre and two ligands must leave the complex; therefore the process is 
a reductive elimination. One of the main problems with platinum chemotherapy is its 
lack of selectivity which can result in some severe side-effects. The ability to 
generate a reactive species (e.g. a Pt" complex), from a non-toxic compound (e.g. an 
inert Pt's' complex) site specifically by photoactivation, has the potential to overcome 
this problem. The photoactivity of platinum complexes is well documented, and has 
been observed for compounds containing a variety of halogen and psuedohalogen 
ligands. [2-4] 
Investigations into the photoactivity and DNA binding of PtrTdOdO  complexes, 
such as trans, cis-[Pt(en)(OA0212] have been carried out by Bednarski et al. 571 After 
many promising results, this compound was unfortunately found to be readily 
reduced to a cytotoxic Pt" species by biological thiols, thus rendering Pt"-iodo 
complexes unsuitable as site-specific photoactivated prodrugs. 
The photoactivity of Pt's' complexes containing the pseudohalogen azide (N3) is well 
known. 8 " 1 To photoreduce Pt1" to Pt two azide ligands are required. One possible 
mechanism is that upon irradiation the azides leave in the form of radicals (N3) 
(Figure 3.1). Azide radicals are very unstable, and decompose in water rapidly into 
molecular nitrogen (N2) which prevents reoxidation of the platinum centre. This fast 
decomposition is believed to be the reason for the efficiency of photoredox reactions 
involving complexes containing azide ligands. Halogen radicals do not decompose in 
water, and therefore recombination to generate the starting material is an efficient 
process. [12] 
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Figure 3.1 Possible mechanism for the photoreduction of a Pt-diazido complex. 
Two compounds containing azide ligands attached to a Pta' centre were designed and 
synthesised in our laboratory by Dr. Phil MUller, cis, trans, cis- [Pt(N3)2(OH)2(NH3)21 
and cis, trans-[Pt(en)(N3)2(OH)2]. The structures were based on cisplatin and its 
chelated analogue cis-[Pt(en)C12]. The hydroxo ligands enhance aqueous solubility 
and also stabilize the Pt" oxidation state. "31  These complexes were found to reduce 
and bind to DNA upon irradiation, and importantly were stable in the presence of 
glutathione (the strongest reducing agent found in cells).["' 51 For structures of 
complexes 1 and 2 see Appendix I. 
Ideally, a photoactivated drug would absorb in the red region (ca. 650 - 710 nm) of 
the visible spectrum. The benefits of red light lie in the greater depth of skin 
penetration and the fact that it is of lower energy than blue light. However, cis, trans, 
cis-[Pt(N3)2(OH)2(NH3)2] and cis, trans-[Pt(en)(N3)2(OH)21 both absorb mainly in the 
UV region (< 400 nn). One of the aims of this project was to increase the 
wavelength of absorbance of Pt"-azide compounds by changing the amine ligands 
and I or the stereochemistry. 
Azide compounds must be handled with care! When complexed to heavy metals 
they are known to be shock-sensitive detonators, and as salts are highly toxic. 
[161 
Azides decompose and release N2  at high temperatures. Therefore after the azide 
ligands are attached to platinum, the compounds should not be subjected to 
temperatures above 313 K. When handling Pt-azides in the solid form, certain 
precautions should always be taken: plastic spatulas instead of metal spatulas, and 
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buchner funnels with paper filters are used rather than glass sintered funnels. 
The following sections describe the synthesis and characterisation of various novel 
Pt-azide compounds. The photoactivity, stability and DNA binding ability is 
discussed in subsequent chapters. The structures of all the Pt IV azide complexes 
synthesised can be found in Appendix 1. 
3.2 Experimental 
3.2.1 Materials 
Silver nitrate, 15NH4C1, methylamine (40 % solution, MeNH2), ethylamine (70 % 
solution, EtNH2), thiazole (tz), pyridine (py), 2-picoline (2-pic), 3-picoline (3-pic), 4-
picoline (4-pic), ethylenediamine (en), cyclohexylarnine (c-HexNH2), ethanol, d6-
acetone, d6-DMSO, D20 and 1 ,4-dioxane were purchased from Aldrich. NaN3, HCl 
(37 %), KI, KOH, acetone, methanol, acetic acid (> 99 %) and NaCl were from 
Fisher. H202 and 1,10-phenanthroline (phen) from Sigma. HC104 (60 %) and 
ammonia from Fisons. DMF and DMSO from Fluka. K2[PtC14] from Alfa Aesar, 
NH4C1 from BDH and 2,2'-bipyridine (bpy) from Acros. H20 was deionised with a 
USF Elga deioniser. 
3.2.2 Synthesis and Characterisation 
3.2.2.1 Cis-[Pt12(NH3)2] 
K2[PtC14] (1.481 g, 3.57 mmol) was dissolved in H20 (70 mL) and KI (6.02 g, 35.67 
mmol) added. After stirring for 30 min NH4C1 (0.382 g, 7.14 mmol) was added and 
the pH adjusted to 10 with 2 M KOH. The pH was continually readjusted to 10 every 
2-5 min until it no longer decreased. The mixture was left stirring for 30 min and 
then the yellow precipitate collected by filtration, washed with water, ethanol and 
diethyl ether and dried under vacuum. 
Cis-[Pt12(15NH3)2] was prepared as described above using 15NH4C1 as the source of 
5N. 
Yield: 1.545 g (89.6 
CHIN: Found: C, 0.00; H, 0.91; N, 5.67. Calculated for PtH6I2N2: C, 0.00; H, 1,24; N, 
5.80. 
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'H NMR (90% H20/10%D20):64.03 ppm (d, "NH3 'J('5N-'H) 73.0 Hz, 6H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N / 4.03, -52.20), 'J('95Pt-15N) 268.8 Hz, 2J('95Pt-
'H) 58.5 Hz. 
3.2.2.2 Cis-[PtC12(NH3)2] (Cisplatin) 
Cis-{Pt12(NH3)2] (0.698 g, 1.44 mmol) was suspended in H20 (100 mL) and AgNO3 
(0.486 g, 2.87 mmol) added. After stirring at 333 K for 24 h, AgI was filtered off 
with an inorganic membrane filter (Whatman, Anotop 10, 0.02 jim). NaCl (0.338 g, 
5.78 mmol) was added and the solvent reduced to 10 mL and stored at 277 K for 24 
h. Cis-[PtC12(NH3)2] was filtered off washed with water, ethanol and diethyl ether 
and dried under vacuum. 
Cis-[PtC12(15NH3)2] was prepared from cis-[Pt12(15NH3)2] by the above method. 
Yield: 0.391 g (90.3 %) 
CHIN: Found: H, 1.93; N, 9.03; Calculated for PtH6C12N2: H, 2.00; N, 9.33. 
'H NMR (90% H20/10% D20): 6 4.07 ppm (d, 15 NH3, 
1 J( 15N-'H) 73.0 Hz, 61-I). 
'H NMR (d6-DMSO): 6 3.96 ppm (br s, '4 NH3, 6H). 
2D [1 H,15N] HSQC NMR (90% H20/10% D20): 6 ('H, '5N / 4.07, -69.32), 'J(195 Pt-
'5N) 324.6 Hz, 2J('95Pt-'H) 63.0 Hz. 
3.2.2.3 Trans-[PtCJ 2(NH3)2J (Transpiatin) 
Cisplatin (0.157 g, 0.524 mmol) was suspended in H20 (15 mL) and NH3 (35 
7.855 mmol, 0.434 mL) added. After refluxing for 1 h all the solvent was removed. 
The pure white solid was re-dissolved in HC1 (1.6 M, 11 mL), and stirred in the dark 
at 378 K for 4 d. After cooling to room temperature the flask was placed on ice to 
complete precipitation. Trans-[PtC12(NH3)2 } was filtered off, washed with water, 
ethanol and diethyl ether and dried under vacuum, then recrystallised from hot HC1 
(0.1 M). 
Yield: 0.114 g (72.7%) 
CHIN: Found: H, 1.50; N, 9.82. Calculated for PtH6C12N2: H, 2.00; N, 9.33. 
'H NMR (do-DMSO): 6 4.39 ppm (br s, 14  NH3, 6H). 
Trans-[PtCl2(15NH3)2] was prepared by refluxing a suspension of cis-[PtC12('5NH3)2] 
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(57.0 mg, 0.19 mmol) in water containing 15NH4CI (1.9 mmol) at pH 11 (adjusted 
with 2 M KOH). After 24 h the pH was readjusted from 7 to 11 and refluxing 
continued for 6 h or until a clear, colorless solution was obtained. The solvent was 
removed and HC1 (2.3 M, 2.5 mL) added. The solution was refluxed for 4 days, then 
cooled, placed on ice for 2 h, filtered off, washed with water, ethanol and diethyl 
ether and dried under vacuum. 
Yield: 46.63 mg (81.8 %) 
'H NMR (90% H20/10% D20):8  3.60 ppm (d, "NH3, 'J('5N-'H) 72.0 Hz, 6H). 
2D ['H,'5N] HSQC NMR: ö ('H, '5N I 3.60, -66.95), 'J('95Pt-'5N) 277.5 Hz, 2J(195Pt-
'H) 52.0 Hz. 
3.2.2.4 [Pt(en)C12] 
K2[PtC14] ( 1.528 g, 3.682 mmol) was dissolved in H20 (30 mL) and ethylenediamine 
(en) (0.98 mol eq, 0.077 mL) added. The volume was reduced and after storing at 
277 K for 1 h the yellow precipitate was filtered off, washed with water, ethanol and 
diethyl ether and dried under vacuum. 
[Pt('5N-en)C12J was synthesized by Dr. Phil Muller as previously described.[ 171 
Yield: 0.884 g (73.7 %) 
'H NMR (90 % H20/10 % DO): 6 2.61 ppm (s, en CH2). 
3.2.2.5 Cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (1) 
a) Cis-[Pt(N3)2(NH3)2] 
Cis-[Pt12(NH3)2] (0.497 g, 1.029 mmol) was suspended in H20 (100 mL) and AgNO3  
(1.98 mol eq, 0.346 g) added. The mixture was stirred at 333 K in the dark for 24 h. 
After cooling to room temperature, the AgI precipitate was removed by filtration 
with an inorganic membrane filter (Whatman, Anotop 10, 0.02 tm). NaN3 (20.57 
mmol, 1.34 g) was added to the solution which was stirred for 1 h in the dark at room 
temperature. The volume was reduced until precipitation was observed and then 
placed at 277 K for 24 h for further precipitation. The yellow crystals of cis-
[Pt(N3)2(NH3)2] were filtered off and washed with water, ethanol and diethyl ether 
then dried under vacuum. 
Yield: 0.223 g (69.2 %) 
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'H NMR (90% H20/10% D20): 6 3.84 ppm (d, "NH3, 'J('5N-H) 75.0 Hz, 6H). 
2D ['H,'5N] HSQC NMR: ö ('H, '5N / 3.84,-69.47), 'J(195Pt-15N) 295.6 Hz, 2j(195  Pt-
'H) 55.0 Hz. 
b) Cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] 
Cis-[Pt(N3)2(NH3)2] (0.222 g, 0.709 mmol) was suspended in H20 (100 mL) and 
H202 (30 %, 28.4 mmol, 2.89 mL) added. After stirring in the dark at room 
temperature for 1 h, the yellow solution was reduced in volume until precipitation 
was observed and then placed at 277 K for 24 h for further precipitation. The yellow 
crystals of cis, trans, cis-[Pt(N 3)2(OH)2(NH3)2] were filtered off, washed with water, 
ethanol and diethyl ether and dried under vacuum. 
Cis, trans, cis-[Pt(N3)2(OH)2( 15NH3)2] was prepared from cis- [Pt12(15  NH3)21 
Yield: 0.186 g (75.4 %) 
'H NMR (90% H20/10% D20, pH 4.82): 6 5.12 ppm (d, "NH3, 'J('5N-'H) 73.5 Hz, 
6H). 
2D ['H, 'IN] HSQC NMR: 6 ('H, '5N / 5.12, -40.27), 'J('95Pt-'5N) 259.8 Hz, 2J(195Pt-
'H) 46.0 Hz. 
"'Pt NMR (90% H20/10% D20): 902 ppm 
UV-vis: 2max = 257 nm (c = 13,721 M'cm'). 
3.2.2.6 Cis, trans-[Pt(en)(N 3)2(OH)2 } (2) 
The synthesis of cis, trans- [Pt(en)(N3)2(OH)2 } was as described in section 3.2.2.5 for 
cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] using [Pt(en)C12] as the starting material. 
[Pt(' 5N-en)C12] was used in the preparation of cis, trans- [Pt(' 5N-en)(N3)2(OH)2]. 
Cis, trans-[Pt(en)(N 3)2(OH)2] 
Yield: 64.7 % 
'H NMR (90 % H20/10 % D20, pH 5.05): 6 6.38 ppm (d, 15NH2, 'J('5N-H) 76.0 Hz, 
411), 2.94 ppm (s, en CH2, 4H). 
2D ['H, '5N] HSQC NMR: 6 ('H, '5N / 6.38, -7.22), 'J(195Pt-'5N) 278.0 Hz, 2J('95Pt- 
H) 43.0 Hz. 
IJV-vis: Xl ,ax = 257 nm (s = 14,340 M' cm- '). 
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3.2.2.7 Trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) 
Trans-[PtCl2(NH3)2] (0.102 g, 0.341 mmol) was suspended in H20 and AgNO3 
(0.664 mmol, 0.113 g) was added. The suspension was stirred in the dark at 333 K 
for 48 h, and then the AgC1 precipitate was removed by filtration with an inorganic 
membrane filter (Whatman, Anotop 10, 0.02 jim). NaN3 (1.32 mmol, 0.086 g) was 
added and the solution stirred in the dark for 24 h. Trans-[Pt(N3)2(NH3)2] was 
collected by filtration and resuspended in H20 (100 mL). Addition of H202 (30 %, 
2.64 mmol) followed by stirring for a further 6 h resulted in a cloudy yellow solution. 
The insoluble AgN3 was filtered off and the solution concentrated. Crystals appeared 
after storing at 277 K for 24 h. The bright yellow crystals were filtered off, washed 
with water, ethanol and diethyl ether and dried under vacuum. Crystals suitable for 
X-ray analysis were grown from H20 at 277 K.1 18] 
Trans, trans, trans-{Pt(N3)2(OH)2(' 5NH3)2] was prepared from trans- [PtCl2(15  NH3)21 
Yield: 66.4 mg (56.2 %) 
'H NMR (90% H20/10% D20, pH 4.75): 6 5.32 ppm (d, 15 NH3, 
1J(15N-'H) 72.0 Hz, 
6H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N / 5.32, -41.65), 'J(195Pt-'5N) 282 Hz, 2J(195Pt-
'H) 47.5 Hz. 
195 Pt NMR (90% H20/10% D20): 875 ppm 
ESI-MS: [M+Na] 370.1 m/z 
UV-vis: 2ax = 286 nm (c = 18,945 M'cm'). 
3.2.2.8 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)] (4) 
a) Trans-[PtC12(NH3)(py)] 
Cisplatin (0.106 g, 0.352 mmol) was suspended in H20 (3 mL) and pyridine (py) 
added (1.056 mmol, 84.6 jiL). After stirring at 348 K for 90 mm, the clear solution 
was cooled to room temperature and reduced to dryness to give a white solid. HC1 (2 
M, 2 mL) was added and the solution stirred at 343 K for 4 days. After cooling on 
ice, the yellow solid was filtered off, washed with water, ethanol and diethyl ether 
and dried under vacuum. 
Trans-[PtC12( 15 NH3)(PY)l  was prepared from cis- [PtCl2( 15 NH3)21 
Yield: 0.100 g (78.7 %) 
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'H NMR (d6-acetone): 6 8.85 (d, H, 'J(,m 6.8 Hz, 2H), 7.98 (t, H, 1 p,. 7.6 Hz, 111), 
7.45 (dd, Hm, 2H), 3.86 (d, "NH3, 1 J(15N-'H) 72.0 Hz, 3H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N I 3.86, -70.28), 'J(195Pt-15N) 276.7 Hz, 2J(195Pt-
'H) 52.0 Hz. 
Trans-[Pt(N3)2(NH3)(py)J 
Trans-[PtC12(NH3)(py)] (97.4 mg, 0.269 mmol) was suspended in H20 (25 mL) and 
AgNO3 (1.98 mol eq, 89.1 mg) added. After stirring at 333 K for 24 h in the dark 
AgCl was removed by filtration with an inorganic membrane filter (Whatman, 
Anotop 10, 0.02 tm). NaN3 (0.538 mmol, 35.0 mg) was added and the suspension 
stirred for 6 h in the dark. The volume was reduced to 2 mL and left at 277 K for 24 
h. The yellow precipitate was filtered off, washed with water, ethanol and diethyl 
ether and dried under vacuum. 
Yield: 92.9 mg (92.1 %) 
'H NMR (d6-acetone): 8 8.77 (d, H0, 'Jom  6.8 Hz, 2H), 8.08 (t, H, 'Jp,m  7.5 Hz, 1H), 
7.59 (dd, Hm, 2H), 3.97 (d, 15 NH3, 'J('5N'H) 72.0 Hz, 3H) 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N I 3.97, -67.39), 'J('95Pt-'5N) 322.4 Hz, 2J(195Pt-
'H) 53.5 Hz. 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] 
Trans-[Pt(N3)2(NH3)(py)} (92.0 mg, 0.245 mmol) was suspended in H20 (300 mL) 
and H202 (30 %, 1.470 mmol 0.150 mL) added. After stirring overnight at room 
temperature in the dark, the volume was reduced to 20 mL and the remaining 
insoluble AgN3 was removed by filtration. All the solvent was removed and acetone 
was added to precipitate the product, which was collect by filtration and washed 
sparingly with ice cold water, ethanol and diethyl ether, then dried under vacuum. 
Crystals suitable for X-ray analysis were grown from H20 at 277 K. 
Yield: 75.8 mg (74.8 %) 
1H NMR (90 % H20 I 10 % D20, pH 5.12): 6 8.72 (d, H0, 'J(,,m 6.0 Hz, 2H), 8.25 (t, 
H, 'Jp,m 7.6 Hz, 1H), 7.78 (dd, Hm, 2H), 5.65 (d, 
15 
NH3, 
1J(15N-1 H) 74.0 Hz, 3H) 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N I 5.65, -46.00), 'J('95Pt-15N) 282.3 Hz, 2j(195  Pt-
'H) 49.5 Hz. 
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ESI-MS: [M + Na] 432.0 m/z 
UV-vis: Amax = 289 nm (c = 18,816 M'cm'), 268 nm (E = 10,800 M'cm'). 
3.2.2.9 Trans, trans, trans- [Pt(N3)2(OH)2 (NH3)(MeNH2)] (5) 
Trans-[PtC12(NH3)(MeNH2)] 
Cisplatin (0.105 g, 0.351 mmol) was suspended in H20 (2 mL) and methylamine 
(MeNH2, 40 % solution, 1.404 mmol, 0.121 mL) added. The mixture was stirred 
under nitrogen at 343 K for 2 h or until the solution was colourless. The volume was 
reduced to dryness and then HC1 (1.7 M, 2.5 mL) was added. The reaction was 
stirred under nitrogen at 348 K for 24 h then cooled on ice and filtered. The filtrate 
was placed back under nitrogen and heated at 373 K for 6 h, then 348 K for 12 h, 
cooled on ice and filtered again, this was repeated once more and all three batches of 
solid were combined and washed with water, ethanol and diethyl ether then dried 
under vacuum. 
Yield: 77.5 mg (70.3 %) 
'H NMR (d6-acetone): ö 3.97 (s, NH2, 2H), 3.37 (s, NH3, 31-1), 2.43 (t, CH3, 'J(CH3-
NH2) 6.5 Hz, 3H). 
Trans-[Pt(N3 )2(NH3)(MeNH2)] 
Trans-[PtCl2(NH3)(MeNH2)] (75.9 mg, 0.242 mmol) was suspended in H20 (25 mL) 
and AgNO3 (1.95 mol eq, 80.1 mg) added. The reaction was stirred in the dark at 333 
K for 24 h then filtered with an inorganic membrane filter (Whatman, Anotop 10, 
0.02 tm). NaN3 (0.968 mmol, 63.0 mg) was added and the yellow solution was 
stirred for 4 h, then reduced to dryness. Small amounts of H20 were added and the 
product filtered, washed with ethanol and diethyl ether then dried under vacuum. 
Crystals suitable for X-ray analysis were grown from H20 at 277 K. 
Yield: 61.3 mg (77.6 %) 
1H NMR (d6-acetone): 6 4.20 (s, NH2, 2H), 3.70 (s, NH3, 314), 2.45 (t, CH3, 'J(CH3-
NH2) 6.5 Hz, 3H). 
c) Trans, trans, trans- [Pt(N3)2(OH)2(NH3) (MeNH2)] 
Trans-[Pt(N3)2(NH3)(MeNH2)] (59.8 mg, 0.183 mmol) was suspended in H20 (20 
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mL) and H202 (0.732 mmol, 0.083 mL) added. After stirring in the dark at room 
temperature for 1 h the solvent was removed. Ethanol was added to precipitate the 
product which was filtered, washed sparingly with ice cold water, ethanol and diethyl 
ether then dried under vacuum. 
Yield: 53.7 mg (81.3 %) 
'H NMR (90 % H20 / 10 % D20): 6 2.36 (septet, CH3, 3H). 
ESI-MS: [M + H] 362.1 m/z 
UV-vis: Xrnax = 286 nm (c = 19,384 M'cm'). 
3.2.2.10 Trans, trans, trans-[Pt(N 3)2(OH)2(NH3)(EtNH2)} (6) 
Trans-[PtCl2(NH3)(EtNH2)] 
Cisplatin (94.6 mg, 0.315 mmol) was suspended in H20 (1.5 mL) and ethylamine 
(EtNH2, 70 % solution, 2.520 mmol, 0.121 mL) added. The reaction was heated at 
363 K for 2 h or until the solution was colourless, and then the solvent removed. The 
white solid was redissolved in HC1 (2.5 M, 1.5 mL). The solution was stirred at 363 
K for 48 h, cooled to room temperature and placed on ice for 2 h. The bright yellow 
solid was filtered, washed with water, ethanol and diethyl ether and dried under 
vacuum. 
Yield: 76.6 mg (74.1 %) 
'H NMR (d6-acetone): ö 3.98 (s, 14  N142, 2H), 3.38 (d, "NH3, 'J(15N-'H) 72.0 Hz, 
3H), 2.75 (sextet, CH2, 2H), 1.27 (t, CH3, 'J(CH2-CH3) 7.0 Hz, 3H). 
2D ['H,'5N] HSQC NMR: ö ('H, '5N / 3.38, -68.38), 'J('95Pt-'5N) 258.7 Hz, 2J(195Pt-
'H) 5 1. 0 Hz. 
Trans- [Pt(N3)2 (NH3)(EtNH2)] 
Trans- [PtC12(NH3) (EtNH2)] (40.6 mg, 0.124 mmol) was suspended in H20 (20 mL) 
and AgNO3 (1.95 mol eq, 41.1 mg) added. The reaction was stirred in the dark at 333 
K for 24 h then filtered with an inorganic membrane filter (Whatman, Anotop 10, 
0.02 jtm). NaN3 (0.744 mmol, 48.3 mg) was added and the yellow solution was 
stirred for 24 h, then reduced to dryness. Small amounts of H20 were added and the 
product filtered, washed with ethanol and diethyl ether and dried under vacuum. 
Yield: 33.9 mg (80.3 %) 
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'H NMR (d6-acetone): 6 4.20 (s, 14NH2, 2H), 3.70 (d, "NH,, 'J('5N-'H) 60.0 Hz, 
3H), 2.77 (sextet, CH2, 211), 1.32 (t, CH3, 'J(CH2-CH3) 6.0 Hz, 3H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N / 3.70, -43.59), 'J(195Pt-'5N) 247.4 Hz, 2j(195  Pt-
1H) 41.5 Hz. 
c) Trans, trans, trans-{Pt(N3)2(OH)2(NH3)(EtNH2)] 
Trans-[Pt(N3)2(N113)(EtNH2)] (33.5 mg, 0.098 mmol) was suspended in H20 (30 
mL) and H202 (0.392 mmol, 0.041 mL) added. After stirring in the dark at room 
temperature for 1 h the solution was filtered. All the solvent was removed and then 
ethanol added to precipitate the product. The yellow solid was collected by filtration, 
washed sparingly with ice cold water, ethanol and diethyl ether and dried under 
vacuum. 
Yield: 26.7 mg (72.7 %) 
ESI-MS: [M + H] 375.9 m/z 
UV-vis: 2max = 285 nm (16,516 M'cni') 
'H NMR (90 % H20 / 10 % D20, pH 4.87): 5.71 (s, NH2, 211), 5.29 (d, 15 NH3, 
'J('5N-'H) 73.3 Hz, 311), 2.89 (sextet, CH2, 211), 1.33 (t, CH3, 'J(CH2-CH3) 7.3 Hz, 
3H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N / 5.29, -41.35), 'J(195Pt-'5N) 265.2 Hz, 2J(195Pt-
'H) 46.7 Hz. 
3.2.2.11 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(tz)] (7) 
a) Trans- {PtC12(NH3)(tz)] 
Cisplatin (81.8 mg, 0.273 mmol) was suspended in H20 (2 mL) and thiazole (tz, 
0.819 mmol, 0.058 mL) added. The reaction was stirred at 343 K for 2 h, brought to 
reflux, then cooled. HC1 (3.276 mmol, 0.273 mL) was added and the solution stirred 
at 378 K for 6 h. After cooling to room temperature the product was further 
precipitated by cooling on ice, then filtered, washed with water, ethanol and diethyl 
ether and dried under vacuum. 
Yield: 77.7 mg (77.3 %) 
'H NMR (d6-acetone): 6 9.53 (dd, H-2, 2J2,4 0.9 Hz, 2J2,5 2.4 Hz, 1H), 8.29 (dd, 11-4, 
'J4,5 3.7 Hz, 111), 7.81 (dd, 11-5, 1H), 3.81 (s, NH3, 311). 
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Trans-[Pt(N3)2(NH3)(tz)] 
Trans-[PtCl2(NH3)(tz)] (40.3 mg, 0.110 mmol) was suspended in H20 (20 mL) and 
AgNO3 (1.98 mol eq, 36.9 mg) added. The reaction was stirred in the dark at 333 K 
for 24 h, then filtered with an inorganic membrane filter (Whatman, Anotop 10, 0.02 
j.im). NaN3 (0.440 mmol, 28.6 mg) was added and the solution stirred in the dark at 
room temperature for 24 h. The volume was reduced to 2 mL and the yellow product 
collected by filtration, washed with water, ethanol and diethyl ether and dried under 
vacuum. 
Yield: 32.3 mg (77.4 %) 
'H NMR (d6-acetone): 6 9.42 (dd, H-2, 2J2,4 0.9 Hz, 2J2,5 2.4 Hz, 1H), 8.12 (dd, H-4, 
'J4,5 3.7 Hz, 1H), 7.95 (dd, H-5, 1H), 4.07 (s, NH3, 3H). 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(tz)] 
Trans-[Pt(N 3)2(NH3)(tz)] (31.7 mg, 0.083 mmol) was suspended in H20 (500 mL) 
and H202 (30 %, 0.332 mmol, 0.034 mL) added. After stirring in the dark at room 
temperature for 24 h, the volume was reduced to 15 mL and filtered. All solvent was 
then removed and acetone added to precipitate product. The yellow solid was filtered 
off and washed sparingly with ice-cold water, ethanol and diethyl ether, and dried 
under vacuum. 
Yield: 24.8 mg (71.2 %) 
ESI-MS: [M + H] 415.9 m/z 
UV-vis: 2max = 289 nm (15,234 M'cm'), 236 nm (8,630 M 1 cm1). 
'H NMR (90 % H20 / 10 % D20): 6 9.51 (dd, H-2, 2J2,4 1.0 Hz, 2J2,5 2.4 Hz, 114), 
8.24 (dd, H-4, 'J4,5 3.6 Hz, 1H), 8.04 (dd, H-5, 1H). 
3.2.2.12 Trans, trans, trans-[Pt(N3)2(OH)2(NH3) (2-pie)] (8) 
a) Trans- [PtC12(NH3)  (2-pic)] 
Cisplatin (0.103 g, 0.343 mmol) was suspended in H20 (1 mL) and 2-picoline (1.372 
mmol, 0.1277 g) added. The reaction was stirred at 348 K for 2.5 h and then refluxed 
for 30 mm. The solvent was removed and HC1 (2.7 M, 1.5 mL) added. The solution 
was stirred at 378 K for 5 h then cooled to 277 K for 24 h and filtered. The filtrate 
was returned to heat at 378 K for a further 6 h and then cooled to 277 K and filtered 
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again. The two batches of yellow solid were combined and washed with water, 
ethanol and diethyl ether and dried under vacuum. 
Trans- [PtC]2(' 5NH3)(2-picoline)] was synthesized from 15N-cisplatin. 
Yield: 88.3 mg (68.5 %) 
'H NMR (d6-acetone): 6 8.80 (d, H-6, 'J5.7 Hz, 1H), 7.78 (td, H-4, 'J7.7 Hz, 2J 1.5 
Hz, 1H), 7.43 (d, H-3, '17.7 Hz, 1H), 7.27 (t, H-5, 1H), 3.68 (s, NH3, 'J('5N-'H) 72.0 
Hz, 1H), 3.13(s, CH3, 3H). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N I 3.68, -69.67), 'J(195Pt-15N) 267.0 Hz, 2J('95Pt-
'H) 53.0 Hz. 
Trans-[Pt(N 3)2(NH3)(2-pic)] 
Trans-[PtC12(NH3)(2-pic)] (87.3 mg, 0.232 mmol) was suspended in H20 (50 mL) 
and DMF (0.5 mL). AgNO3 (1.95 mol eq, 76.9 mg) was added and the reaction 
stirred in the dark at 333 K for 24 h. All the solvent was removed and the solid 
redissolved in H20 (50 mL). NaN3 (0.928 mmol, 60.3 mg) was added and the 
solution stirred for 4 h, the volume was then reduced to 3 mL and the bright yellow 
solid filtered, washed with water, ethanol and diethyl ether and dried under vacuum. 
Yield: 81.2 mg (90.0 %) 
'H NMR (d6-acetone): 6 8.95 (d, H-6, '15.9 Hz, 111), 7.89 (td, H-4, 'J 7.7 Hz, 2j  1.7 
Hz, 1H), 7.59 (d, H-3, 1H) 7.42 (t, H-5, 1H), 3.74 (s, NH3, 1 J(15N-'H) 72.0 Hz, 3H), 
3.20(s, CH3, 314). 
2D ['H,'5N] HSQC NMR: 6 ('H, '5N I 3.74, -65.78), 'J('95Pt-'5N) 334.0 Hz, 2J(195Pt-
'H) 55.2 Hz. 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(2-pic)] 
Trans-{Pt(N3)2(NH3)(2-pic)] (80.0 mg, 0.206 mmol) was suspended in H20 (500 mL) 
and H202 (30 %, 0.824 mmol, 0.085 mL) added. The reaction was stirred in the dark 
at room temperature for 24 h and then the volume was reduced to 50 mL. The yellow 
solution was filtered to remove any remaining AgN3 and then reduced to dryness. 
Small amounts of H20 were added and the solid recovered by filtration and washed 
with water, ethanol and diethyl ether then dried under vacuum. Crystals suitable for 
X-ray analysis were grown from H20 at 277 K. 
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Yield: 64.9 mg (73.4 %) 
ESI-MS: [M + Na] 446.6 m/z 
UV-vis: ?max = 292 nm (17,888 M'cm'), 276 nm (sh, 14,500 M'cm') 
'H NMR (90% H20 / 10 % D20, pH 5.04): 6 8.66 (d, H-6, 'J6.4 Hz, 1H), 8.04 (td, 
H-4, '.J 7.7 Hz, 1H), 7.54 (d, H-3, 1H) 7.51 (t, H-5, 1H), 5.67 (d, "NH,, 1J(15N-'H) 
74.2 Hz, 3H), 3.06 (d, CH3, 3H). 
2D ['H,'5N] HSQC NMR: 6 (1 H, '5N I 5.67, -44.65), 'J(195Pt-'5N) 300.6 Hz, 2j(195  Pt-
1H) 50.4 Hz. 
3.2.2.13 Trans, trans, trans- [Pt(N 3)2(OH)2(NH3)(3-pic)] (9) 
Trans-[PtC12(NH3)(3 -pie)] 
Cisplatin (50.3 mg, 0.168 mmol) was suspended in H20 (4 mL) and 3-picoline 
(0.504 mmol, 46.9 mg) added. The reaction was stirred at 378 K for 1 h or until 
colourless, then HC1 (2.02 mmol, 0.168 mL) added. The solution was stirred at 363 
K for 12 h then cooled and placed on ice to precipitate the product, which was 
collected by filtration. The filtrate was returned to heat at 363 K for a further 12 h 
and then cooled and filtered again. The two batches of yellow solid were combined 
and washed with water, ethanol and diethyl ether and dried under vacuum. 
Yield: 31.1 mg (49.3 %) 
'H NMR (d6-acetone): ö 8.66 (s, H-2, 1H), 8.64 (d, H-6, 'J5,6 5.9 Hz, 1H), 7.78 (d, H-
4, 'J45 7.9 Hz, 1H), 7.32 (dd, H-5, 1H), 3.74 (s, NH3, 3H), 2.37 (s, CH3, 3H). 
Trans- [Pt(N3)2(NH3)(3-pic)] 
Trans- [PtCl2(NH3)(3-pic)] (9.5 mg, 0.025 mmol) was suspended in H20 (10 mL) and 
DMF (200 L). AgNO3 (2 mol eq, 8.5 mg) was added and the reaction stirred in the 
dark at 333 K for 24 h. NaN3 (0.100 mmol, 6.6 mg) was added and the solution 
stirred for 24 h, then all the solvent was removed. H20 (2 mL) was added and the 
yellow solid collected by filtration and washed with water, ethanol and diethyl ether 
and dried under vacuum. 
Yield: 7.2 mg (73.2 %) 
'H NMR (d6-acetone): 6 8.59 (s, H-2, 1H), 8.57 (d, H-6, 'J5,6 5.9 Hz, 1H), 7.88 (d, H-
4, If4,5 7.9 Hz, 1H), 7.46 (dd, H-5, 1H), 3.95 (s, NH3, 3H), 2.42 (s, CH3, 3H). 
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Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(3 -pi c)] 
Trans- [Pt(N3)2(NH3)(3 -pic)] (6.9 mg, 0.018 mmol) was suspended in H20 (20 mL) 
and H202 (30 %, 0.071 mmol, 7 tL) added. The reaction was stirred in the dark at 
room temperature for 24 h and then the volume reduced to 3 mL. The yellow 
solution was filtered to remove any remaining AgN3 and then reduced to dryness. 
Small amounts of H20 were added and the solid recovered by filtration and washed 
with water, ethanol and diethyl ether then dried under vacuum. 
Yield: 6.2 mg (81.4%) 
ESI-MS: [M + Na] 424.0 mlz 
UV-vis: ?max = 289 nm (13,575 M'cm') 
'H NMR (90 % H20 / 10 % D20): 8 8.53 (s, H-2, 1H), 8.51 (d, H-6, 1H), 8.07 (d, H-
4, 'J4,5 7.9 Hz, 1H), 7.65 (dd, H-5, 1H), 2.50 (s, CH3, 3H). 
3.2.2.14 Trans, trans, trans- [Pt(N 3)2(OH)2(NH3)(4-pic)J (10) 
Trans-[PtC12(NH3)(4-pic)] 
Cisplatin (0.148 g, 0.494 mmol) was suspended in H20 (4 mL) and 4-picoline (1.483 
mmol, 0.138 1 g) added. The reaction was stirred at 378 K for 1 h or until colourless, 
then HC1 (5.93 mmol, 0.495 mL) added. The solution was stirred at 363 K for 12 h 
then cooled and placed on ice to precipitate the product, which was collected by 
filtration. The filtrate was returned to heat at 363 K for a further 12 h and then cooled 
and filtered again. The two batches of yellow solid were combined and washed with 
water, ethanol and diethyl ether and dried under vacuum. 
Yield: 0.126 g (67.9 %) 
'H NMR (d6-acetone): 8 8.66 (d, H-2, H-6, J(2,63,5)  6.6 Hz, 214), 7.26 (d, H-3, H-5, 
2H), 3.71 (s, NH3, 3H), 2.41 (s, CH3, 3H). 
Trans-[Pt(N 3)2(NH3)(4-pic)] 
Trans- {PtCl2(NH3)(4-pic)] (45.9 mg, 0.122 mmol) was suspended in H20 (40 mL) 
and DMF (200 jtL). AgNO3 (2 mol eq, 41.3 mg) was added and the reaction stirred 
in the dark at 333 K for 24 h. NaN3 (1.22 mmol, 79.4 mg) was added and the solution 
stirred for 24 h, then all the solvent was removed. H20 (2 mL) was added and the 
yellow solid collected by filtration and washed with water, ethanol and diethyl ether 
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and dried under vacuum. 
Yield: 40.0 mg (84.2 %) 
'H NMR (d6-acetone): 8 8.57 (d, H-2, H-6, 1J(2635) 6.6 Hz, 214), 7.41 (d, H-3, 11-5, 
2H), 3.94 (s, NH3, 314), 2.46 (s, CH3, 3H). 
c) Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(4-pic)] 
Trans-[Pt(N3)2(NH3)(4-pic)] (19.4 mg, 0.050 mmol) was suspended in H20 (200 mL) 
and H202 (30 %, 0.20 mmol, 0.020 mL) added. The reaction was stirred in the dark 
at room temperature for 24 h and then the volume was reduced to 20 mL. The 
yellow solution was filtered to remove any remaining AgN3 and then reduced to 
dryness. Small amounts of H20 were added and the solid recovered by filtration and 
washed with water, ethanol and diethyl ether then dried under vacuum. 
Yield: 14.4 mg (68.2 %) 
ESI-MS: [M + Na] 424.0 mlz 
UV-vis: ?rnax = 289 nm (14,318 M' cm') 
'H NMR (90 % H20 / 10 % D20): 8 8.51 (d, H-2, H-6, '.J(2,63,5)  6.8 Hz, 2H), 7.60 (d, 
11-3, H-5, 211), 2.58 (s, CH3, 3H). 
3.2.2.15 Trans, trans, trans- [PtN3)2(OH)2(NH3)(c-HexNH2)] (11) 
a) Trans-[PtC12(N113)(c-HexNH2)] 
Cisplatin (0.127 g, 0.422 mmol) was suspended in H20 (2 mL) and cyclohexylamine 
(c-HexNH2, 1.265 mmol, 0.144 mL) added. After stirring at 343 K for 4 h, HCI (5.06 
mmol, 0.422 mL) was added to the clear solution and heating and stirring was 
continued for a further 6 h. The flask was cooled to 277 K for 12 h then the yellow 
precipitate was collected by filtration, washed with water, ethanol and diethyl ether 
and dried under vacuum. 
Yield: 84.5 mg (52.4 %) 
'H NMR (d6-acetone): 6 3.89 (s, NH2), 3.39 (s, NH3), 2.36 (m, H- 1, 1H), 1.74 (m, H-
2a,5a, 214), 1.58 (d, H-3a,5a, 214), 1.29 (t, 144a, 111), 1.16 (m, H-2b,3b,5b,6b, 4H), 
0.88 (m, H-4b, 114). a are equatorial, b are axial hydrogens. 
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Trans-[Pt(N3)2(NH3)(c-HexNH2)] 
Trans-[PtC12(NH3)(c-HexNH2)] (7.97 mg, 0.021 mmol) was dissolved in DMF (2 
mL), NaN3 (0.044 mmol, 2.87 mg) was dissolved in methanol (0.5 mL) and then the 
two solutions added together and stirred at 298 K for 2 days. The volume was 
reduced and crystals suitable for structure determination were grown at 298 K. 
'H NMR (d6-acetone): 6 4.18 (s, NH2), 3.75 (s, NH3), 2.35 (m, H- 1, 1H), 1.76 (m, H-
2a,5a, 2H), 1.61 (d, H-3a,5a, 2H), 1.33 (t, H4a, 1H), 1.16 (m, H-2b,3b,5b,6b, 4H), 
0.88 (m, H-4b, lH). 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(c-HexNH2)} 
Trans-[Pt(N3)2(NH 3)(c-HexNH2)J (5.0 mg, 0.013 mmol) was suspended in H20 (2 
mL) and H202 (0.500 mmol, 51 iL) was added. After stirring at 298 K for 12 h the 
volume was reduced and the solution stored at 277 K. This produced crystals suitable 
for structure determination. 
ESI-MS: [M + Na] 452.1 mlz 
'H NMR (90% H20 / 10 % D20): 2.94 (m, H- 1, 1H), 2.14 (m, H-2a,5a, 2H), 1.76 (d, 
H-3a,5a, 2H), 1.63 (t, H4a, 1H), 1.35 (m, H-2b,3b,5b,6b, 4H), 1.18 (m, H-4b, 1H). 
3.2.2.16 Cis, trans, cis-[Pt(N3)2C12(NH3)2J (12) 
Cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (31.2 mg, 0.090 mmol) was dissolved in H20 
(10 mL) and HCI (0.359 mmol, 0.030 mL) added. The solution was stirred in the 
dark at room temperature for 24 h, then concentrated and stored at 277 K until 
crystals appeared. These crystals were suitable for X-ray analysis. 
Cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] was used in the preparation of cis, trans, cis-
[Pt(N3)2C12('5NH3)2]. However 21) ['H,'5N] HSQC NMR analysis of the solution 
after stirring for 24 h with 4 mol eq of HCI revealed the presence of several species. 
The solution was concentrated and crystals grown at 277 K. During filtration this 
solid exploded and all work on this compound was stopped. Presumably the 
explosive complex is a side product from the reaction. 
'H NMR (90 % H20 / 10 % D20): 8 5.49 (septet, NH3, 'J('H-' 4N) 105 Hz, 2J('H-
'95Pt) 51.0 Hz, 6H). 
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2D ['H,'5N] HSQC NMR (natural abundance): 8 ('H, '5N / 5.49, -41.27), 'J(195Pt-
15N) 242.7 Hz, 2J(195Pt-1 H) 46.5 Hz. 
ESI-MS: [M + H] 385 mlz 
UV-vis: max = 264 nm 
3.2.2.17 Cis, trans-[Pt(bpy)(N3)2(OH)2] (13) 
[Pt(bpy)C121 
K2[PtC14] (0.151 g, 0.363 mmol) was dissolved in H20 (8 mL) and 2,2-bipyridine 
(bpy) (1.05 mol eq, 59.4 mg) in acetone (2.36 mL) was added. Stirring at 338 K for 
12 h produced a yellow solid which was collected by filtration and washed with 
water, ethanol and diethyl ether, then dried under vacuum. 
Yield: 136.8 mg (89.3 %) 
'H NMR (do-DMSO): 6 9.51 (d, H6,6 , 1J56 5.9 Hz, 2H), 8.59 (d, H3,3 , ' J3,4 8.0 Hz, 
2H), 8.42 (t, H4,4 , ' J45 7.7 Hz, 2H), 7.85 (t, H55 , 214). 
[Pt(bpy)(N3)2] 
[Pt(bpy)C12] (98.5 mg, 0.233 mmol) was suspended in DMF (15 mL) and NaN3  
(0.152 g, 2.14 mmol) added. The solution was stirred for 3 days, and the colour 
changed from bright yellow to orange. The volume was reduced to 1-2 mL and H20 
added to precipitate the product. [Pt(bpy)(N3)2] was filtered off and washed with 
water, ethanol and diethyl ether then dried under vacuum. Crystals suitable for X-ray 
structure determination were grown from DMF at 277 K. 
Yield: 93.1 mg (91.7 %) 
'H NMR (d6-DMSO): 6 8.91 (d, H66 , 'J56 5.7 Hz, 2H), 8.57 (d, H3,3 , 'J3,4 8.0 Hz, 
2H), 8.40 (t, H4,45 'J45 7.7 Hz, 2H), 7.82 (t, H55 , 2H). 
Cis, trans-[Pt(bpy)(N3)2(OH)2] 
[Pt(bpy)(N3)2} (7.8 mg, 0.018 mmol) was suspended in H20 (1.5 mL) and acetone 
(0.5 mL). H202 (0.036 mmol, 3.7 jiL) was added and the mixture stirred at 298 K for 
24 h. After being left to evaporate to dryness in the back of a fume hood, H20 (7 mL) 
was added. There was no dissolution therefore oxidation had not occurred. H202 
(0.720 mmol, 73 jit) was added and the solution stirred for 24 h and again left to 
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evaporate in the back of a fume hood. Crystals appeared after several weeks and 
were submitted for X-ray structure determination. All attempts to repeat this 
synthesis were unsuccessful. 
ESI-MS: [M + H] 470.1 m/z, [M + Na] 492.0 mlz. 
'H NMR (d6-DMSO): ö 9.03 (d, H66 , J56 5.8 Hz, 2H), 8.82 (d, H,y, 1i3,4 7.7 Hz, 
211), 8.48 (t, H4,4 , J4,5 7.7 Hz, 2H), 8.03 (t, 	2H). 
3.2.2.18 Trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) 
Acetic acid (>99 %, 0.82 mL) was added to a small amount of [Pt(bpy)(N3)2] (17.8 
mg, 0.041 mrnol), then H202 (30 %, 0.410 mmol, 42 j.iL) was added and the 
suspension stirred for 24 h. 
Caution! Mixing H202 and acetic acid can result in the formation of explosive 
compounds)191 No such reactions were reported in references which used a similar 
oxidation procedure to that described here. [20,2  11 However, care was taken and the 
reaction was carried out on a small scale behind a blast screen. 
The bright orange solution produced was left to evaporate at the back of the fume 
hood. After 24 h, 100 mL 1120 was added to the dry vessel, after stirring and 
sonicating briefly any undissolved solid was removed by filtration. The volume was 
reduced to 3 mL. A precipitate appeared, the solution was then refiltered and stored 
at 277 K for crystallization. Crystals suitable for X-ray structure determination were 
obtained. 
1H NMR (90 % H20 / 10 % D20): 8 9.27 (d, H6,6, I J5,6 5.8 Hz, 2H), 8.56 (d, H3,3 , 
J3,4 8.1 Hz, 2H), 8.43 (t, 114,4', 1i4,5 7.9 Hz, 2H), 7.98 (t, H5,5 , 2H), 1.84 (s, CH3, 6H). 
ESI-MS: [M + H] 554.1 mlz; [M + Na] 576.0 mlz 
UV-vis: 250 nm ( = 19,102 M'cm), 304 nm (8 = 11,402 M'cm'), 315 nm (c 
9,756 Mcm'). 
3.2.2.19 Trans, cis- [Pt(phen)(OAc)2(N3)2] (15) 
a) [Pt(phen)C12] 
Synthesised by the same method as [Pt(bpy)C121. 
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Yield: 82.3 % 
'H NMR (d6-DMSO): 6 9.71 (d, H2,9, ' J 5.3 Hz, 2H), 9.05 (d, H47, ' J 8.3 Hz, 2H), 
8.30 (s, H56, 2H), 8.18 (d, H3,8, 214). 
[Pt(phen)(N3)2] 
Synthesised by the same method as [Pt(bpy)(N3)2]. Crystals suitable for structure 
determination were grown from DMF at 277 K. 
Yield: 82.8 % 
'H NMR (d6-DMSO): 6 9.20 (d, H2,9, ' J 5.3 Hz, 2H), 9.02 (d, H4,7, ' J 8.3 Hz, 214), 
8.28 (s, H5,6, 2H), 8.14 (d, H3,8, 2H). 
Trans, cis-[Pt(phen)(OAc)2(N3)2] 
Synthesised by the same method as trans, cis-[Pt(bpy)(OAc)2(N3)2]. Crystals suitable 
for structure determination were grown from water at 277 K. 
'H NMR (90 % H20 /10 % D20): ö 9.52 (d, H2,9, ' J5.3 Hz, 2H), 8.95 (d, H4,7, ' J8.3 
Hz, 2H), 8.30 (s, H5,6, 214), 8.27 (d, H3,8, 2H), 1.74 (s, CH3, 3H). 
UV-vis: 204 nm, 224 nm (sh), 271 nm, 304 nm (sh). 
3.2.2.20 Trans-[Pt(N3)2(py)2] (16) 
Trans-[PtC12(py)2] 
K2[PtC14] (0.136 g, 0.327 mmol) was dissolved in H20 (3.3 mL) and pyridine (8.18 
mmol, 0.66 mL) in H20 (6.6 mL) was added. After stirring at 358 K for 1 h, a clear 
solution was obtained, removal of all the solvent left a white solid. This solid was 
redissolved in HCI (1 M, 3.5 mL). After stirring at 348 K for 24 h, then cooling to 
277 K for 2 h the yellow solid was collected by filtration, washed with water, ethanol 
and diethyl ether, then dried under vacuum. 
Yield: 49.3 g (35.5 %) 
'H NMR (d6-acetone): 6 8.90 (dd, H0, 'Jo,m = 6.6 Hz, 2J0,, = 1.7 Hz, 4H), 8.03 (tt, H, 
'Jp,m = 7.7 Hz, 2H), 7.53 (dd, f1m, 4H). 
Trans-{Pt(N3)2(py)2] 
Trans-[PtCl2(py)2 J (48.6 mg, 0.115 mmol) was suspended in DMF (200 L) and H20 
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(10 mL) and AgNO3 (1.98 mol eq, 38.6 mg) added. After stirring at 333 K overnight 
the AgC1 precipitate was filtered off with an inorganic membrane filter (Whatman, 
Anotop 10, 0.02 j.im). NaN3 (0.4584 mmol, 29.8 mg) was added and the solution 
stirred for 4 h. All solvent was removed and acetone added, the undissolved AgN3  
and excess NaN3 were collected leaving a yellow solution. All solvent was removed 
again, small amounts of H20 added and the yellow solid of trans-[Pt(N3)2(py)2] 
filtered off, washed with water, ethanol and diethyl ether, then dried under vacuum. 
Yield: 34.0 mg (67.9 %) 
'H NMR (d6-acetone): 6 8.86 (dd, H0, 'Jo,m = 6.6 Hz, 2J0,,, = 1.7 Hz, 4H), 8.12 (tt, H, 
1Jp,m = 7.7 Hz, 2H), 7.67 (dd, H11 , 4H). 
3.3 	Results and Discussion 
Caution! Heavy metal azides (e.g. Pb(N3)2 and Hg(N3)2) are known to be 
shock sensitive detonators, therefore it is essential that any platinum azide 
compound be handled with extreme care. It is important to avoid the 
application of any pressure to these materials in the crystalline form. 
The structures of all the Pt" azide complexes synthesised can be found in 
Appendix 1. 
3.3.1 Cis-[Pt12(NH3)2] 
Cis-[Pt12(NH3)2] was synthesized according to the Dhara method. 221 The chloride 
ligands of K2[PtC14] were replaced by iodide before the addition of NH4 . The 
stronger trans-directing effect of iodide [23]  ensures that only the cis diammine isomer 
is produced. The pH was adjusted to 10 to increase the concentration of ammonia. 
The purity of the product was checked by CHN, or by NMR spectroscopy when 15N-
labelled. 
3.3.2 Cis-[PtC12(NH3)2] (Cisplatin) 
Cisplatin was synthesized from cis-[Pt12(NH3)2] by removal of the iodide ligands 
with silver nitrate (AgNO3) which readily forms the insoluble silver salt AgI. The 
reaction was accelerated by heating to 333 K, and carried out in the dark due to the 
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photoactivity of silver. Slightly less than 2 molar equivalents of AgNO3 were used to 
avoid any excess silver in the product. Inorganic membrane filters had previously 
been found to be the best filtration method for removal of AgI. 241 The complex now 
contains aqua ligands in place of the iodide ligands and is therefore more reactive 
towards the entering chlorides. Cis-[PtC12(NH3)2] is much less soluble than cis-
[Pt(0H2)2(NH3)2] (NO3)2 and so precipitated when the volume was reduced. 
The yellow solid was characterized by CHIN and 1D ['H] NMR spectroscopy in d6-
DMSO, or by 1D ['H] and 2D ['H,'5N] NMR spectroscopy in 90 % H20 / 10 % D20 
when '5N-labelled. After preparing the NMR sample in d6-DMSO, it was essential to 
record the spectrum immediately as platinum compounds are reactive to DMSO 
which can bind as a ligand. Indeed this reaction was followed by NMR to ensure the 
original peak observed was due to cisplatin and not a DMSO-adduct. The chemical 
shifts of the peak in the 2D spectrum agreed well with literature values. [251  
3.3.3 Trans- [PtC12(NH3)21 (Transplatin) 
Transplatin was prepared by the published method. [261  Excess ammonia was added to 
cisplatin which resulted in the displacement of the two chloride ligands to form the 
tetra-ammine complex [Pt(NH3)41C12. Removal of the solvent was necessary to get 
rid of the excess ammonia, and if the reaction was complete a pure white solid was 
produced. Addition of HCl resulted in two chloride ligands binding to platinum trans 
to each other due to the greater trans-directing effect of chloride compared to 
ammonia. [41  The first ammonia is labilized at low pH and subsequently substituted by 
chloride. This, in turn, directs the second chloride ligand into the trans position. 
Transplatin was characterized in the same way as cisplatin. It is more reactive than 
cisplatin and even if the NMR spectra were recorded immediately after preparation 
in either d6-DMSO or 90 % H20 / 10 % D20, peaks corresponding to a DMSO-
adduct or the mono-aqua species trans-[PtCI(OH2)(NH3)2] were seen. However, 
aquation in the aqueous sample was avoided by the addition of excess NaCl. The 
NMR spectra were recorded in d6-DMSO to check for cisplatin impurities in 14N-
transpiatin, the Pt-NH 'H NMR resonances for Pt am(m)ine complexes are not easily 
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detected in D20 solutions as the half-life for H-D exchange is only a few minutes at 
ambient temperatures. L291 Even though the peaks are broad, the chemical shifts of 
transpiatin and cisplatin are far enough apart (4.39 ppm and 3.96 ppm, respectively) 
to enable the detection of impurities. 
The preparation of 15N-transplatin first involved the synthesis of the tetra-ammine 
from '5N-cisplatin using excess 15NH4C1. The pH was increased to provide a high 
enough concentration of NH3 to bind to platinum, as described for the synthesis of 
cis-[Pt12(NH3)2]. After this, the method was continued as for 14N-transplatin. 
Characterization was by 2D [1 H,15N] HSQC NMR spectroscopy and the peaks 
agreed well with literature values. [251 
3.3.4 [Pt(en)C121 
[Pt(en)C12] was synthesized from an aqueous solution of K2[PtCI4] by adding 
ethylenediamine, which had been purified by distillation and stored under argon. 
Upon addition of en, the product immediately began to precipitate. The labelled 
compound [Pt(15N-en)C12] had been previously synthesized by Dr. Phil Muller from 
15N-en.2HCI by the literature method. [271  The chemical shifts in the 1D ['H] and 2D 
['H,'5N] NMR spectroscopy agreed well with the literature values. 251  
3.3.5 Cis, trans, cis- [Pt(N3)2(OH)2(NH3)21 (1) 
Cis, trans, cis-[Pt(N 3)2(OH)2(NH3)J was synthesized using the method described by 
Dr. Phil MUller. 241 The azides are inserted after first removing the chloride ligands 
from cisplatin with AgNO3 to produce cis-[Pt(NH3)2(0H2)2](NO3)2, and then adding 
excess NaN3. A 20-fold molar excess of NaN3 was used to accelerate the reaction, 
upon addition the solution immediately turns from colourless to bright yellow. This 
colour change is caused by azide binding to platinum, which leads to a ligand-to-
metal charge-transfer band (LMCT) in the visible region of the spectrumJ'° The 
product cis-[Pt(N3)2(NH3)2] is much less soluble in water than NaN3 and so the 
excess azide salt stays in the solution. 
Oxidation from Pt" to Pta' was carried out with H202 (30 % vol/vol) which was also 
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added in a large excess (40 mol eq). In the syntheses described later these reagents 
(NaN3 and H202) were not used in such large amounts as it was found to be 
unnecessary. 
The UV-visible spectrum of 1 contains one main absorption band at 256 nm (Emax 
13,700 M'cm) which is assigned as a LMCT band from the azide ligand to 
This band has a tail which extends out into the visible region. The extinction 
coefficients at the various excitation wavelengths used for photoactivation are listed 
in Table 3.1. 
The 1D ['H] and 2D ['H,'5N] HSQC NMR spectroscopy results agreed well with the 
published values. '7'241 The '95pt NMR spectrum was also recorded and a peak at + 
902 ppm was observed. This is in the expected region and compares well with the 
195Pt chemical shift of cis, trans, cis-[PtCl2(OH)2(NH3)2] of+ 860 ppm. 28' 
The aqueous solubility of 1 is ca. 13 mM. It is one of the least soluble compounds 
synthesized in this work. Solubility properties and electronic absorption spectra are 
discussed and compared in more detail in section 3.3.7. 
3.3.6 Cis, trans- [Pt(en)(N3)2(OH)21 (2) 
Cis, trans-[Pt(en)(N3)2(OH)2] was also synthesized using the method of Dr. Phil 
Miffler. [17,211  The LMCT absorption band is centred at 258 nm with an extinction 
coefficient of 14,300 M'cm' which is higher than that of 1. However, the aqueous 
solubility of 2 was lower (ca. 9 mM) when compared with 1. 
3.3.7 Trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) 
The synthesis of trans-[Pt(N3)2(NH3)2] was carried out in a similar way to that of 
cisplatin. The chlorides were removed from trans-[PtCl2(NH3)2] with AgNO3, which 
resulted in the formation of the insoluble AgCl This reaction did not go to 
completion. The first chloride is easily lost, but it is very difficult to remove the 
second. After the AgCl has been filtered off, excess NaN3 was added and a yellow 
colour immediately appeared, however, a cloudy precipitate was also formed. A 
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yellow colour was produced by the formation of platinum-azide bonds which have a 
LMCT band in the visible regionJ101 The cloudy precipitate was AgN3 which, like 
the silver halides is also insoluble in water. At this point there was probably still 
some platinum-bound chloride, and so to remove this, the mixture was stirred for at 
least 24 h. During this time any residual bound chloride was replaced by azide. The 
yellow solid trans-[Pt(N3)2(NH3)2J was recovered by filtration but AgN3 was also 
still present. The product was resuspended in water and 8 molar equivalents of H202 
(30 % vol/vol) added. The progress of the reaction was easily followed by observing 
the dissolution of the yellow solid. This left a cloudy yellow solution, from which the 
AgN3 impurity was removed by filtration. It was found unnecessary to add 40 molar 
equivalents of hydrogen peroxide to oxidize Pt" to Pt1v, (as' for previous 
syntheses), '7'241 the reaction was found to occur almost as fast with only 8 
equivalents. Smaller volumes of H202 are safer and easier to handle, especially when 
the solutions are concentrated for crystallisation of the product. 
The '5N chemical shift of an am(m)ine is dependent on the ligand trans to it. [2'1 The 
2D ['H,'5N] HSQC NMR chemical shifts of trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] 
('H, '5N / 5.32, -41.65) are in the expected region for a Pt''-NH3 unit with a nitrogen 
ligand in the trans position. [2'1 The 'J('95Pt-'5N) value of 282 Hz is also in the range 
expected for an amine trans to ammonia. 29 The purity of the product was confirmed 
by the presence of only one cross-peak. 
A 195  Pt NMR peak at 875 ppm was observed. This peak is shifted to a higher field 
compared to that of complex 1 (902 ppm), which agrees with published data for PtIV 
cis / trans isomers. 30'311 This could possibly be explained by the trans influence, 
which is discussed in Chapter 1. By comparing the Pt-N bond lengths of the azide 
ligands for the two isomers it can be seen that the trans isomer (3) contains longer 
Pt-azide bonds (2.045 A cf. 2.034 A). This longer bond would result in more electron 
density on the platinum centre and consequently more shielding and a shift to higher 
field. 
The positive electrospray mass spectrum exhibited a peak with the typical platinum 
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isotope pattern at 370.1 m/z which can be assigned as the sodium adduct ([M + Na] 
= 347.0 + 23). 
The purpose of synthesising the trans isomer (3) was to investigate whether Pt"  
diazido compounds retained their photoactivity and DNA binding ability when the 
azides were trans to one another. Not only was trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2] found to be as (if not more) photoactive than the cis isomers, 
several other properties were also enhanced. These include the solubility, the 2 max 
and the extinction coefficient. The solubility of 3 is ca. 19 mM, whereas the 
solubility of 1 is only ca. 13 mM. 
Figure 3.2 Electronic absorption spectra of cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (1) 
(dashed line) and trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) (solid line). 
The LMCT band of the trans isomer is shifted towards the visible region with a 
maximum at 285 nm, compared to 256 nm for the cis isomer (Figure 3.2). This is 
quite a significant wavelength increase and means the "tail" of the absorbance will 
extend further into the visible region (Table 3.1). The magnitude of the extinction 
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coefficient was also increased (19,500 M'cm' cf. 13,305 M'cm') . The increase in 
2 max can be accounted for in a similar way to the 195Pt chemical shift change. In cis, 
trans, cis-[Pt(N3)2(OH)2(NH3)2] the azides are more tightly bound and so A0 will be 
greater and hence the LMCT band energy increases. So by simply changing the 
geometry, several important properties have been improved. 
3.3.8 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)] (4) 
The synthesis of trans-[PtCl2(NH3)(py)] was carried out in a similar way to the 
published method, [321 but with some conditions changed slightly to improve the yield. 
The first step in the synthesis involved replacing the chlorides of cisplatin with 
pyridine. Only a slight excess (3 molar equivalents) of pyridine was required for this 
step. Incorporation of chloride ligands in a trans position was accomplished by the 
addition of HC1, as in the synthesis of transplatin. Increasing the temperature can 
increase the rate of the reaction, however this can also lead to decomposition and the 
formation of black Pt°. The yield was slightly improved by cooling and filtering the 
reaction after 2 days, and then continuing to heat the filtrate as before for a further 2 
days. 
The synthesis of trans- [Pt(N3)2(NH3)(py)] was carried out as for the preparation of 
trans-[Pt(N3)2(NH3)2]. Occasionally a small amount of chloride was found (by NMR 
spectroscopy), to be still bound to platinum. This can be rectified by resuspending 
the product in plenty (ca. 50 mL for 10 mg sample) of water and stirring with 10-20 
molar equivalents of NaN3 for a further 24 h. 
Oxidation of trans- [Pt(N3)2(NH3)(py)] was relatively difficult compared to most of 
the other compounds synthesised. This is believed to be due to its insolubility. A 
large volume of water was required in order to solubilise sufficient complex for the 
oxidation step, however only a small amount of H202 (:!~ 6 mol eq) could be used 
because the product trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] was extremely 
water soluble. All of the solvent had to be removed to recover the product and any 
significant amount of excess H202 could have made this unsafe. Hydrogen peroxide 
has a significantly higher boiling point than water (414 K), and so there is the 
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potential for the production of a concentrated solution of H202. 
The NMR chemical shifts of trans, trans, trans-[Pt(N3)2(OH)2('5NH3)(py)J ('H, '5N / 
5.65, -46.00) are similar to those of trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] (1 H, 
"5N / 5.32, -41.65), and the coupling constants also compare well (Table 3.2). 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] was designed with trans geometry, in 
the hope that it would retain some of the beneficial properties of trans, trans, trans-
{Pt(N3)2(OH)2(NH3)21. The pyridine ring was incorporated in place of one of the 
ammonia ligands because it was thought that the presence of an aromatic group 
might improve the photoactivity. The LMCT absorption band shifted only slightly 
(Xmax 289 nm), and the extinction coefficient was lower than that of trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)2] (18,880 cf. 19,500 M'cm'), but an extra band appeared 
as a shoulder at 268 nm due to the pyridine ring. Free pyridine in water was found to 
absorb at 256 nm, and a red shift on metal complexation is expected. 331 Trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)(py)] was, however, very soluble in water giving 
concentrations of> 50 mM. 
3.3.9 Trans, trans, trans- [Pt(N3)2 (OH)2(NH3) (MeNH2)] (5) 
The synthesis of trans-[PtC12(NH3)(MeNH2)] was carried out under nitrogen, as 
extremely low yields were obtained for this reaction in air. The 'H NMR spectra of 
the reaction mixture indicated the presence of Pt" species and so it was concluded 
that oxidation was taking place. Oxidation from Pt" to Pt"' in aqueous solution has 
been observed for similar compounds. [34] It was important not to place the flask 
containing cisplatin and methylamine into a hot oil bath because of the volatility of 
methylamine. Cooling, filtering and then reheating the filtrate several times was 
found to improve the yield. Trans-[Pt(N3)2(NH3)(MeNH2)] was prepared in a similar 
way to trans-[Pt(N3)2(NH3)2] and trans-[Pt(N3)2(NH3)(Dy)], and was then easily 
oxidised using only 4 equivalents of hydrogen peroxide. 
The absorption spectrum of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(MeNH2)] closely 
resembles that of trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (Table 3.1), which is not 
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surprising as their structures are very similar. Trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(MeNH2)] is the more soluble compound though and the aqueous 
solubility is > 20 mM. 
3.3.10 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(EtNH2)] (6) 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(EtNH2)] was synthesised in the same way as 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(MeNH2)] except that it was not necessary to 
prepare trans-[PtC12(NH3)(EtNH2)] under nitrogen as no oxidation in air was 
observed. 
The absorption spectrum contains a band in exactly the same position as trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)2] and the extinction coefficient is 16,516 M' cm- '. The 
NMR chemical shifts ('H, '5N / 5.29, -41.35) are also very close to those of trans, 
trans, trans- [Pt(N3)2(OH)2(' 5NH3)2] ('H, '5N/ 5.32, -41.65). 
3.3.11 Trans, trans, trans-IPt(N3)2(OH)2(NH3)(tz)J (7) 
The synthesis of trans-[PtC12(NH 3)(tz)] has been described previously, [351  however 
this method led to relatively low yields (ca. 50 %) and recrystallisation was 
necessary to obtain a pure product. It was found that high yields of pure trans-
[PtC12(NH3)(tz)J could be obtained by a similar method to that of trans-
[PtC12(NH3)(py)]. The preparation of trans-[Pt(N3)2(NH3)(tz)] and subsequent 
oxidation were also carried out in the same way as for trans-{Pt(N3)(NH 3)(py)] and 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)]. This is because of the similarities 
between the respective compounds, i.e. the insolubility of the diazido-Pt" species and 
the solubility of the Pt'"  product. The N3 - Pt LMCT band is centred at 289 nm and 
has an extinction coefficient of 15,234 M- cm There is also a peak at 236 nm due 
to absorption by the thiazole ring. Free thiazole in water absorbs at 233 nm. 
The X-ray crystal structures of trans-[PtC12(tz)2] and trans[PtCl2(NH3)(tz)] have 
been determined by the Farrell group. [11,36]  In both cases platinum is bound to the 
nitrogen atom of thiazole. Although Pt" is a soft metal centre and is known to have a 
large affinity for sulphur donors, calculations on the electronic structure of thiazole 
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have shown that the net charge of the thioether-type sulphur is positive. 361 The 
negative charge resides on the nitrogen and it is therefore a much better donor to 
platinum. For this reason it is assumed that trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(tz)] also has thiazole bound through the nitrogen. 
3.3.12 Trans, trans, trans- IPt(N3)2(OH)2(NH3)(2-pic)1 (8) 
Cis-[PtCl2(NH3)(2-pic)] is currently in Phase I Ill clinical anticancer trials, [371  and is 
discussed in more detail in Chapter 1. The steric hindrance caused by the methyl 
group is believed to destabilize the trigonal bipyrarnidal transition state formed 
during deactivating substitution reactions, thereby leading to enhanced cytotoxicity. 
The promising phototoxicity of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] against 
several different cell lines (Appendix 2), led to the design of complexes containing 
substituted ring systems in an attempt to gain some insight into the structure-activity 
relationships of these PtIVazide  compounds. 
Trans-[PtCl2(NH3)(2-pic)] was prepared in the same way as trans-[PtC12(NH3)(py)J. 
An alternative preparation with slightly higher yields (- 80 % cf. 70 %) uses cis-
[PtC12(2-pic)2] as the starting material instead of cisplatin, 381 but due to the extra 
steps and only a slight improvement in the yield this method was not used. 
For the silver nitrate reaction, it was decided to add a small amount of DMF (0.5 mL) 
to help solubilise the Pt"  starting material and hopefully allow the reaction to go 
further towards completion. However, upon addition of NaN3 a precipitate was still 
produced. This precipitate may be the silver salt AgN3 which is one of the more 
shock sensitive metal azides. Care should be taken and the formation of this 
compound in large amounts avoided. Trans-[Pt(N3)2(NH3)(2-pic)] was very insoluble 
in water and so the oxidation step was always carried out in a large volume of water, 
as for the pyridine- and thiazole- containing complexes. 
The NMR chemical shifts compare well with those of trans, trans, trans- 
[Pt(N3)2(OH)2(NH3)(py)] (Table 3.2). The LMCT (N3 - Pt) band in the electronic 
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absorbance spectrum is at 292 nm (Table 3.1). This is at a longer wavelength than 
any of the other Pt' azide compounds synthesised. There is also an absorbance at 
276 nm from the 2-picoline ring. Although trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-
pie)] does not retain the high aqueous solubility seen for trans, trans, trans-
{Pt(N3)2(OH)2(NH3)(py)], it is still reasonably soluble (ca. 20 mM). 
3.3.13 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(3-pic)1 (9) 
Problems with spontaneous oxidation to Pt"  occurred during the synthesis of trans, 
trans. trans- [Pt(N3)2(OH)2(NH3)(3-pic)]. This was not surprising as oxidation in 
aqueous solutions of Pt" 3-picoline compounds has been previously observed. 391  
Methyl substituents in positions 2 and 4 on the ring have an electron-donating effect 
and so increase electron density on the platinum centre. This means that nucleophilic 
attack is less favourable. The opposite is true of 3-picoline as it is electron 
withdrawing and so promotes nucleophilic attack, resulting in a Pt" product. 
3.3.14 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(4-pic)I (10) 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-pic)] was prepared in a very similar way to 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)]. The LMCT (N3 - Pt) band was at 
289 nm with the absorbance from the ring at 274 nm. 
3.3.15 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(c-HexNH2)] (11) 
A Pt'" compound containing a cyclohexylamine ring is currently in Phase II clinical 
trials. 401 Satraplatin, also known as JM2 16 (trans, cis, cis- [Pt(OCOCH3)2Cl2(NH3)(c-
HexNH2)] is discussed in more detail in Chapter 1. Problems were encountered 
during the synthesis of 11 and often the Pt" species oxidized to Pt" in water. Pt"' N-
H NMR peaks were seen in the 'H spectra carried out in d6-acetone. This may be the 
reason for the relatively low yield of trans-[PtC12(NH3)(c-HexNH2)] ('- 50 %), and is 
why the chlorides were converted to azides in DMF / methanol rather than by the 
usual silver nitrate method in water. Unfortunately this reaction was only successful 
once, every other attempt gave a mixture of products, thought to be DMF adducts. 
However, crystals of both the pt" and Pt" diazido-compounds were successfully 
grown and the structures of the complexes determined (Chapter 4). 
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It would be interesting to investigate the phototoxicity of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(c-HexNH2)] due to its structural similarities to JM2 16, however 
the synthesis would have to be optimized to produce sufficient amounts for these 
studies. 
3.3.16 Cis, trans, cis-[Pt(N3)2C12(N113)2] (12) 
Cis, trans, cis-{Pt(N3)2C12(NH3)2J was synthesized to determine whether replacing 
the hydroxide ligands with chloride had an appreciable effect on the photoactivity. 
The chloride concentration outside cells is ca. 0.1 M and it has previously been 
shown that cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] can react with NaCl (0.1 M) to 
produce cis, trans, cis- [Pt(N3)2C12(NH3)21 [24]  
There are two possible synthetic routes to cis, trans, cis-[Pt(N3)2C12(NH3)2]. The 
hydroxide ligands of cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] can be replaced with 
chloride using HCI, or the chlorides can be added by oxidation of cis-[Pt(N3)2(NH3)2] 
with Pd 5 or chlorine gas. Previous work which involved the synthesis of the 
carboplatin analogue trans, cis- [Pt(cbdca)Cl2(NH3)2] found that replacement of the 
hydroxide ligands using HCI is the best method. [24] 
The presence of chloride in the product was confirmed by the isotope splitting 
pattern in the mass spectrum (Figure 3.3). Crystals were submitted for X-ray 
structure determination and it was confirmed that the hydroxides had been replaced 
by chlorides. 
The synthesis was repeated using cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2J as the 
starting material so that the photoactivity of the products could be followed by 2D 
['H,'5N] HSQC NMR spectroscopy. After 24 h, 200 pL of the solution was removed 
for NMR spectroscopic analysis. Several peaks could be seen, but the main peak 
corresponded to cis, trans, cis-[Pt(N3)2C12(NH3)2]. The solution was concentrated 
and crystals grown at 277 K. These crystals were filtered and dried but while 
weighing them out with a polystyrene spatula a small explosion occurred within the 
glass vial. A black solid coated the inside of the vial but it did not break. It was 
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thought perhaps the crystals had accidently been put under pressure between the 
glass and the spatula. More crystals had grown in the filtrate and so these were 
filtered. Upon dropping the second drop of crystals and supernatant onto the filter 
paper, again there was a small explosion. The second explosion is less likely to have 
been caused by the crystals being put under pressure, but could have been due to two 
crystals knocking together and then detonating. 
a) 
Figure 3.3 Positive ion electrospray ionisation mass spectroscopy of cis, trans, cis-
[Pt(N3)2C12(NH3)2]. a) Simulated spectrum for PtN8H6C12, b) Observed spectrum of 
cis, trans, cis-[Pt(N3)2C12(NH3)2] in water. 
3.3.17 Cis, trans- [Pt(bpy)(N3)2(OH)21 (13) 
One of the methods employed to extend the wavelength of absorption into the visible 
region was to incorporate chelating aromatic ligands. Platinum(II) complexes such as 
[Pt(N-N)X2] (where N-N = bpy or phen, and X = Cl or N3) absorb relatively strongly 
at wavelengths > 350 nm.1"I Although it has been stated that LF excitation does not 
lead to photoactivation,'°1 evidence of reduction upon irradiation at wavelengths 
where only ligand-field transitions are present has been reported. [42431  These 
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photoreductions are believed to be due to internal conversion or intersystem crossing. 
The wavelength of absorption can be further increased by careful choice and 
positioning of substituents on the aromatic rings. [44-46] 
Platinum(II) a.-diimine complexes are capable of photosensitizing the production of 
singlet oxygen ( b 02).[47491 The efficiency of photogeneration of 1 02 has been 
investigated for the compounds [Pt(Me-bpy)X2] (where X = N3 , C1, F, NO2 , ) and 
[Pt(N-N)X2] (where N-N = phen or bpy and X = N3 , Cl-, F, Br, SCN or CN). 57'58' 
In all cases the most efficient photosensitizers were the azide-containing complexes. 
[Pt(Me-bpy)(N3)2] was found to be 34.6 % as efficient as hematoporphyrin-IX (a 
precursor of PDT porphyrin drugs). 
Several groups have investigated the cytotoxicity of Pt"-bipyridine compounds. 
Complexes containing chelating amino acids have shown growth inhibition against 
P-388 lymphocytic leukemic cells, [50,511  and work has now turned to dinuclear 
compounds. [12,531  Another active compound found to have an IC50 value comparable 
to that of cisplatin is the carboplatin analogue {Pt(bpy)(cbdca)]. 54 I However, no 
examples of cytotoxicity testing on Pt"'-bipyridine compounds could be found. 
[Pt(bpy)C12] and [Pt(bpy)(N3)2] were synthesised by known procedures, where the 
chloride ligands were substituted for azides in DMF by stirring at 298 K for several 
days. 41'551 The silver nitrate method was not used to remove the chlorides because 
this reaction has been reported to produce an oxygen-bridged dimer which can only 
be cleaved under harsh conditions (e.g. boiling in acid). [561  Upon complexation of the 
bipyridine to Pt", a low-field shift of the ligand protons is observed in the 'H NMR 
spectrum. Subsititution of the chloride ligands of [Pt(bpy)C12} for azide ligands leads 
to a high field shift of the bipyridine protons, due to the stronger bonding of azide 
ions to the platinum centre and the larger degree of back bonding from platinum to 
bipyridine. 4'1 
The photoactivity of [Pt(bpy)(N3)2] has been investigated, 57'581 but no examples of a 
Pt"-bpy-azide complex could be found in the literature. The attempted oxidation of 
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[Pt(bpy)(N3)2] with H202 repeatedly failed. This is believed to be due to the stability 
of the Pt" complex. The it-bonding of ligands such as bipyridine and phenanthroline 
imparts some aromatic character to the chelate ring. They are it-acceptors and so help 
to stabilise compounds. [59] 
In [Pt(bpy)(N3)2], the highest occupied molecular orbital (HOMO) is the metal-based 
d22 orbital, and the lowest unoccupied molecular orbital (LUMO) is the 	orbital 
situated on the bipyridine. (33,41,581  The transition between the HOMO and LUMO 
leads to a metal-to-ligand charge-transfer (MLCT) band corresponding to the lowest 
energy absorption in the UV-visible spectrum. The analogous palladium compound 
{Pd(bpy)(N3)2] is harder to oxidise as the energy of the d22 orbital is lower and thus 
the MLCT band is at a higher energyJ33' By the same reasoning, changing the energy 
of the LUMO also leads to compounds which are easier to oxidise and have 
absorption at longer wavelengths. [4  Electron-withdrawing groups lower the LUMO; 
bipyridine is more electron withdrawing than phenanthroline and consequently is 
easier to oxidise and has its MLCT band at a slightly longer wavelength. The 
decrease of electron density by electron-withdrawing groups on the metal centre also 
promotes nucleophilic attack. 611  
Most oxidations of [Pt(bpy)X2] compounds found in the literature were carried out 
under conditions which could not be used in the presence of azide ligands (eg. high 
temperatures, photocatalysis). 60621 Eventually a preparation which had been left to 
sit for several weeks was found to contain yellow crystals of cis, trans-
[Pt(bpy)(N3)2(OH)2]. 
3.3.18 Trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) 
The exchange of hydroxide ligands for acetate ligands on Pta' diazido complexes has 
previously been carried out by Dr. Phil Miller, who synthesised trans, cis, cis-
{Pt(OCOCH3)2(N3)2(NH3)2] from cis, trans, cis- [Pt(N3)2(OH)2(NH3)2] in 
dichloromethane and acetic anhydride. The acetate complex was found to be 
photoactive upon irradiation with blue light, but no further studies (e.g. DNA 
binding) were carried out. [24] 
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The oxidation of a Pt"-bpy complex in acetic acid has been reportedJ201 Hydrogen 
peroxide is the oxidising agent and the reaction is carried out at room temperature. 
This method was found to be successful for the oxidation of [Pt(bpy)(N3)2] to 
produce trans, cis- {Pt(bpy)(OCOCH3)2(N3)2]. 
Initially a mixture of products was obtained, as well as trans, cis-
[Pt(bpy)(OCOCH3)2(N3)2], several other compounds including cis, trans-
[Pt(bpy)(N3)2(OH)2] and trans, cis- [Pt(bpy)(OCOCH3)(N3)2(OH)] were also present. 
Purification was carried out by recrystallisation from water. Further recrystallisation 
of the filtrate produced crystals of trans, cis-[Pt(bpy)(OCOCH3)(N3)2(OH)] as 
confirmed by 'H NMR and ESI-MS. From the 'H NMR spectrum of the unpurified 
solution the main species was identified as the mono-acetate compound cis, trans-
[Pt(bpy)(N3)2(OH)(OAc)]. A theory to explain the difficulty of substituting the 
second hydroxide by acetate has been proposed, and involves pKa values. 631 The first 
step in the substitution is believed to be protonation of the hydroxide ligand by the 
acid to form an aqua ligand. Acetate is a much stronger nucleophile than water and 
so a nucleophilic substitution takes place. The pKa of the second hydroxide has been 
estimated to be lower than ca. 4.7 and so protonation does not occur so readily. [63]  
The 'H NMR chemical shifts of the bipyridine ligands in trans, cis-
[Pt(bpy)(OCOCH3)2(N3)2] (14) and cis, trans-[Pt(bpy)(N3)2(OH)2] (13) are far 
enough apart to allow them to be distinguished. The UV-visible spectrum of 14 
contains 3 main peaks at 250, 304, 317 nm (Figure 3.4). By comparison with 
previous assignments of Pt"-bipyridine compounds, the peaks at 304 and 317 nm are 
due to it-ir' transitions of the bipyridine rings. [33,44]  In Pt" complexes the high energy 
band is usually assigned as a MLCT absorption. However this seems unlikely for a 
Pt'' complex and so the absorbance at 250 nm is probably at least partly due to a 
LMCT from N3 to Pt. The UV-visible spectrum and assignments are further 
discussed in Chapter 5. The extinction coefficient at 647 nm is 38 M'cm' (Table 
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Figure 3.4 Electronic absorption spectrum of cis, trans-[Pt(bpy)(N3)2(OAc)2] (14) in 
water (0.048 mM). 
3.3.19 Trans, cis- [Pt(phen)(OAc)2(N3)2] (15) 
Trans, cis-[Pt(phen)(OAc)2(N3)2] was synthesised and crystallised in the same way 
as trans, cis-[Pt(bpy)(OAc)2(N3)2]. [Pt(çhen)(N3)2] is reported to be more difficult to 
oxidise than [Pt(bpy)(N3)2] as discussed in Section 
3.3.20 Trans-[Pt(N 3)2(py)2] (16) 
Trans-[Pt(N3)2(Dy)2J was synthesised directly from K2[PtC14] by a slight variation of 
the literature method. [641  The chlorides were replaced by pyridine to give a colourless 
solution of [Pt(py)4]C12 which was then converted to trans-[PtC12(py)2] by heating 
with excess HC1. The chlorides were then removed with silver nitrate and upon 
addition of NaN3, trans- [Pt(N3)2(py)2] precipitated. 
Oxidation of trans- [Pt(N3)2(py)2] proved very difficult. This could be due to 
electronic effects similar to those of the Pt"-bipyridine complexes, or it could simply 
be due to insolubility in water. Oxidation of trans-[Pt(N3)2(NH3)(py)] was carried out 
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with only 4 molar equivalents of 11202, but required large volumes of water to 
achieve sufficient solubilisation of the Pt" starting material (section 3.2.2.8). 
Unfortunately the use of large volumes of water or addition of small amounts of 
acetone or DMF to the oxidation reaction of trans-[Pt(N 3)2(py)2] did not give rise to 
product. 
Table 3.1 Electronic spectral data for Pt'Vdiazide  complexes. The ?max (run) and 6 
(M'cm') values at the absorption maximum and at various wavelengths of 











1 257 13,721 274 18 6 
2 257 14,340 298 8 < 1 
3 286 18,945 547 44 8 
4 289 18,816 535 42 3 
5 286 19,384 567 39 1 
6 285 16,516 545 25 <1 
7 288 15,234 510 32 <1 
8 292 17,888 603 58 8 
9 289 13,575 441 21 <1 
10 289 14,318 536 40 < 1 
14 250 19,102 738 199 38 
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Table 3.2 'H and '5N NMR chemical shifts and coupling constants (J / Hz) for Pt''-
diazide complexes. 







(195Pt-' 5N) (195Pt- 'H) 
1 5.12 -40.27 73.5 259.8 46.0 
2 6.38 -7.22 76.0 278.0 43.0 
3 5.32 -41.65 72.0 282 47.5 
4 5.65 -46.00 74.0 282.3 49.5 
6 5.29 -41.35 73.3 265.2 46.7 
8 5.67 -44.65 74.2 300.6 50.4 
12 5.49 -41.27 - 242.7 46.5 
3.4 Conclusions 
Thirteen novel Pt1v diazido complexes were successfully synthesised and 
characterised. By incorporation of the azides in a trans position, the LMCT (N3 - 
Pt) absorption band was shifted towards the visible region, and the extinction 
coefficient increased. Several compounds with high aqueous solubility (> 20 mM) 
were also prepared. This work shows that there is a vast number of potential 
compounds which could be produced by varying the am(m)ine ligands alone, and 
therefore the scope for further improving the properties of these Pt"  diazido 
complexes is great. 
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4.1 Introduction 
The azide ion (N3 ) is linear and symmetric, possessing equal N-N distances of ca. 
1.154 API However, when bound through one of the terminal nitrogens (Figure 
4.1a), azide becomes asymmetric with bond lengths which compare well with those 
of diimide (1.23 A), and nitrogen (1.10 A). 2' The bound structure is best described as 
a resonance hybrid (Figure 4.1b). 
a) 	
1.24A 1.13 A 
1.01/J 	N 	N 
120 
H 
b) 	 + 	 + 
/1' N N. 	 /N N N 
M 	 M 
Figure 4.1 Structure of azide. a) Bond lengths and angles when bound to hydrogen 
(hydrazoic acid HN3), b) resonance structures of azide ligand bound to a metal (M). 
Seven crystal structures of Pt'" azide compounds have been published with a 
crystallographic R-factor of < 0.05: trans- [Pt(N3)4(SCN)2] (PPh4)2, trans- 
[Pt(N3)4(SeCN)2] (PPh4)2, 3' 	trans-[Pt(N 3)4C12] (PPh4)2, 4' 	[Pt(N3)C15] (AsPh4)2, 
[Pt(N3)6] (AsPh4)2, 51 [Pt(N3)6] (PPh4)2, and [Pt(N3)5.28C10.72] (AsPh4)2. [6]  All of these 
complexes crystallise in a triclinic crystal system with the space group P-i. 
The crystal structures of cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (1) and cis, trans-
{Pt(en)(N3)2(OH)2] (2) have previously been reported by Dr. Phil Müller. 7"31 These 
compounds have the azide ligands in a cis configuration. Complex 1 crystallised in a 
triclinic crystal system with the space group P-i, while complex 2 crystallised in a 
monoclinic crystal system with the space group P21 /c. The bond lengths and angles 
generally agreed well with the seven other published Pt" azide structures. [3-61  
However, the Pt-Na bond lengths for 1 and 2 are amongst the shortest reported, this 
can be explained by the stronger trans influence of azide and chloride ligands 
compared to ammonia. Overall, 1 and 2 have close to octahedral geometry, and the 
azide ligands are almost linear (L N-N-N 173.2 ° - 175.7 0). 
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This chapter describes the X-ray crystal structures of platinum azide complexes 
obtained during this work. The complexes are discussed with focus on the azide 
ligands, and compared to similar structures where possible. There are five sections, 
divided according to the structures of the complexes; trans-Pt'V, trans-Pt", cis-Pt", 
Pt" with chelating aromatic ligands and Pt" with chelating aromatic ligands (cis or 
trans refers to the geometry of the azide ligands). 
4.2 Experimental 
X-ray crystal structure data were collected and solved by Dr Simon Parsons and 
colleagues. Diffraction data were collected with MOKa radiation on a Bruker Smart 
Apex CCD diffractometer equipped with an Oxford Cryosystems low-temperature 
device operating at 150 K. Data were corrected for absorption using the SADABS 
procedure, [8]  and the structures solved by either direct (SHELXS) 9' or Patterson 
(DIRDIF)'°' methods. The structures were refined by full-matrix least-squares 
against F2 (SHELXL)." 
4.3 	X-ray Crystal Structures 
The crystallographic data for complexes 1, 2 and 3 can be obtained from the 
Cambridge Crystallographic Data Centre. The depository numbers are CSD-412674 
(1), CCDC-190265 (2) and CCDC-288954 (3). Data for all the X-ray structures 
described here can be found on the enclosed CD. 
4.3.1 Trans-Pt IV  Diazido Complexes 
The X-ray crystal structures of four trans-Pt"-diazido complexes have been 
determined, trans, trans, trans-{Pt(N3)2(OH)2(NH3)2} (3), trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(py)] (4), trans, trans, trans- [Pt(N3)2 (OH)2(NH3) (2-pic)] (8), and 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(c-HexNH2)J (11). The crystallographic data 
are listed in Table 4.1, and the bond lengths and angles of the azide ligands of each 
compound are in Table 4.2. To facilitate comparison of the azide ligands in Table 
4.2, the nitrogens are labelled according to the generic structure shown in Figure 4.2. 
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Table 4.1 Crystal structure data for the trans Pt'"  diazido complexes trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)2] (3), trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)] (4), 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)J (8) and trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(c-HexNH2)] (11). 
Property 3 4 8 11 
Empirical formula H16N8O6Pt C5H10N802Pt C6H12N802Pt C6H18N802Pt 
Formula weight 419.30 409.30 423.33 429.35 
Crystal description yellow block yellow block Pale yellow lath yellow block 
Crystal size (mm) 0.520.300.29 0.270.160.13 0.52x0.280.12 0.240.140.12 
Crystal system Triclinic Orthorhombic Monoclinic Triclinic 
Space group P-i Pbca 12/a P-1 
Unit cell 
dimensions (A) 
a = 5.4038(5) 
b = 5.8538(5) 
c = 9.0518(8) 
a= 87.813 (1) 
/3= 78.790(1) 
72.456(1) ° 
a = 7.9640(7) 
b = 11.585(1) 
c = 24.150(2) 
a= 90 
/3=90 ° 
v= 90 ° 
a = 12.9666(2) 
b = 7.8790(1) 




a = 5.5050(2) 
b = 13.3500(4) 




Z 1 8 8 4 
Density (calc.) 
(mg/m3) 
2.600 2.440 2.559 2.281 
Absorption coeff. 
(mm') 
13.133 12.597 12.778 11.232 
F(000) 198 1520 1584 816 
Orange for data 
2.29 to 28.64 
collection (0)  




15616 15237 7070 
Independent 
reflections 
1226 3310 3171 7070 
Volume (A3) 267.74(4) 2228.2(3) 2197.46(6) 1250.07(7) 
Temperature (K) 150(2) 150(2) 150(2) 150(2) 
Wavelength (A) 0.71073 0.71073 0.71073 0.71073 
Conventional R 0.0157 0.0270 0.0191 0.0355 
wR2  0.0384 0.0646 0.0467 0.0817 
72 12 a2 OH 
N=NN, 	NH3  
Pt 
= N = N 
OH a1 	Pl '11 
Figure 4.2 Labelling of azide ligands in trans-Pt"' diazido complexes. R is NH3 for 
complex 3, pyridine for 4, 2-picoline for 8 and cyclohexylamine for 11. 
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Table 4.2 Bond lengths (A) and angles (°) of azide ligands in trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2] (3), trans, trans, trans- {Pt(N3)2(OH)2(NH3)(py)] (4), trans, 
trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)] (8) and trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(c-HexNH2)J (11, 11'). 
Bond / Angle 3 4 8 11 11' 
Pt-N(a1 ) 2.046(3) 2.044(3) 2.054(2) 2.041(7) 2.028(7) 
Pt-N(cL2) - 2.046(3) 2.051(2) 2.032(7) 2.053(7) 
N(a l )-N(f31) 1.210(4) 1.203(5) 1.212(4) 1.224(10) 1.190(10) 
N(J31 )-N('yi ) 1.143(5) 1.139(6) 1.158(4) 1.139(11) 1.149(11) 
N((X2)-N(132) - 1.216(5) 1.222(4) 1.194(11) 1.213(10) 
N(32)-N(y2) - 1.138(5) 1.141(4) 1.148(11) 1.142(10) 
Pt-N(ct j)-N(131 ) 117.2(2) 119.0(3) 115.7(2) 114.9(5) 123.5(6) 
N(ai )-N(j3i)-N(y i ) 174.5(3) 174.4(5) 175.3(3) 175.6(9) 174.0(9) 
Pt-N(a2)-N(32) - 114.5(3) 115.3(2) 119.0(6) 116.5(6) 
N(a2)-N(32)-N(y2) - 175.9(5) 175.0(3) 174.0(9) 174.5(9) 
N(cti)-Pt-N(ct2)-N(132) 0 -154.1 -114.5 -119.4 104.2 
N(ci2)-Pt-N(ui)-N(J31 ) 0 -124.5 164.4 -91.2 127.0 
4.3.1.1 Trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) 
X-ray crystallography of trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] .4H20 confirmed 
the octahedral stereochemistry and the presence of an inversion centre (Figure 
4.3)J'2' The azide ligands are almost linear (L N((xi)-N(f31 )-N(yi) 174.5 O)  and the Pt-
N(a)-N(13) angle is 117.2° (Table 4.2). The azide N-N bond closest to platinum 
(N(a)-N(f3) 1.210 A) is ca. 0.07 A longer than the terminal azide N-N bond (N()-
N(?) 1.143 A), which is typical for azide ligands and can be explained by the 
resonance structure (Figure 4. 1).[21  The bond lengths and angles of 3.41-120 are 
comparable to those of the cis isomer 1,[13]  and are in good agreement with literature 
values for related PtW  azide complexes. [3-6] 
The crystal structure of 3.4H20 consists of layers of molecules formed through 
OH ... N3  and NH OH hydrogen bonds which connect molecules in pairs across 
inversion centres (Figure 4.4). The layers are interleaved with water molecules which 
H-bond to the NH3 groups. Details of the H-bonds are listed in Table 4.3. 
108 
Chapter 4 Crystal Structures of Platinum Azide Complexes 
Table 4.3 Hydrogen bonding distances (A) and angles (°) in the crystal structure of 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)21.4H20  - 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
01-Hi 0.845 2.175 156.45 2.969 N1a 
Ni-Hia 0.910 1.978 164.97 2.867 0l1 
NI-fib 0.910 2.074 161.04 2.950 01W 
01 W-Hi Wi 0.839 2.003 175.44 2.840 02W 1 
OIW-H2W1 0.835 2.197 163.05 3.006 O2W'1  
02W-H1W2 0.832 1.926 168.92 2.748 01 
02W-H2W2 0.826 2.343 129.72 2.941 61WLeI 
01 W-Hi Wi 0.826 2.628 144.87 3.338 01W 
Symmetry operations : a] x, y+i, z J tt3l L x-1, y, z ] cj L  x, y-i, z j LU1 L - 
x+1, -y, -z-1 J [e] [-x, -y, -z-1 
H2W2>/ciW2 
Figure 4.3 X-ray 	crystal 	structure 	of 	trans, trans. 	trans- 
[Pt(N3)2(OH)2(NH3)2].4H20 (3). Thermal ellipsoids at 50 % probability level. Two 
water molecules have been omitted, they are related by symmetry to the two 
molecules of H20 shown. 
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4, 
-W 
Figure 4.4 Hydrogen bonding involved in the layering of molecules of trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)21.4H20  . Water molecules are not shown. 
The crystal structure of the dichloro analogue of complex 3 has been 
determined.t 141 Trans, trans, trans- [PtC12(OH)2(NH3)2] also contains an 
inversion centre and has an extensive hydrogen bonding network. The Pt-NH3  
and Pt-OH bond lengths are very similar to those of 3.4H20, but the Pt-Cl 
bonds are significantly longer than the Pt-N3 bonds (Table 4.4). This was 
expected as nitrogen is a stronger donor ligand than chloride towards platinum. 
The geometry of trans, trans, trans-[PtCl2(OH)2(NH3)2] is closer to octahedral 
than 3.4H20, this is probably due to steric hindrance caused by the bulky azide 
groups. 
Table 4.4 Bond lengths (A) in the crystal structures of 3.4H20 and trans, trans, 
trans-[PtC12(OH)2(NH3)2] [14] 
Bonds 3.41120 t,t,t-[PtC12(OH)2(NH3)2] 
Pt-NH3  2.036(3) 2.038(4) 
Pt-OH 2.006(2) 2.000(5) 
0-H 0.845(19) 0.89(7) 
Pt-N3  2.046(3) - 
Pt-Cl - 2.303(1) 
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4.3.1.2 Trans, trans, trans-[Pt(N3)2(OH)2(N}13)(Py)] (4) 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (Figure 4.5) crystallised in an 
orthorhombic crystal system with the space group Pbca (Table 4.1). This is the only 
known Pta' azide compound with this space group, and one of only two which exist 
in an orthorhombic crystal system, the other being trans, cis-[Pt(bpy)(OAc)2(N3)2] 
(Section 4.3.4.2). The azide bond lengths of complex 4 are all within experimental 
error of those of trans, trans, trans-[Pt(N 3)2(OH)2(NH3)2] (3) (Table 4.2). Complex 4 
deviates from an octahedral geometry by a few degrees more than complex 3, most 
likely due to steric hindrance between the azides and pyridine. The Pt - NH3 I 
pyridine bond lengths agree well with related structures. (15-171 
Figure 4.5 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] 
(4). Thermal ellipsoids at 50 % probability level. 
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— J, 
L 
Figure 4.6 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] 
with intermolecular hydrogen bonds indicated by the dashed green lines. Some weak 
- it stacking between the pyridine ligands also exists. 
There are intermolecular hydrogen bonds present (Figure 4.6), though they are 
generally weaker than those of complex 3 (Table 4.5). The pyridine ring only forms 
one H-bond, which is to a terminal azide nitrogen. Both the terminal and platinum-
bound nitrogens of azide are involved in H-bonding. The it - it stacking between the 
pyridine ligands, with centroid spacing is 4.372 A and a dihedral angle of 8.7 is 
very weak. 
Table 4.5 Hydrogen bonding distances (A) and angles (°) in the crystal structure of 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)J (4). 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
N2-H 0.911 2.238 168.80 3.136 N231a] 
01-H 0.841 2.178 161.22 2.987 N21 1 
N2-H 0.910 2.295 142.21 3.065 NilLal 
C5-H5 0.949 2.489 155.38 3.376 N13 
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4.3.1.3 Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)] (8) 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)] (Figure 4.7) crystallised in an 
monoclinic crystal system with the space group 12/a (Table 4.1). The azide bond 
lengths and angles are very similar to the other Pt1" azide compounds (Table 4.2). 
The Pt-N(2-pic) bond length is significantly longer (2.092(5) A) than that of Pt- 
N(py) in compound 4 (2.059(4) A), which is presumably due to steric hindrance 
caused by the methyl group of 2-picoline. In the crystal structure of trans- 
[Pt"C12(NH3)(2-pic)] the methyl group lies over the square-plane above the platinum 
atom. [18,191 
Figure 4.7 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)I 
(8). Thermal ellipsoids at 50 % probability level. 
The 2-picoline ligand is disordered by a 180 rotation about the Pt-N bond. The 
system is hydrogen-bonded to produce "slabs" of molecules bound either side of the 
hydrophobic picolines (Figure 4.8). The centroid-centroid separation of the it - it 
stacked picoline rings is 3.355 A with a dihedral angle of 0.00(27) O• 
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a) 
Figure 4.8 X-ray 	crystal 	structure 	of 	trans, 	trans, 	trans- 
[Pt(N3)2(OH)2(NH3)(2-pic)1 from two different projections illustrating a) the 
layers of molecules and b) intermolecular hydrogen bonding (green dashed 
lines). 
4.3.1.4 Trans, trans, trans-Pt(N3)2(OH)2(NH3)(c-HexNH2)1 (11) 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(c-HexNH2)] (Figure 4.9) crystallised 
in a triclinic crystal system with the space group P-i, as did complex 3 (Table 
4.1). The azide bond lengths and angles are very similar to the other Pt" azide 
compounds (Table 4.2). The X-ray structure of trans, cis, cis-
[Pt(OAc)2Cl2(NH3)(c-HexNH2)] (JM2 16, Chapter 1) has been determined; it 
crystallised in a monoclinic crystal system with space group P21 /a. 201 The 
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cyclohexylamine bond lengths and angles of complex 11 compare well with 
those of JM216, as do the Pt - am(m)ine bond lengths. The geometry of 11 is 
nearly octahedral with the cyclohexylamine ring adopting a chair 
conformation. 
10 
NI 	r N 7 OJ4.,  
C10 	N8 
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n 	 C20 
11' 
Figure 4.9 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(c-
HexNH2)] (11). Thermal ellipsoids at 50 % probability level. 
Complex 11 crystallised with four molecules in the unit cell, two of which were 
different. Intermolecular hydrogen bonding between the ammonia, hydroxide and 
azide ligands is present (Figure 4.10), as for complexes 3, 4 and 8. An NH2 hydrogen 
and the equatorial ring hydrogen attached to C2 are also involved in intramolecular 
hydrogen bonding to the azide ligands. 
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11 	 • 
Figure 4.10 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(c-
HexNH2)J (11 and 11') with intermolecular hydrogen bonds indicated by the dashed 
green lines. 
4.3.2 Trans-Pt11  Diazido Complexes 
The X-ray crystal structures of two trans-Pt"-diazido complexes were determined, 
trans-[Pt(N3)2(NH3)2(MeNH2)] (5a) and trans-[Pt(N3)2(NT-13)(c-HexNFI2)] (11 a). The 
crystallographic data are listed in Table 4.6, and the bond lengths and angles of the 
azide ligands are in Table 4.7. As for the Pt ' compounds, the azide ligands have 
been given generic labels (Figure 4.11). 
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Table 4.6 Crystal structure data for the trans Pt"  diazido complexes trans-
[Pt(N3)2(NH3)(MeNH2)] (5a) and trans- [PtN3)2(NH3)(c-HexNH2)J (11 a). 
Property 5a ha 
Empirical formula CH8N8Pt C6H16N8Pt 
Formula weight 327.24 395.36 
Crystal description yellow block yellow block 
Crystal size (mm) 0.28 x 0.16 x 0.10 0.39 x 0.37 x 0.22 
Crystal system Monoclinic Monoclinic 
Space group 1`2 1 1c P21 /n 
Unit cell dimensions 
(A) 
a = 13.4380(2) 
b=7.65630(l0) 




a = 6.12230(10) 
b=21.9394(5) 
c = 8.1404(2) 
a=90° 
/3= 98.8660(10)° 







F(000) 592 744 
Orange for data 
collection (°)  
3.05 to 30.35 1.86 to 43.18 




Volume (A) 714.756(17) 1080.35(4 
Temperature (K) 150(2) 150(2) 
Wavelength (A) 0.71073 0.71073 
Conventional R 0.0197 0.0329 
wR2  0.0503 0.0710 
72 	f2 	a2 
	




U1 	Ili 	Yi 
Figure 4.11 Labelling of azide ligands in trans-Pt" diazido complexes. R is MeNH2 
for complex 5a and cyclohexylamine for 11. 
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Table 4.7 Bond lengths (A) and angles (°) in azide ligands in trans-
{Pt(N3)2(NH3)(MeNH2)] (5a) and trans- [Pt(N3)2(NH3) (c-HexNH2)] (11 a). 
Bond/Angle 5a ha 
Pt-N(a l ) 2.030(2) 2.039(3) 
Pt-N(a2) 2.027(2) 2.041(3) 
N(a1 )-N(3,) 1.204(3) 1.197(4) 
N(f3,)-N(y,) 1.152(3) 1.150(4) 
N(a2)-N(f32) 1.202(3) 1.203(4) 
N(132)-N(72) 1.155(3) 1.146(5) 
Pt-N(a i )-N(13,) 124.48(19) 121.1(2) 
N((x,)-N(f3,)-N(y,) 173.8(3) 175.7(3) 
Pt-N(a2)-N(132) 122.48(19) 121.0(2) 
N(a2)-N(132)-N(-y2) 174.5(3) 174.7(3) 
N(ci,)-Pt-N(a)-N(I32) -44.2 175.4 
N(a2)-Pt-N(a, )-N(13,) -149.1 -2.97 
4.3.2.1 Trans-[Pt(N3)2(NH3)(MeNH2)] (5a) 
Trans-[Pt(N3)2(NH3)(MeNH2)] crystallised in a monoclinic crystal system with the 
space group P21 /c (Figure 4.12). The azide bond lengths compare very well with 
other platinum azide compounds (Pt" and Pta') (Table 4.2 and Table 4.7). The Pt-
N(u)-N(J3) angles agreed well with the other Pt" complexes, but were found to be 
significantly larger than those of the Pt's' compounds (3, 4, 8 and 11). This same 
difference is seen for the cis-diazido pt" and pt" structures. 7"31 The smaller Pt-N(a)-
N(3) angle for Pt1V  complexes could be a result of intramolecular hydrogen bonding 
between the axial hydroxide hydrogen and the azide ligand. 
The X-ray structure of trans-[PtCl2(MeNH2)2] has been published, 1211 the bond 
lengths did not differ significantly from those of transplatin. 221 These am(m)ine bond 
lengths are also very similar to those of complex 5a. The geometry of 5a is square 
planar and the angles are all very close to 90 
There is intermolecular hydrogen bonding between the NH2 hydrogens and both the 
terminal and platinum-bound nitrogens of azide, and also between an ammonia 
hydrogen and a platinum-bound azide nitrogen. 
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Figure 4.12 X-ray crystal structure of trans-[Pt(N3)2(NH3)(MeNH2)1 (5a). Thermal 
ellipsoids at 50 % probability level. 
4.3.2.2 Trans-[Pt(N3)2(NH3)(c-HeXNH2)Il (1 la) 
Trans-[Pt(N3)2(NH3)(C-HeXNH2)1 crystallised in a monoclinic crystal system with 
the space group P21/n (Figure 4.13). The azide bond lengths and angles compare well 
with the other platinum azide structures (Table 4.2 and Table 4.7). The geometry is 
distorted from square planar (Figure 4.14), the angle between the cyclohexylamine 
ring and the azide ligand which is orientated towards it (N(12)-N(22)-N(32)) is Ca. 
95 0  (Table 4.8). This distortion is not seen for trans-[PtC12(NH3)(c-HexNH2)II where 
the angles are all 90 ± 1 o23I  The complex is still relatively planar around the 
platinum centre with angles very close to 180 0 (Table 4.8) Trans-[PtCl2(NH3)(C-
HexNH2)] also crystallised in a monoclinic crystal system, but with the space group 
P21/c. 
The molecules form hydrogen-bonded chains as shown in Figure 4.15, the bond 
distances are given in Table 4.9. Similar hydrogen bonds are found in the analogous 
chloride compound trans-[PtC12(NH3)(c-HexNH2)] [231 
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Table 4.8 Bond angles around the platinum centre of trans-[Pt(N3)2(NH3)(c-
HexNH2)1 (11 a). 
Bond Angle (°) 
N(1 1)-Pt-N(12) 95.69(10) 
N(12)-Pt-N(l) 84.99(11) 
N(l)-Pt-N(13) 94.52(11) 




Figure 4.13 X-ray crystal structure of trans-[Pt(N3)2(NH3)(c-HexNH2)1 (11a)-
Thermal 
la).
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N32 
11 
Figure 4.14 X-ray crystal structure of trans-{Pt(N3)2(NH3)(c-HexNH2)] (1 la) 
showing the angles between the ligands attached to platinum to illustrate the 
distortion from square-planar geometry. 
Figure 4.15 X-ray crystal structure of trans-[Pt(N3)2(NH3)(c-HexNH2)] (ha) with 
intermolecular hydrogen bonds indicated by the dashed green lines. 
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Table 4.9 H-bonding distances (A) and angles (°) of complex ha. 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
Ni-H 0.910 2.289 150.44 3.113 N12 Lai 
NI-H 0.910 2.542 133.98 3.241 N32 
Ni-H 0.910 2.200 162.45 3.079 N3 3'c' 
NI 1-H 0.920 2.598 156.11 3.459 Nl2kj 
Nil-H 0.920 2.419 141.81 3.193 N33Lei 
Symmetry operations [a] [-x+l, -y, -z+i ] [b] [ x, y, z-1 ] [c] [-x, -y, -z] [d] 
[x-1,y,z] [c] [x,y,z+l 
4.3.3 CisPtn  Diazido Complexes 
Although the main focus of this work was on compounds with trans geometry, the 
X-ray crystal structure of one cis-Pt'-diazido complex was determined. 
4.3.3.1 Cis, trans, cis-[Pt(N3)2C12(NH3)2] (12) 
The crystallographic data, and bond lengths and angles of the azide ligands of cis, 
trans, cis-[Pt(N3)2C12(NH3)2] are listed in Table 4.10 and Table 4.11, respectively. 
Table 4.10 Crystal structure data for cis, trans, cis-[Pt(N3)2C12(NH3)2] (12). 
Property 12 
Empirical formula H4C12N602Pt 
Formula weight 386.08 
Crystal description yellow block 
Crystal size (mm) 0.35 x 0.31 x 0.25 
Crystal system Monoclinic twinned on 2[100] 
Space group P21 
Unit cell dimensions (A) a = 5.1954(4) 	a = 90 
b = 10.6764(9) /3= 90.585(5) 
c=7.3518(6) 	i=90 °  
Z 2 
Density (caic.) (Mg/M3) 3.144 
Absorption coefficient (mm-') 17.824 
F(000) 348 
Orange for data collection (°) 1.91 to 30.49 
Reflections collected 3043 
Independent reflections 1681 
Volume (A) 407.77(6) 
Wavelength (A) 0.71073 
Conventional R 0.0867 
wR2  0.2271 
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N(1 l)-N(21)  1.22(4) 
N(21)-N(31) 1.13(5) 
Pt-N(1 2)-N(22) 119(2) 
N(12)-N(22)-N(32) 174(4) 
Pt-N(1 1)-N(21) 115(2) 
N(1 1)-N(21)-N(31) 170(4) 
N(12)-Pt-N(1 1)-N(21) 79.6 
N(1 1)-Pt-N(12)-N(22) -86.2 
The crystals of cis, trans, cis-[Pt(N3)2C12(NH3)2J (12) had a "crazed" appearance, and 
the crystal analysed was twinned. This is believed to be the reason for inadequate 
absorption correction. No attempt was made to place the hydrogens. From the cell 
dimensions, the system was assumed to be orthorhombic, but subsequent analysis 
showed that it was a monoclinic twin. 









NI 	 Nil 
C12 
Figure 4.16 X-ray crystal structure of cis, trans, cis-[Pt(N3)2C12(NH3)2] (12). 
Thermal ellipsoids at 50 % probability level. 
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4•3•4 Pt" Diazido Complexes with Chelating Ligands 
The X-ray crystal structures of three PtWdiazido  complexes with chelating ligands 
were determined, cis, trans- [Pt(bpy)(N3)2(OH)2] .2 [Me2C(OOH)2] (13), trans, cis-
[Pt(bpy)(OAc)2(N3)2] (14) and trans, cis-[Pt(phen)(OAc)2(N3)2] (15). The 
crystallographic data are listed in Table 4.12, and the bond lengths and angles of the 
azide ligands can be found in Table 4.13. The azide labelling scheme is shown in 
Figure 4.17. 
Table 4.12 Crystal structure data for cis, trans- [Pt(bpy)(N3)2(OH)2] .2 [Me2C(OOH)2] 
(13), trans, cis- [Pt(bpy)(OAc)2(N3)2] (14) and trans, cis- [Pt(phen)(OAc)2(N3)2} (15). 
Property 13 14 15 
Empirical formula C 6H26N8O10Pt C14H14N8O4Pt C16H 4N8O4Pt 
Formula weight 685.54 553.42 577.43 
Crystal description yellow block Yellow platedeveloped yellow block in (00 1) 
Crystal size (mm) 0.26 x 0.25 x 0.20 0.84 x 0.55 x 0.04 0.35 x 0.20 x 0.15 
Crystal system Monoclinic Orthorhombic Monoclinic 
Space group P21 /c Pbcn P2/n 
Unit cell dimensions a = 11.7262(4) a = 8.0488(4) a = 7.03030(10) 
(A) b=20.1996(7)) b= 14.1103(7) b= 11.7849(2) 
c = 10.3283(4) c = 15.3280(7) c = 11.3271(2) 
a=90° a=90° a90°. 
/3= 100.572(2) /3=90 /3= 101.2360(10)° 
y=90° y90° 
Z 4 4 2 
Density (calc.) 
(Mg/M3)  
1.893 2.112 2.083 
Absorption coefficient 
(mm)  
5.902 8.101 7.665 
F(000) 1344 1056 552 
O range for data 
1.77 to 38.67 2.66 to 29.61 1.728 to 29.544 
collection (°)  
Reflections collected 55188 21880 14648 
Independent 
reflections  
9271 2307 2454 
Volume (A3) 2404.88(15) 1740.82(15) 920.48(3) 
Temperature (K) 150(2) 150(2) 150(2) 
Wavelength (A) 0.71073 0.71073 0.71073 
Conventional R 0.0248 0.0243 0.0305 
wR2  0.0562 0.0582 0.0690 
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Figure 4.17 Labelling of azide ligands in chelated Pta' diazido complexes. 
Table 4.13 Bond lengths (A) and angles (°) of azide ligands in cis, trans-
[Pt(bpy)(N3)2(OH)2].2[Me2C(OOH)2] (13), trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) and 
trans, cis-[Pt(phen)(OAc)2(N3)2] (15). 
Bond I Angle 13 14 15 
Pt-N(a l ) 2.0196(16) 2.022(3) 2.001(3) 
Pt-N(a2) 2.0561(17) - - 
N(a1 )-N(f31 ) 1.229(2) 1.225(5) 1.175(6) 
N(f31 )-N(yi ) 1.138(2) 1.147(5) 1.154(6) 
1.193(3) - - 
N(132)-N(72) 1.147(3) - - 
Pt-N(ct i )-N(f31 ) 115.90(14) 115.0(3) 118.5(4) 
N(ui )-N(3 i )-N('y i ) 174.0(2) 175.2(5) 173.1(5) 
Pt-N((12)-N(P2) 114.03(15) - - 
N(a2)-N(02)-N(72) 175.9(3) - - 
N(a1 )-Pt-N(a2)-N(f32) -49.8 -45.2 35.33 
N(0 2)-Pt-N(a i )-N(3i ) -56.5 -45.2 35.33 
4.3.4.1 Cis, trans- [Pt(bpy)(N3)2(OH)2] .2[Me2C(00H)2] (13) 
Cis, trans- [Pt(bpy)(N3)3(OH)2] (13) co-crystallised with two molecules of the 
explosive compound peroxyacetone (C31480,) J241 This is believed to have been 
formed by oxidation of residual acetone with hydrogen peroxide. The synthesis is 
described in Section 3.2.2.17 in Chapter 3. Peroxyacetone is an unusual molecule to 
find as a co-crystallite and only one other entry was found in the CCDC '[211  a crystal 
structure which consisted of the 1:2 adduct (bis(diphenylphosphinoyl)ethane).2(2,2-
dihydroperoxypropane)(dppeO2) .2 [Me2C(OOH)2], and was synthesised from a 
solution containing acetone and H202. The peroxyacetone moiety was reported to be 
stabilised by hydrogen bonds formed between its OH groups and the oxygens of 
dppe02. Similar hydrogen bonds are found in the structure of 13.Me2C(OOH)2, the 
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OH hydrogen of peroxyacetone bonds to both the oxygens attached to platinum (01 
and 02) and also to one of the middle azide nitrogens (N22). 
Table 4.14 Hydrogen bonding distances (A) and angles (°) in the crystal structure of 
cis, trans-[Pt(bpy)(N 3)3(OH)2] .2 [Me2C(00H)2]. 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
054-H 0840 1.940 155.38 2.726 0  
074-H 0.840 1.963 160.42 2.769 
055-H 0.840 2.034 152.35 2.805 O2 
055-H 0.840 2.685 133.33 3.318 N22 
- 075-H 0.840 1.902 158.62 2.702 O2 T57 
Symmetry operations: [a] [x, -y+1/2, z+1/2], [b] [x+1, y, z] 
Complex 13.Me2C(OOH)2 crystallised in an monoclinic crystal system with the 
space group P21 /c. The bond lengths and angles of the bipyridine ligand compare 
well with the related structure [Pt(bpy)C14]. 261 The Pt-N bond lengths of 
13.Me2C(OOH)2 are slightly different than those of the Pt" analogue [Pt"(bpy)(N3)2] 
(13a, Section 4.3.5.1), the Pt-N(bpy) bonds are Ca. 0.02 A longer in the Pt1" complex. 
This difference is also seen for [Pt"''(bpy)C14] 261 and [Pt"(bpy)Cl2] 271 where the Pt-
N(bpy) bonds of Pt1" were reported to be ca. 0.04 A longer. The azide bond lengths 
are very similar to other Pt azide complexes (Table 4.2 and Table 4.13). 
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Figure 4.18 X-ray crystal structure of trans, cis- [Pt(bpy)(N3)2(OH)2] .2{MeC(OOH)2] 
(13). Thermal ellipsoids at 50 % probability level. 
4.3.4.2 Trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) 
Trans, cis[Pt(bpy)(OAc)2(N3)2J (14) crystallised in an orthorhombic crystal system 
with space group Pbcn. The only other known orthorhombic Pt IV  azide compound 
was complex 4 (Section 4.3.1.2), and no other platinum azides have been crystallised 
in space group Pbcn. The platinum sits on a 2-fold axis and so there is only one set of 
azide bond lengths and angles in Table 4.13. 
The azide bond lengths of complex 14 compare well with other platinum azide 
compounds (Figure 4.2 and Table 4.13), and the bipyridine ligand bond lengths and 
angles are very similar to related structures, complexes 13 and 13a. The Pt-N(bpy) 
bond lengths are very similar to those of complex 13 and consequently are larger 
than those of complex 13a, as described in Section 4.3.4.1. 
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The intermolecular bonds are shown in Figure 4.20; intramolecular bonds exist 
between the platinum bound azide nitrogens and the hydrogens on C22 of bipyridine. 
Figure 4.19 X-ray crystal structure of trans, cis-[Pt(bpy)(OAc)2(N3)2 J (14). Thermal 
ellipsoids at 50 % probability level. 
Figure 4.20 X-ray crystal structure of trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) with 
intermolecular hydrogen bonds indicated by the dashed green lines. 
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4.3.4.3 Trans, cis- [Pt(phen)(OAc)2(N3)21 (15) 
Trans, cis-[Pt(phen)(OAc)2(N3)2J crystallised in a monoclinic crystal system with the 
space group P2/n (Figure 4.21). The azide bond lengths and angles compare well 
with the other platinum azide structures (Table 4.2 and Table 4.13). The 
phenanthroline and acetate bond lengths and angles are also within the expected 
range. Like the bipyridne structure (14), the platinum in complex 15 sits on a 2-fold 
axis. 
The Pt-N(phen) bond lengths of complex 15 are significantly longer than those of the 
analogous Pt" compound [Pt(phen)(N3)2] (iSa, Section 4.3.5.2). This was also 
observed for the bipyridine complexes and has been reported in the literature. 26' The 
intermolecular hydrogen bonding of complex 15 is similar to that of complex 14 
which is expected due to the similarity of these structures. However, some weak it-it 
stacking also exists between molecules of the phenanthroline complex. The centroid-





Figure 4.21 X-ray crystal structure of trans, cis-[Pt(phen)(OAc)2(N3)2] (15). 
Thermal ellipsoids at 50 % probability level. 
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4.3.5 Pt" Diazido Complexes with Chelating Ligands 
The X-ray crystal structures of two Pt"-diazido complexes with chelating ligands 
were determined, [Pt(bpy)(N3)2] (13a) and [Pt(hen)(N3)21 (15a). The 
crystallographic data are listed in Table 4.15, and the bond lengths and angles of the 
azide ligands are in Figure 4.16. The azide labelling scheme is shown in Figure 4.22. 
Table 4.15 Crystal structure data for [Pt(bpy)(N3)2] (13a) and [Pt(phen)(N3)2] (iSa). 
Property 13a iSa 
Empirical formula C 1oH8NPt C 12H8NPt 
Formula weight 435.32 459.34 
Crystal description orange needle yellow block 
Crystal size (mm) 0.82 x 0.10 x 0.10 0.26 x 0.12 x 0.10 
Crystal system Monoclinic Monoclinic 
Space group C21c C21c 
Unit cell dimensions 
(A) 
a = 10.9346(5) 
b = 15.3328(8) 
c = 7.0453(4) 
a90° 
/3= 94.717(3) 0 
a =  19.35 84(7) 
b = 10.1802(4) 
c = 13.8692(4) 
a=90° 
/3= 113.816(2) 0 
y=90° 
Z 4 8 




F(000) 808 1712 
Orange for data 
collection (deg)  
2.293 to 28.731 2.300 to 28.824 
Reflections collected 6926 9019 
Independent reflections 1453 3057 
Volume (A) 1177.20(11) 2500.49(16) 
Temperature (K) 150 150 
Wavelength (A) 0.71073 0.71073 
Conventional R 0.0192 0.0326 
wR2 0.0478 0.0825 




N' 	N = N = N 
ai 	fEL, 	Yi 
Figure 4.22 Labelling of azide ligands in chelated Pt"  diazido complexes. 
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Table 4.16 Bond lengths (A) and angles (°) in azide ligands in [Pt(bpy)(N3)2] (13a) 
and [Pt(phen)(N3)2] (15a). 
Bond/Angle 13a iSa 
Pt-N(al) 2.034(3) 2.022(6) 
Pt-N(a2) - 2.037(5) 
N(al)-N(ft) 1.190(4) 1.179(8) 
N( 1 )-Ny1) 1.150(5) 1.167(8) 
N(u2)-N(P2) - 1.182(7) 
N(132)-N(72) - 1.164(8) 
Pt-N(ai)-N(131) 119.3(2) 125.1(4) 
N(cti)-N(131)-N(71) 175.2(4) 174.2(7) 
Pt-N(a2)-N(f32) - 121.8(4) 
N(u2)-N( 2)-N(yi ) - 174.5(6) 
N(ai)-Pt-N(u2)-N(f32) 40.3 29.8 
N((12)-Pt-N(ai)-N(13i) 40.3 29.5 
4.3.5.1 [Pt(bpy)(N3)2] (13a) 
[Pt(bpy)(N3)21 (13a) crystallised in a monoclinic crystal system with the space group 
C21c (Figure 4.23). The azide bond lengths and angles compare well with the other 
platinum azide structures (Table 4.7 and Table 4.16). The molecule sits on a 2-fold 
axis, as do complexes 14 and 15. 
A 
Figure 4.23 X-ray crystal structure of [Pt(bpy)(N3)2] (13a). Thermal ellipsoids at 50 
% probability level. 
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The two rings within a single molecule are skewed with respect to each other at an 
angle of 5.12 0  This is also seen for the Pt"  bipyridine complexes, although it is less 
pronounced; the angle of complex 13 is 3.71 0  and for complex 14 is 3.41 0•  Some 
weak intermolecular hydrogen bonding exists between the azide ligands and the ring 
hydrogens. The centroid-centroid distance (4.036 A) and angle (6.117 0)  indicate that 
it-it stacking does not play a large role in the structure of complex 13a. 
4.3.5.2 [Pt(phen)(N3)2] (15a) 
[Pt(phen)(N3)21 (15a) crystallised in a monoclinic crystal system with the space 
group C2/c (Figure 4.24). Interestingly this is the same crystal system and space 
group as complex 13a, but [Pt(phen)(N3)2] does not contain a 2-fold axis of 
symmetry. 
Figure 4.24 X-ray crystal structure of [Pt(phen)(N3)2] (15a). Thermal ellipsoids at 50 
% probability level. 
There is some intermolecular hydrogen bonding between ring hydrogens and 
terminal azide nitrogens. The structure consists of dimers which are connected by a 
short platinum-platinum bond (Figure 4.25). It is not unusual to find Pt-Pt bonds in 
square-planar Pt" complexes, often linear chains are formed bonded through the 
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platinum centres. 281 Such bonds are found in Pt"-bipyridine complexes where the Pt-
Pt bond is generally around 3.4 A, however there were no platinum-platinum bonds 
present in the crystal structure of complex 13a [Pt(bpy)(N3)21 (Section 4.3.5.1). The 
[Pt(phen)(N3)2] dimers are also t-n stacked at a distance of 3.631 A and a dihedral 
angle of 5.334(204) 
Lq 
Figure 4.25 X-ray crystal structure of [Pt(phen)(N3)2] (15) showing the short Pt - Pt 
contact between molecules. 
4.4 Conclusions 
The X-ray crystal structures of twelve novel platinum azide complexes have been 
determined. These structures include Pt" and Pt'"  complexes, and compounds with 
cis and trans geometry with respect to the azide ligands. Several Pta' complexes 
containing the chelating aromatic ligands 2,2'-bipyridine and 1,10-phenanthroline 
were crystallised and their structures solved. The difficulty in oxidising Pt" 
bipyridine and phenanathroline complexes has been reported and was experienced 
during this work (Chapter 3);[29]  these problems are exacerbated by the presence of 
the azide ligands which are not stable under harsh conditions (e.g. high 
temperatures). Therefore it was particularly important to have determined the 
structures of the three pt"' complexes containing bipyridine and phenanthroline 
ligands to confirm their identities. 
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5.1 Introduction 
The stability of photoactive complexes under physiological conditions is an 
important factor to consider for potential photochemotherapeutic drugs. A previous 
class of photoactive Pt" di-iodo complexes was found to be too easily reduced by 
thiols to cytotoxic Pt" species)'' Pt'v diazido complexes 1 and 2 have previously 
been found to be relatively stable)'4'51 This chapter further investigates the stability of 
complex 1 and also includes stability studies on the trans complexes 3, 4, 5, and 8. 
Metal azides have been found to undergo a variety of different photoreactions which 
include (i) photosubstitution of the azide ligand,16'71 (ii) photoreduction of an 
oxidising metal,['-"] (iii) the generation of metal -nitrenes,'9251 and (iv) production of 
singlet oxygen. '26'27' Determining the mechanism of photoactivation of Pt1v azide 
compounds is therefore not a simple task. The photoreactivity of the PtVazide 
complexes was studied by both 'H and 2D ['H,'5N] HSQC NMR spectroscopy as 




Complexes 1-14, 15N-cisplatin, 15N-transplatin and [Pt(15NH3)(py)C12] were 
synthesised as previously described (Chapter 3). Silver nitrate, D20 and 1 ,4-dioxane 
were purchased from Aldrich; NaCl and NaOH from Fisher; 5 '-GMP and reduced 
glutathione from Acros; EBSS and H202 from Sigma, and HC104 from Fisons. 
5.2.2 Syntheses 
5.2.2.1 Cis-[Pt''('5NH3)2(OH/OH2)4] 
15N-cisplatin (7.5 mg, 0.025 mmol) was suspended in H20 (5 mL) and AgNO3 (8.4 
mg, 0.05 mmol) added. After stirring for 24 h at 333 K, the insoluble AgCl was 
filtered off. An NMR sample was prepared using 0.54 mL of the above solution and 
60 p.L of D20, and the pH adjusted to 5 ± 0.2. The 'H and 2D [1 H,'5N] HSQC NMR 
spectra were acquired, and then 4 mol equiv H202 (30 % v/v, 1.1 pL) added to the 
tube. The solution was stirred in the NMR tube overnight, the pH was readjusted to 5 
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± 0.2 and the NMR spectra acquired again. 
5.2.2.2 Trans-[Pt'v('5NH3)2(OH)4] 
15N-transplatin (4.6 mg, 0.015 mmol) was suspended in 1120 (3.1 mL) and AgNO3  
(5.1 mg, 0.030 mmol) added. The reaction was continued as described for cis-
[Pt"('5NH3)2(OH/0H2)4] (section 5.2.2.1). The Pt'v NMR sample was then analysed 
by ESI-MS. 
5.2.2.3 Trans-[Pt"'( 1 5  NH3)(py)(OH)41 
{Pt"('5NH3)(py)C12] (3.4 mg, 0.009 mmol) was suspended in H20 (3 mL) and 
AgNO3 (3.2 mg, 0.018 mmol) added. The reaction was continued as described for 
cis-[Pt"'('5NH3)2(OH/0H2)4] (section 5.2.2.1). The Pt" NMR sample was then 
analysed by ESI-MS. 
5.2.3 Stability Studies 
The stability of several Pt"' azide compounds was monitored by 1D 'H and 21) 
['H,'5N] HSQC NMR spectroscopy. The samples were all prepared in 90 % 1120 / 10 
% D20 with 1,4-dioxane (1 %, 2 ,IL) added as the internal 'H reference, the only 
exceptions were those set-up to determine the stability in cell culture media. These 
samples were prepared in 90 % Earle's Balanced Salt Solution (EBSS) / 10 % D20. 
All samples were kept in the dark at 294 K in between measurements, except for the 
sample used to determine stability at physiological temperatures; this sample was 
incubated at 310 K also in the dark. NMR spectra were acquired on a DMX500 
NMR spectrometer as previously described (Chapter 2.1.2). 
5.2.4 Photoreactions 
Details of the acquisition of NMR spectra, ESI-MS and pH adjustments are described 
in Chapter 2.1.2. 
UV irradiation (365 nm) was carried out with a UV lamp, the experimental set-up is 
described in detail in Chapter 2.3. 
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5.3 Results 
5.3.1 Stability Studies 
Reactions of Pt"  diazido-dihydroxy complexes can be followed by 'H NMR studies 
of the am(m)ine protons if the reactions are carried out in H20. However, at neutral 
pH, no 'H am(m)ine peaks are detected due to fast exchange of the NH protons with 
the solvent. With decreasing pH the signals appear, and so the pH is usually adjusted 
to 5 in order to observe the Pt's' am(m)ine protons by NMR. 
For each sample the spectrum reported as recorded at '0 h' was the first one acquired 
after preparation. For samples where the pH was not adjusted this will be less than 5 
mm. Adjusting the pH generally takes approximately 5 mm, so samples where the 
pH is changed were acquired ca. 10 min after preparation. 
The NMR spectra for all experiments are shown in Appendix 3, for peak assignments 
and coupling constants see Chapter 3. A single peak for dioxane is present at 3.764 
ppm in all 'H NMR spectra. 
5.3.1.1 Aqueous Stability 
Trans, trans, trans-[Pt(N3)2(OH)2('5NH3)2] (3) 
A 3 mM solution of complex 3 was prepared and the pH adjusted from 6.4 to 4.8. 1D 
'H and 2D ['H,'5N] HSQC NMR spectra were acquired after 0 h, 24 h, 6 d, 12 d, 93 
and 154 d. After 154 d no new peaks appeared in either the 1D or 2D spectra and 
only a peak for complex 3 was present, therefore no hydrolysis had occurred 
(Appendix 3, Figure A3. 1). 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (4) 
A 3 mM solution of complex 4 was prepared. The pH was measured as 6.3, but as 
the complex was not 15N-labellcd no pH adjustment was necessary. 'H NMR spectra 
were recorded after 0 h, 24 h, 6 d, 47 d, 93 d and 154 d. This compound was found to 
be very stable, after 154 d only peaks for complex 4 were present (Appendix 3, 
Figure A3.2). 
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Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(MeNH2)] (5) 
This sample was prepared and spectra obtained as described above for complex 4. 
The pH was measured as 6.4. This compound was also found to be very stable, after 
154 d only peaks for complex 5 were present (Appendix 3, Figure A3.3). Therefore 
no hydrolysis had occurred. 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3)(2-pic)] (8) 
This sample was prepared and spectra obtained as described above for complex 4. 
The pH was measured as 6.4. This compound was also found to be very stable, after 
154 d only peaks for complex 8 were present (Appendix 3, Figure A3.4). Therefore 
no hydrolysis had occurred. 
5.3.1.2 Stability towards Chloride 
The stability towards chloride was investigated by adding NaCl (100 mM) to 3 mM 
solutions of cis, trans, cis-{Pt(N3)2(OH)2(15NH3)2] (1) and trans, trans, trans-
[Pt(N3)2(OH)2(15NH3)2] (3). The pH of both samples was adjusted to 5 before 
recording the 0 h spectra. 1D 'H and 2D ['H,'5N] HSQC NMR spectra were acquired 
after 0 h, 2h, 5 h, 24 h, 6 d, 12 d, 47 d, 93 d and 154 d for complex 1 and 0 h, 24 h, 6 
d, 47 d, 79 d and 140 d for complex 3. The '5 NH3 peaks were observed to decrease in 
intensity in both the 1D 'H and 2D [11-1,15N] HSQC NMR spectra over the course of 
the stability study (Appendix 3, Figure A3.5 and A3.6), however no new peaks 
appeared. The pH of both samples had risen significantly by the end of the 
experiment (complex 1 pH 6.19; complex 3 pH 6.93). This pH rise along with the 
decrease of the 15  NH3  peaks suggests chloride is replacing the ammonia ligands. If 
this happened on a short time scale (e.g < 48 h) it could be a problem, however after 
12 d for 1 and 6 d for 3 the majority of the '5 NH3 is still bound to platinum 
(Appendix 3, Figure A3.5 and A3.6). 
5.3.1.3 Stability towards Nucleotides 
Trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] (3) 
Two molar equivalents of 5'-GMP were added to a 3 mM solution of complex 3 and 
the pH adjusted from 8.0 to 4.8. 1D 'H and 2D ['H,'5N] HSQC NMR spectra were 
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recorded after 0 h, 24 h, 9 d, 21 d and 47 d. There were no new peaks visible after 47 
days (Appendix 3, Figure A3.7). 
5.3.1.4 Stability in Cell Culture Media 
These samples were prepared in 90 % Earle's Balanced Salt Solution (EBSS) I 10 % 
D20. The pH of EBSS was 7.5 before the addition of any platinum complex. An 
extra 4 jiL of dioxane was added as the signal was masked by those of EBSS. 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (4) 
A 3 mM sample of complex 4 was prepared and the pH measured as 8.4. 'H NMR 
spectra were acquired after 0 h, 1.5 h, 5 h, 24 h, 6 d, 47 d, 93 d and 154 d. After 154 
d only peaks corresponding to complex 4 and EBSS were present, no new peaks 
appeared (Appendix 3, Figure A3.8). 
Trans, trans, trans- [Pt(N3)2(OH)2(NH3) (MeNH2)] (5) 
This reaction was carried out as described above for complex 4. After 154 d only 
peaks corresponding to complex 5 and EBSS were present, no new peaks appeared 
(Appendix 3, Figure A3.9). 
5.3.1.5 Stability towards Glutathione 
The stability towards glutathione (GSH) was investigated by adding 2 mol equiv of 
reduced GSH to a 3.3 mM solution of complex 3. The pH was measured as 3.7, 
therefore adjustment to <7 was not necessary. 1D 'H and 2D ['H,'5N] HSQC NMR 
spectra were recorded after 0 h, 24 h, 9 d and 21 d. There was no change in the 
spectra after 24 h. After 9 d, two new Pt" peaks had appeared at ('H,'5N) 3.87, 
-61.24 ppm (18) and 3.55, -64.92 ppm (19) in the HSQC spectrum. These peaks had 
increased slightly in intensity by 21 d, and accounted for 2.6 % (18) and 1.5 % (19) 
of all Pt-NH3 present (Appendix 3, Figure A3.10). These new peaks are in the region 
for Pt"-'5NH3 trans to N or Cl.[301  By comparison with literature chemical shifts '[28]  it 
seems likely that these Pt" products are { {trans-Pt(SG)(NH3)2}2-4u-SG] (18) and 
trans-[Pt(NH3)2(GS)2] (19). There are small peaks in the 'H spectrum which could 
correspond to platinum bound glutathione. Also visible in the 'H spectrum are peaks 
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for oxidised glutathione (GSSG), however after 21 d only 15 % had been converted 
to the oxidised form. The spectra of oxidised (GSSG) and reduced (GSH) glutathione 
are shown in Appendix 3, Figure A3.1 1. Oxidation may be caused by either air 
and/or complex 3, the majority of 3 was still in the Pta' state after 21 d, so 
autooxidation of glutathione by air might have occurred. 
These results demonstrate the remarkable stability of complex 3, less than 5 % had 
been reduced after 21 d in the presence of 6.6 mM glutathione. 
5.3.1.6 Stability at 310 K 
A 3 mM sample of complex 3 was prepared, and the pH adjusted from 6.2 to 4.9. 
The 1D 'H and 2D ['H,'5N] HSQC NMR spectra were recorded, and then the sample 
was incubated at 310 K. Spectra were rerecorded after 24 h, 9 d and 21 d. The 
spectrum after 21 d only contained peaks for complex 3 (Appendix 3, Figure A3.12). 
5.3.2 Photoreactions 
To observe the 'H am(m)ine peaks of PtW  diazido dihydroxy complexes it was 
necessary to adjust the pH to 5 as explained in section 5.3.1. However, when these 
complexes were irradiated with UVA light, even for a very short amount of time (e.g. 
1 mm), the pH was found to increase. Therefore to follow the course of the Pta' 
species during the photoreactions, the pH was readjusted to 5 after each irradiation, 
but before acquiring the NMR spectra. 
The change in pH with increasing irradiation time can be seen in Figure 5.1 for 
complexes 1, 3 and 4. The pH of solutions of the cis compound (1) increased much 
more than either of the trans compounds (3 and 4) upon irradiation. Adjustment of 
the pH to 5 throughout the photoreactions was carried out for the majority of 
experiments described in this chapter, however occasionally the pH was only 
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Time of Irradiation (mm) 
Figure 5.1 The increase in pH (from 5 ± 0.2) after each irradiation for cis, trans, cis-
[Pt(N3)2(OH)2('5NH3)2] (1), trans, trans,  trans- [Pt(N3)2(OH)2('5NH3)2 (3) and trans, 
trans, trans- [Pt(N3)2(OH)2(15  NH3)(PY)l   (4). 
5.3.2.1 NMR Spectroscopy 
a) Cis, trans, cis-[Pt(N3)2(OH)2(' 5NH3)2] (1) 
A 3 mM sample of cis, trans, cis-[Pt(N3)2(OH)2(15  NH3)21   was prepared, and the pH 
adjusted to 5. The sample was irradiated in an NMR tube with the UV lamp, and the 
1D 'H and 2D ['I-1,'5N] HSQC spectra recorded after 0, 1, 3, 6, 11, 16, 26, 36, 46, 66, 
96, 126 and 246 mm. During irradiation the pH increased, after 246 min it was 8.9 
and, therefore no PtV)5NH3  ['H,15N] peaks were visible (Figure 5.2a). Upon 
readjusting the pH to 5 with HC104, several new peaks appeared (Figure 5.2b). 
Overall there was a large loss in signal intensity by the end of irradiation, which is 
most likely due to the formation of an insoluble precipitate. 
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Figure 5.2 2D [1 H,15N] FISQC NMR spectra of cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] 
(3 mM) after irradiation with UVA light for 246 min at a) pH 8.9, and b) pH 5.0. 
* 195Pt satellites. 
Peak 25 is the only peak visible in the region for Pt1" compounds, in the spectrum 
recorded after 246 min irradiation with the pH adjusted to 5 (Figure 5.2b). As the pH 
had previously been high (- 9) for this sample, peak 25 could be due to a stable Pt" 
hydroxy-bridged dimer, which was not cleaved into monomers upon lowering the 
pH. Hydroxy-bridged dimers have been observed for Pt" compounds at pH values 
lower than 5J291  
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Figure 5.3 2D ['H,'5N] HSQC NMR spectra of cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] 
(3 mM) after irradiation with UVA light for a) 30 min and b) 120 mm. * 195Pt 
satellites. 
Peak 23 is most likely assignable to cis-{Pt(15NH3)2(OH)2]; it is in the region for Pt"-
15 NH3 trans to 0 and as the pH is high, the water ligands will be deprotonated (cis-
[Pt11(NH3)2(OH)(0H2)1+  pKa 7.21),' this assignment is consistent with the fact that 
peak 23 disappears when the pH was lowered to 5; the chemical shifts also agree 
well with published values. 52'541 Peaks 20 and 21 became more intense when the pH 
was lowered, but did not change position. Peak 22 disappeared completely and peak 
26 appeared. These peaks could be due to bridged dimers or even trimers which 
would explain the pH effects. 
145 
Chapter 5 Stability and Photoreactions 
The reaction was repeated, with the pH readjusted to 5 after each irradiation. Spectra 
were acquired after 0, 1, 5, 15, 30, 60 and 120 min of irradiation. Three main Pt" 
peaks (20, 21, 26) were seen after 120 mm, several PtV  peaks were also still present 
(Figure 5.3). 
Table 5.1 'H and 15N NMR chemical shifts (ppm), coupling constants (Hz) and 
assignments to pt" and PtIV  compounds. 





1 5.12 -40.27 260 46 c,t,c-[Pt(N3)2(OH)2(15NH3)2] 
20 4.04 -68.48 281 55 Pt" photoproduct 
21 3.90 -66.86 286 55 Pt photoproduct 
22 3.82 -66.23 - - Pt" photoproduct 
23 3.79 -82.26 - - c-[Pt('5NH3)2(OH)2] 
24 4.27 -54.80 - - Pt" photoproduct 
25 4.95 -49.25 276 50 Pt IV  photoproduct 
26 4.03 -72.47 - - Pt" photoproduct 
27 5.09 -40.04 259 
c-[PtC 5NH3)2(N3)(OH)2(OH/0H2)] 
15 NH3 trans to N3  
28 5.19 -40.22 261 50 Pt''photoproduct 
29 5.03 -49.11 274 45 
c-[Pt(' 5NH3)2(N3)(OH)2(OHJOH2)] 
, NH3 trans to 0 
30 4.97 -48.39 - - Pt" photoproduct 
31 5.08 -48.78 269 45 Pt"" photoproduct 
32 5.19 -50.38 269 45 c-[Pt''(15NH3)2(OH/OH2)4] 
a) See Figure 5.2 and Figure 5.3 for peak labels. 
Peaks 27 and 29 are tentatively assigned as the mono-azide species with an oxygen 
donor (OH or OH2) replacing the other azide ligand. Both 27 and 29 appear at the 
same time and increase at roughly the same rate; it was not possible to measure 
accurate integrals due to overlapping peaks. They also both begin to disappear 
between 30 and 60 min of irradiation, and are very small after 120 mm; this is 
146 
Chapter 5 Stability and Photoreactions 
consistent with the second azide subsequently being lost. These two peaks were not 
visible in the first reaction when the pH was lowered (Figure 5.2b), but this sample 
had undergone irradiation for 246 mm (nearly twice as long), and so it is unlikely 
that any azide would still be bound to platinum. The most intense peak for Pt"-
15NH3  species after 120 min irradiation is peak 32 which is in the region for Pt"'-
' 5NH3 trans to 0,1301  and has been assigned as Pt1" with 2 ammonia and 4 oxygen-
donor ligands (either OH or OH2). The synthesis of cis-[Pt(15NH3)2(OHIOH2)4 ] was 
carried out by oxidising cis-[Pt( 15NH3)2(0H2)2] with H202; the pH was adjusted to 5 
and the ID ['H] and 2D ['H,' 5N] HSQC NMR spectra recorded. The chemical shifts 
of the main product (5.20, -49.71) and the coupling constants (2J(195Pt-'H) 47.4 Hz, 
'J('95Pt-' 5N) 276 Hz) agree well with those of 32 (Table 5.1). None of the Pt" peaks 
seen upon irradiation of 1 were due to cis-[Pt('5NH3)2(OH2)2] which has chemical 
shifts of 6('H,15N), 4.44, -87.03 ppm at pH 5. 
b) Cis, trans-[Pt( 15N-en)(N3)2(OH)2 ] (2) 
A 3 mM sample of cis, trans- [Pt(' 5N-en)(N3)2(OH)2 ] (2) was prepared and the pH 
adjusted to 5. The solution was irradiated in an NMR tube with the UV lamp, and 2D 
[ 1 H,15N] HSQC spectra recorded after 0, 1, 3, 6, 11, 16, 26, 36, 46, 66, 96 and 126 
mm. Irradiation led to two new sets of peaks in the 2D [ 1 H,15N] HSQC NMR spectra. 
The pattern of peaks in box 33 (Figure 5.4a) is characteristic of inequivalent 15NH2  
protons, [511  and is in the region for pIV)S2  trans to OJMI The main product is a 
Pt" compound (34, 5.11, -33.43) which was first detected after 11 mm. Overall there 
was a large loss in signal intensity, this is at least partly due to the formation of an 
insoluble yellow precipitate (as seen during irradiation of compound 1), but could 
also be caused by the pH. The pH of this reaction was adjusted to 5 at the start, but 
by the end of the reaction it had risen to > 7. Above pH 7 the Pt IV  peaks are no longer 
visible due to fast exchange of the 15  NH protons. Compound 34 is not the diaqua 
species [Pt(15N-en)(0H2)2] which has been reported at 5(15N) -45.9 	however 
it could be the hydroxide complex, which given the higher pH would be more likely. 
Another possibility is an oxygen-bridged dimer, such complexes have previously 
been reported at high pH and studied by 195Pt NMR spectroscopy. 32' 
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The photoreaction of complex 2 on its own appears to be a much more 
straightforward reaction than those of the other Pt''-azide complexes (1 or 3). Only 
two new compounds appear in the 2D [11-1,13N] HSQC NMR spectra (33 and 34), 
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Figure 5.4 2D ['H,'5N] HSQC NMR spectra of cis, trans-[Pt(15N-en)(N3)2(OH)2 j (3 
mM) after irradiation with UVA light for a) 11 and b) 26 mm. The pH was adjusted 
to 5 before irradiation. * 195Pt satellites. 
Trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) 
A 3 mM solution of trans, trans, trans- [Pt(N3)2(OH)2(15NH3)2] was prepared and the 
pH adjusted to 5. The sample was irradiated with UVA light in an NMR tube and 1D 
'H and 2D [1H,'5N] HSQC NMR spectra were acquired after 0, 1, 5, 15, 30, 60 and 
120 min of irradiation with the pH was readjusted to 5 each time. 
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Figure 5.5 	2D ['H,'5N] HSQC NMR spectra of trans, trans, trans- 
[Pt(N3)2(OH)2('5NH3)2] (3) after irradiation with UVA light for a) 30 min and b) 120 
min * 195Pt satellites. 
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Figure 5.6 	Structures of the six geometric isomers of [Pt(N3)2(OH)2(NH3)2]. 
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Table 5.2 'H and '5N NMR chemical shifts (ppm), coupling constants (Hz) and 
assignments to Pt" and Pt" diammine compounds. 





1 5.12 -40.27 259.8 46.0 c,t,c-{Pt(N3)2(OH)2(15NH3)21 
3 5.32 -41.65 282 47.5 t,t,t-[Pt(N3)2(OH)2(15NH3)2] 
35 5.34 -41.56 278 50 PtVphotoproduct 
36 5.48 -42.56 278 45 Pt'' photoproduct 
37 5.63 -43.68 280 45 Pt" photoproduct 
38 5.21 -40.78 280 50 trans- [Pt(N3)(OH)3('5NH3)2] 
39 5.12 -40.07 279 50 trans- [Pt(OH)4)(' 5NH3)2J 
40 5.42 -31.35 291 50 Pt"" photoproduct 
41 3.91 -66.56 - - Pt" photoproduct 
42 4.10 -64.61 - - Pt" photoproduct 
43 3.78 -64.86 - - Pt" photoproduct 
44 4.17 -51.13 - - Pt" photoproduct 
45 3.94 -64.02 - - trans-[Pt('5NH3)2(OH2)2]2 
46 3.82 -65.64 - - trans- [Pt(' 5NH3)2Cl(OH2)] 
47 5.14 -40.05 285 49 trans-[Pt(' 5NH3)2(OH)4 ] 
48 5.25 -40.20 276 50 trans- [Pt(' 5NH3)2(OH)3C1] 
a) See Figure 5.5 and Figure 5.8 for peak labels. 
After 30 min irradiation of complex 3 six new Pt"' peaks were present (35-40), 
initially these peaks were believed to be due to isomers. Photoisomerisation of Pt" 
compounds has previously been reported and utilised in synthesis. 33'34 There are six 
possible geometric isomers of trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2} (Figure 
5.6). Peak 39 has very similar chemical shifts to those of complex 1 (cis, trans, cis-
[Pt(N3)2(OH)2(NH3)21), but the coupling constants do not compare well.(Table 5.2) 
Mass spectra of an irradiated solution of 3 contained peaks at 320.1, 345.2 and 370.3 
mlz (Figure 5.7). Table 5.3 lists compounds which these peaks could correspond to. 
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Figure 5.7 Positive ion electrospray ionisation mass spectrum of a solution of 
complex 3 which had been irradiated for 60 min with UVA light. 






trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3) + Na 370.2 370.3 
trans-[Pt(N3)(OH)3(NH3)2J (38) + Na 345.1 345.2 
trans-[Pt(OH)4(NH3)2] (39) + Na 320.1 320.1 
To determine whether trans-[Pt(NH3)2(OH)4] was indeed a photoproduct, it was 
synthesised from '5N-labelled transplatin and then analysed by 2D [1 H' 5  N] HSQC 
NMR spectroscopy and ESI-MS. The chlorides were removed from transpiatin with 
silver nitrate to yield the diaqua adduct trans- [Pt(NH3)2(OH2)2]2 . The pH was 
adjusted to 5 with NaOH (0.1 M) and the NMR spectrum acquired (Figure 5.8a), the 
two peaks were assigned from literature values [511  as trans- [Pt('5NH3)2(OH2)2]2 (45; 
3.94, -64.02) and trans-[Pt(15NH3)2(OH2)Cl] (46; 3.82, -65.64). Oxidation was 
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carried out with H202, the pH was readjusted to 5, and then the solution was analysed 
by NMR spectroscopy and ESI-MS. Two new Pt"' species were visible in the NMR 
spectrum 47 (5.14, -40.05) and 48 (5.25, -40.20) (Figure 5.8b). These peaks were 
calculated to be of the same ratio to each other as 45 and 46 (Table 5.2). In the mass 
spectrum the major peaks were due to trans-[Pt(15NH3)2(OH)4J + H (mlz 300.0) and 
its sodium adduct trans-[Pt('5NH3)2(OH)4] + Na (mlz 322.0). Peaks for the 
monochioro compound trans-[Pt(' 5NH3)2(OH)3C1] were also present at mlz 318 
(Figure 5.9). Therefore, compounds 47 and 48 can be assigned as trans-
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Figure 5.8 	2D ['H,'5N] HSQC NMR spectra of a) trans- [Pt"('5NH3)2(OH2)2]2 
(45) and trans-[Pt"('5NH3)2Cl(OH2)] (46) and b) trans- [Pt'('5NH3)2(OH)4] (47) and 
trans-[Pt'(15NH3)2Cl(OH)3] (48) at pH 5. * 195Pt. 
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The chemical shifts and coupling constants of peaks 39 and 47 are almost identical 
(Table 5.2) and so photoproduct 39 can be assigned as the tetrahydroxy compound 
trans-{Pt('5NH3)2(OH)4]. These results also help assign peak 38. The chemical shifts 
of the diazide, dihydroxy (3) and the tetrahydroxy (47) compounds are known, and it 
seems likely that the monoazide, trihydroxy complex trans- [Pt(N3)(OH)3('5NH3)2J 
would appear somewhere between these two peaks, therefore compound 38 must be 
trans- [Pt(N3)(OH)3('5NH3)2]. This complex is also clearly visible in the mass 
spectrum of the irradiated solution of complex 3 (Figure 5.7). The position of peaks 
3, 38 and 39 relative to each other is the same as that produced by oxidised 
transplatin (t,t,t-[PtC12(OH)2(15NH3)21, 5.48, -41.14 ppm), 47 and 48. This result was 
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Figure 5.9 	Positive ion electrospray ionisation mass spectrum of trans- 
[Pt"(1 5NH3)2(OH)4] (47) and trans- [Pt''(' 5NH3)2(OH)3C1] (48). 
The '95Pt NMR spectra of 1 and 3 contained peaks at +902 and +875 ppm, 
respectively (Figure 5.10 a and b). After irradiation of 3 for 1 h with IJVA light, 
three new peaks were seen (+862, +1331 and +428 ppm) in the range analysed 
(+2130 to -310 ppm) (Figure 5.10 c, d and e). The largest of these new peaks (+1331 
ppm) could be either compound 38 or 39 by comparison with the chemical shifts of 
similar compounds (Table 5.4). There was no pH control during this experiment, so 
to ensure the products were the same as those produced at pH 5 (Figure 5.5) a natural 
abundance 2D [11-1,15N] HSQC NMR spectrum was acquired. Peaks 3 and 35 to 40 
were all clearly visible. 
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Figure 5.10 195 Pt NMR spectra of a) cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (1), b) 
trans, trans, trans- [Pt(N3)2(OH)2(NH3)21 (3), and c), d) and e) different regions for 
complex 3 after 1 h irradiation. 
Table 5.4 	195Pt chemical shifts of Pt'-hydroxy complexes 
PtW Complexes 6(195Pt) ppm Reference 
c,t,c-[PtC12(OH)2(NH3)2] +860 35 
t-[Pt(OH)4(NH3)2] +1735 36 
C, t, c-[PtC12(OH)2(propylamine)2] +881 35 
t-[Pt(OH)4(propylamine)2] +1521 35 
t,t,t-[Pt(N3)2(OH)2(NH3)2] (3) +875 This work 
t-[Pt(N3)(OH)3(NH3)2] (38) or 
t-[Pt(OH)4(NH3)2] (39)  
+1331 This work 
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Very little reduction to Pt" is seen upon irradiation of 3. After 120 min there are four 
weak Pt" peaks (41-44) present (Figure 5.5, Table 5.2). These peaks do not increase 
significantly upon further irradiation (up to 240 mm), indicating that the PtW 
photoproducts must be relatively stable. All the new Pt" peaks are in the region for 
JJ3 '5N-pt" trans to N or Cl, and since there is no chloride present in the solution all 
the compounds must contain ammonia trans to another nitrogen (probably 15 NH3). 
Peak 42 has similar chemical shifts to trans-[Pt('5NH3)2(0H2)2] (45), and the 
chemical shifts of peak 41 are the same as those of a Pt" product (21), visible after 
irradiation of cis, trans, cis-[Pt(N3)2(OH)2(15  NH3)21   (1) (Figure 5.3). 
There was only a very small amount of precipitation during this photoreaction in 
comparison to the amount generated upon irradiation of complexes 1 and 2. Perhaps 
this can be explained by the position of the ammonia ligands, the trans geometry 
may obstruct oxygen bridging and therefore could hinder the formation of insoluble 
multinuclear species. 
d) Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (4) 
A 3 mM solution of trans, trans, trans- [Pt(N3)2(OH)2('5NH3)(py)] (4) was prepared 
and the pH adjusted to 5. The sample was irradiated with UVA light in an NMR tube 
and 1D ['H] and 2D ['H,'5N] HSQC NMR spectra were acquired after 0, 1, 5, 15, 30, 
60 and 120 min of irradiation with the pH readjusted to 5 each time. 
Interestingly, the same pattern of Pt" peaks was seen in the 2D ['H,'5N] HSQC 
spectrum after 15 min irradiation of complex 4 (Figure 5.11 a), as that produced upon 
irradiation of complex 3 (Figure 5.5). Unlike complex 3 the Pt1" peaks began to 
disappear after 60 min irradiation, and by 120 min only three relatively weak PtF 
peaks remained, however the pt" peaks did not increase in intensity. A pt" peak first 
appeared after 15 min irradiation. After 60 mm, there were two Pt" peaks with 
chemical shifts of ('H,'5N) 3.97, -66.80 ppm (55) and 4.34, -64.35 ppm (56) both 
in the region of H315N-Pt trans to N (Table 55)•[30]  Some precipitation occurred but 
less compared to that produced upon irradiation of complex 1. 
155 
Chapter 5 Stability and Photoreactions 
- 15 min  55  
- 	* *50 
53 
 8 
51 	52 490 
54 





















6.5 	6.0 	5.5 	5.0 	4.5 	ppm 
Figure 5.11 2D [11-1,15N] HSQC NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2('5NH3)(py)] (4) after a) 15 min and b) 60 min irradiation. * 195Pt 
satellites. 
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Table 5.5 'H and '5N NMR chemical shifts (ppm), coupling constants (Hz) and 





4 5.65 -46.00 282.3 49.5 t,t,t[PtV(N3)2(OH)2(5NH3)(py)] 
49 5.74 -45.44 283 49 
50 5.56 -45.62 298 50 t-[Pt'"(15NH3)(py)(OH)3(N3)] 
51 5.94 -47.10 290 48 
52 5.45 -45.03 269 51 t-[Pt"''('5NH3)(py)(OH)4] 
53 6.16 -47.95 - - 
54 5.78 -38.29 - - 
55 3.97 -66.80 - - 
56 4.34 -64.35 - - 
57 4.13 -66.90 - - t-[Pt"(15NH3)(py)(0H2)(OH)] 
58 4.00 -68.55 - - t-[Pt"(15NH3)(py)C1(0H2)] 
59 5.45 -45.08 288 50 t-[Pt'"(15NH3)(py)(OH)4] 
60 5.60 -45.47 278 50 t-[Pt"(15NH3)(py)(OH)3C1] 
a) See Figure 5.11 and Figure 5.12 for peak labels. 
By comparison with the photoproducts of complex 3 it was thought that peak 52 was 
most likely due to trans-[Pt(' 5NH3)(py)(OH)4], to confirm this the tetrahydroxy 
complex was synthesised. The first step in the synthesis of trans-
[Pt('5NH3)(py)(OH)4] involved removing the chlorides from trans-
[Pt(15NH3)(py)C12] with silver nitrate. The pH was adjusted to 5 with NaOH (0.1 M) 
and the NMR spectra acquired (Figure 5.12a). The NMR sample was analysed by 
mass spectrometry and the peaks assigned as trans-[Pt"('5NH3)(py)(OH)(OH2)] (57; 
4.13, -66.90; 327.1 mlz) and trans- [Pt(' 5NH3)(py)Cl(0H2)] (58; 4.00, -68.55; 345.0 
mlz). Oxidation was carried out by addition of 4 mol eq H202 (30 % solution), the 
pH was adjusted to 5 and the solution analysed by NMR spectroscopy (Figure 5.12b) 
and mass spectrometry. Two new peaks were visible in the NMR spectrum 59 (5.45, 
-45.08) and 60 (5.60, -45.47). These peaks were of the same ratio to each other as 57 
and 58 (Table 5.5). In the mass spectrum of this NMR sample, the major peaks were 
157 
Chapter 5 Stability and Photoreactions 
due to trans- [Pt(' 5NH3)(py)(OH)4] + H (361.1 mlz) and its sodium adduct (383.1 
mlz), a small peak for the monochloro compound trans-[Pt(15NH3)(py)Cl(OH)31 + 
(379.5 m/z) was also present. Compounds corresponding to peaks 59 and 60 can 
therefore 	be 	assigned 	as 	trans-[Pt(' 5NH3)(py)(OH)4] 	and 	trans- 
[Pt(15NH3)(py)(OH)3Cl], respectively. The chemical shifts and coupling constants of 
peaks 52 and 59 are almost identical (Table 5.5) and photoproduct 52 can therefore 
be assigned as the tetrahydroxy compound trans-[Pt(15NH3)(py)(OH)4]. By applying 
the same reasoning as for complex 3 peak 50 must be the monoazide compound 
trans-[Pt(' 5NH3)(py)(OH)3(N3)] (see section 5.3.2.1d). 
58 
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Figure 5.12 2D 	['H,'5N] 	HSQC 	NMR 	spectra 	of a) 	trans- 
[Pt"(py)(15NH3)(OH)(Ofl2)1 (57) and trans- [Pt"(py)('5NH3)C1(OH2)] (58) and b) 
trans_{Pt"(py)(1 5NH3)(OH)4] (59) and trans-[Pt"(py)(1 5NH3)(N3)(OH)31 (60), all at 
pH 5. * '95Pt satellites. 
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During irradiation of 4 new peaks emerge in the 'H NMR spectra at -8 and 7.55 
ppm. These are probably due to the Pt" species which are observed in the 2D 
[
1 H,15N] NMR spectra. No new peaks are visible at 8.55 ppm indicating that 
pyridine is not released from the platinum centre (Table 5.6). Another photoreaction 
was carried out without pH adjustment, and so after 120 min irradiation the pH was> 
8. This reaction was followed by 1D ['H] and 2D ['H,'H] COSY NMR spectroscopy 
in an attempt to separate out the pyridine proton signals. In the 1D 'H spectra the 
peaks were much more well-defined than at pH 5. Two new pyridine ring systems 
could be seen in the COSY spectrum after 120 min irradiation, but they were not 
shifted far enough to high-field to be due to free pyridine. These results help to 
confirm that pyridine is not being released from the platinum centre upon irradiation. 
Table 5.6 'H NMR chemical shifts of free pyridine and Pt-pyridine complexes. 
Compound pH 
('H) I ppm  
H0 H P Hin 
Pyridine 5 8.55 7.98 7.54 
Pyridine 8.8 8.49 7.83 7.42 
4 5 8.72 8.25 7.78 
57 5 8.67 8.02 7.56 
59 5 8.67 8.22 7.74 
A solution of pyridine in 90 % H20 / 10 % D20 was prepared. The 1D ['H] and 2D 
['H,'H] COSY NMR spectra were recorded before and after 2 h irradiation with the 
UV lamp. This was too ensure UVA light was not modifying the pyridine ligand in 
complex 4. No changes were observed after 2 h irradiation. 
5.3.2.2 UV-Visible Spectroscopy 
The photoreactions of PtW  azide complexes can also be followed by UV-visible 
spectroscopy. Aqueous solutions containing 50 tM to 80 VtM Pt were used for these 
experiments as the extinction coefficients are all between 13,000 and 20,000 M1cm 
(Chapter 3, Section 3.2.2). Irradiations were carried out with the UV lamp on 3 mL 
samples in UV quartz cuvettes. Compounds 1 - 12 have intense N3 4 Pt ligand-to-
metal charge-transfer (LMCT) bands between 250 - 300 nm.'°"21 Upon irradiation 
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this band decreases indicating loss of the azide ligands. 37' 
There were clear differences in the behaviour of the cis and trans compounds upon 
UVA irradiation. After 1 min irradiation the absorbance between 250 - 300 nm for 
cis, trans-[Pt(en)(N3)2(OH)2J (2) and cis, trans, cis-{Pt(N3)2C12(NT-13)2] (12) 
increased, and for cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (1) there was no change 
(Figure 5.14 and Figure 5.15). Continued irradiation resulted in a decrease of the 
LMCT band. The evolution of a gas, presumed to be nitrogen formed from the azide 
ligands, was clearly visible during these photoreactions (Figure 5.13). 
Gas Bubbles 
Figure 5.13 Cis, trans-{Pt(en)(N3)2(OH)2] (2) after 60 min UV irradiation. Gas 
bubbles are clearly visible. 
When trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] (3) was irradiated a new absorbance 
was seen after 5 mm (Figure 5.14). This new peak was shifted to a higher energy 
(253 run) than the LMCT of complex 3, and is believed to be due to the monoazide 
species trans, trans, trans-[Pt(N3)(OH)3('5NH3)2] (38). This assignment is based on 
the decrease of the new peak upon further irradiation - suggesting that further 
decomposition is occurring. There was also evidence for complex 38 found by NMR 
spectroscopy (Section 5.3.2.1c). The spectrum of trans-[Pt(NH3)2(OH)4] was also 
recorded but it does not contain any bands between 225 and 300 nm. 
The appearance and subsequent decrease (upon further irradiation) of a new band at 
higher energy was also seen for the other complexes with trans geometry (Figure 
5.14 and Figure 5.15). For the pyridine (4) and picoline (8 - 10) complexes the new 
monoazide peak may be masked by intraligand absorbances of the aromatic systems. 
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Figure 5.15 UV-visible spectra of PtW  azide complexes 9 - 12 after UVA 
irradiation for 0 (-), I  (-), 5  (-), 15 (—), 30 ( ) and 60 (-) mm. 
The electronic absorption spectrum of trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) was 
complicated by the presence of the bipyridine ring. The assignment of the bands in 
the spectrum has been discussed previously (Chapter 3, Section 3.3.18). Briefly the 
peaks at 304 and 317 nm are due to t..ic' transitions of the bipyridine ring, and the 
absorbance at 250 nm is believed to be at least partly due to N3 -) Pt LMCT. 38'39  
Upon UVA irradiation, the main band (250 nm) decreased up to 15 mm, but after 30 
min irradiation it began to increase (Figure 5.16). The absorbance now consisted of a 
peak (248 nm) and a shoulder (ca. 267 nm). The intraligand peaks (304 and 317 nm) 
also decreased in intensity up to 15 min and then increased after 30 min irradiation, 
although the effect was less pronounced. An interesting feature was the emergence of 
a peak at 370 nm with increasing irradiation time. By comparison with Pt" bipyridine 
complexes in the literature, it seems likely that this band is due to metal-to-ligand 
charge-transfer (MLCT), 39'401 which suggests that reduction has occurred and Pt ,  
species are now present. MLCT would be less likely to occur for Ptn  due to the lack 
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Figure 5.16 UV-visible spectra of trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) after UV 
irradiation for 0 (—), 1  (—), 5  (—), 15  (—), 30  ( ), 60 (—) and 120 (—) mm. The arrow 
denotes the increase of the absorption at 370 nm with increasing irradiation time. 
The spectrum of complex 14 after 120 min of irradiation, and the published spectra 
of {Pt(bpy)(OH)2] and {{Pt(bpy)(p.-OH)}2] are similar (Figure 5.17)J411 The 
irradiated solution was analysed by ESI-MS and the two main peaks corresponded to 
[Pt(bpy)(OH)21 (M + fl 386.2 mlz) and [{Pt(bpy)(j.t..OH)}2] (M2 368.2 mlz) (Figure 
5.18). 
u_u I 	• 	 I 	• 
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Figure 5.17 UV-visible spectrum of trans, cis-[Pt(bpy)(OAc)2(N3)2] after 120 mm 
UVA irradiation. Blue arrows indicate the peak positions of [Pt(bpy)(OH)2], and the 
red arrows indicate the peak positions of [{Pt(bpy)(t-OH)}2]. 4 II 
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Figure 5.18 Positive ion electrospray mass spectrum of trans, cis-
[Pt(bpy)(OAc)2(N3)2] after 120 min 1.JV irradiation. 
5.4 Discussion 
5.4.1 Stability Studies 
The stability of potential photochemotherapeutic drugs under physiological 
conditions is an important factor to consider. It is essential that a prodrug remains in 
an inactive state until selectively activated, to ensure it exerts its effects site-
specifically, and can therefore reduce side-effects. The stability of the azide ligands 
is of particular importance, as their decomposition would mean loss of photoactivity. 
Glutathione (GSH) is the most abundant reducing agent found in cells with 
concentrations up to 10 mM; 421 therefore it is preferable that photoactive Pt's' 
compounds are not readily reduced by it. Also of concern is whether the diazido 
complexes are stable in solution towards potential targets such as the guanine bases 
of DNA in the dark. 
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5.4.1.1 Aqueous Stability 
Previous studies have shown that cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] (1) is stable 
in aqueous solution for over 90 d at 298 K. 51 Trans, trans, trans-
[Pt(N3)2(OH)2(15NH3)2] (3) was also found to be stable over 154 d at 294 K, the 1D 
'H and 2D ['H,'5N] NMR spectra did not change over this time period. 
The stability of complexes 4, 5 and 8 in water was studied by 1D ['H] NMR 
spectroscopy. After 154 d, there were no new peaks in any of the spectra. There was 
also no significant decrease in intensity of any of the signals. 
These results demonstrate the remarkable stability of four platinum(IV) azide 
complexes (3, 4, 5 and 8) in water over long time periods (> 5 months). 
5.4.1.2 Stability towards Chloride 
The chloride concentration outside cells in blood plasma is ca. 104 mM; [431  it is 
therefore important to determine whether chloride is capable of replacing the azide 
ligands, as such a substitution would mean loss of the photoactivity. 
The stability of complexes 1 and 3 towards chloride in the dark was investigated by 
incubation of each platinum compound (3 mM) with NaCl (100 mM) at 294 K for 
154 and 140 d, respectively. As both samples were '5N-labelled, adjustment of the 
pH to 5 (before addition of the NaCl) was necessary to observe the ammine protons. 
No new peaks were seen in either spectra after 140 and 154 d, however there was a 
decrease in intensity of the '5 NH3 peaks with increasing time. There was also an 
increase in pH and by the end of the experiment the pH had risen to 6.19 for complex 
1 and 6.93 for complex 3. This suggests chloride is replacing the ammonia ligands 
which would account for both the loss of intensity and increase in pH. However, this 
substitution takes place relatively slowly as no significant decrease in intensity can 
be seen after 12 d for complex 1 and 6 d for complex 3 (Appendix 3, Figures A3.5 
and A3.6). It is not possible to measure the rate of substitution by comparing the 
integrals because of the proximity of the '5 NH3 peaks to the water signal. Water 
suppression also results in some suppression of neighbouring peaks. 
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A previous more in-depth study of the stability of complex 1 towards chloride has 
been carried out, [51  the results were somewhat ambiguous, but it was concluded that 
chloride was not replacing the azide ligands. The results shown here for complexes 1 
and 3 support this conclusion, but chlorides do appear to be capable of replacing 
ammonia ligands. However, the reaction was carried out at the maximum 
concentration of chloride found in the body (Ca. 100 mM); and the rate of 
substitution was very slow, so it is not expected that chloride substuituion would 
cause problems in a physiological environment. 
5.4.1.3 Stability towards Nucleotides 
DNA is generally accepted to be the main target of cisplatin.t441 Once inside the cell 
cisplatin hydrolyses to the monoaqua or diaqua species, which form lethal cross-links 
on DNA. The N7 position of two adjacent guanine bases is the preferred binding site 
of cisplatin. [451  The stability of trans, trans, trans- [Pt(N 3)2(OH)2(' 5NH3)2] (3) towards 
5'-GMP in the dark was investigated. Complex 3 was found to be totally unreactive 
in the presence of the mononucleotide; these results compliment previous studies 
which have found cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] (1) and cis, trans-[Pt('5N-
en)(N3)2(OH)2] (2) to be inert to 5'-GMP in the dark. [51  The stability of Pt"  azide 
complexes to 5'-GMP is an important result, as it has been shown that 5'-GMP can 
reduce and activate Pt1v compounds such as [Pt"'(dach)C14] (dach is 
diaminocyclohexane) [46]  
5.4.1.4 Stability in Cell Culture Media 
Earle's balanced salt solution (EBSS) (Table 5.7) was the cell culture media used 
during phototoxicity testing. EBSS is buffered at between pH 7.2 - 7.6 so it is not 
possible to reduce the pH to 5 to observe the Pt'"-"NH signals. Therefore the 
stability of complexes 4 and 5 was investigated as they both contain CH protons and 
the reaction could be followed by 'H NMR spectroscopy. Despite the presence of 
many salts both complexes were found to be totally stable. This is encouraging as it 
means the compounds are likely to remain intact on cell culture plates. 
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Table 5.7 Formulation of Earle's balanced salt solution used for phototoxicity 
testing and stability experiments. 
Components g I L mm 
CaC12.2H20 0.265 1.8 
MgSO4 (anhydrous) 0.09767 0.8 
KCI 0.4 5.4 
NaHCO3  2.2 26.2 
NaCl 6.8 116.2 
NaH2PO4 (anhydrous) 0.122 1.0 
D-glucose 1.0 5.6 
5.4.1.5 Stability towards Glutathione 
Glutathione (GSH, y-L-Glu-L-Cys-Gly) is the most abundant reducing agent found in 
cells, and can be present at concentrations up to 10 mM. 42'471 Reduction of Pt"  
compounds by GSH and other biomolecules is believed to be necessary for 
anticancer activity. 481 However it is essential that a photoactive platinum(IV) 
prodrug is not readily reduced by cellular thiols, and remains intact until selectively 
activated by light. 
Complex 1 has previously been shown to be inert towards GSH, 51 no Pt"-'5NH3 
peaks were seen in the 2D ['H,'5N] HSQC NMR spectrum after 38 d. Complex 3 was 
also found to be relatively stable, only two small Pt" peaks are present after 21 d, the 
only other peak is due to complex 3. 
5.4.1.6 Stability at 310 K 
Azides decompose at high temperatures, and during synthesis care is taken to ensure 
that the platinum azide complexes are never subjected to temperatures above 313 K 
(Chapter 3). The stability at 310 K was investigated as this is the physiological 
temperature and also the temperature the cells are kept at during phototoxicity 
experiments. Complex 3 was found to be stable at 310 K over a period of 21 d which 
means the azides are not lost or disintegrating at the temperatures used during cell 
tests. 
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Overall, the platinum(IV) azide compounds have proved to be very stable under the 
various conditions tested. This is encouraging as previous work carried out by 
Kratochwil et al., on photoactive Pt'-diiodo complexes was abandoned due to 
instability towards reducing agents. 131 Halides are good leaving groups and are 
therefore prone to attack, whereas azide ligands are more strongly bound. 
5.4.2 Photoreactions 
5.4.2.1 NMR Spectroscopy 
a) Cis, trans, cis-[Pt(N3)2(OH)2(' 5NH3)2] (1) 
The irradiation of cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2] (1) was carried out with and 
without pH adjustment. During irradiation of Pta' diazido complexes the pH rises, 
Pt"-'5NH peaks can usually only be observed at pH values below 7; this is due to 
fast exchange of the am(rn)ine protons as discussed earlier (Section 5.3.2). Therefore 
to observe the PtW  photoproducts the pH was adjusted to 5 after each irradiation. 
Interestingly when the pH was only changed to 5 at 0 h and then after 246 mm 
irradiation, the main Pt" products were the same as those produced after 120 mm 
irradiation with the pH adjusted to 5 at each time point (0, 1, 5, 15, 30, 60 and 120 
mm) (Figure 5.2b and Figure 5.3b). The P{" photoproducts were different, but they 
were all in the region for H315N-Pt trans to oxygen-donor ligands, which are believed 
to be either hydroxide or water. The formation of Pt" bridged dimers should also be 
considered. 49'501 Pt" oxygen-bridged dimers have been observed at pH values as low 
as 2.5 .r291 
During irradiation of an aqueous solution of complex 1 the overall signal intensity 
decreased significantly; this is due to the formation of a dark orange insoluble 
precipitate. This solid is insoluble in all common solvents and has not been further 
characterised. It is thought to be a multinuclear platinum species, formed from the 
interaction of highly reactive photoproducts. 
The assignment of peaks 27 and 29 as the monoazide complex cis, trans, cis-
[Pt(N3)(OH)3(15NH3)2], suggests that the azide ligands do not leave the platinum 
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centre in a concerted manner. Results from the photoreactions of complexes 3 and 4 
also support the theory that the two azides within a molecule leave separately. 
The photoreaction of complex 1 had previously been carried out with blue light (488 
nm, 10 mW). 51 After 20 h irradiation, no Pt" peaks were present but 6 new Pt1" 
peaks were visible. Five of these peaks are the same as those produced upon UV 
irradiation (25, 27-30) (Table 5.1). This suggests that the absorbance was so low at 
488 nm that the reaction was much slower, but occured by the same pathway as seen 
upon UVA irradiation. 
There was no evidence to suggest the sample continued reacting after irradiation was 
stopped (i.e during pH adjustment and NMR acquisition). The 2D ['H,'5N] NMR 
peaks were generally well-defined, peaks which are "streaky" are characteristic of an 
ongoing reaction. Several samples were also left in the dark at 294 K overnight after 
irradiation for various lengths of time. The spectra and pH of each of these samples 
had not changed when re-measured after Ca. 12 h. 
b) Cis, trans-[Pt( 15N-en)(N3)2(OH)2] (2) 
Compound 32 (ö 1 H,'5N; 5.11, -33.43 ppm) was the main photoproduct from 
irradiation of cis, trans- [Pt(en)(N 3)2(OH)2]. It is a pfl  complex but is not the diaqua 
species [Pt(15N-en)(01-12)2], which has an '5N shift of -45 ppm. 3" Complex 32 may 
be the dihydroxide complex [Pt('5N-en)(OH)2] or the oxygen bridged dimer [Pt2(15N-
en)2Qi-OH)2]2 which has been reported to form at pH values as low as 5J32' By 
comparison with the '5N NMR chemical shifts of cis-diammonia hydroxy/aqua 
compounds it can be seen that upon deprotonation, the signal is shifted to low field 
by between 5 - 15 ppm (Table 5.8), discrepancies between the values are due to 
different pH values, however the general trend remains the same. If the trans 
hydroxide is bridging the '5N shift remains remarkably similar to the aqua species, 
therefore this indicates that compound 32 is most likely due to [Pt(15N-en)(OH)2 ]. 
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Table 5.8 '5N NMR chemical shifts of cis-Pt"-diammonia hydroxy/aqua 
compounds. Peaks are all referenced to 15NH4C1. 
Cis-Pt"-Diammonia Complexes 8('5N) I ppm 
cis- {Pt('5NH3)2(OH2)2]2 _87.2a 	-91.4 b; 	-92.53' 
cis-[Pt(' 5NH3)2(OH)2]2  -83.6 b -79.9 d 
[{cis-Pt('5NH3)2(OH2)}2(u-OH)]3 -89.8 (trans to 0H2)' 
-88.53 (trans to duOH)C 
[{cis-Pt('5NH3)2(OH)} 2(u-OH)]3  -80.68 (trans to OH)' 
-88.85 (trans to 1UOH)c 
[Pt('5NH3)2(OH)]22 883b 
a) Reference 51, b) reference 52, c) reference 53, d) reference 54. 
The peaks in box 33 of Figure 5.4 are in the region for Pt'-' 5NH2 trans to oJ°' This 
product could arise from isomerisation, but is more likely to be due to replacement of 
the azide ligands by water or hydroxide. The inequivalence of the 15  NH's could 
perhaps be explained by the presence of one aqua and one hydroxide ligand. 
A similar reaction has previously been carried out with blue light (457.9 nm), 5 but 
the results were very different when compared to those produced upon UVA 
irradiation. Many new peaks were observed but none were close to peak 32. Four 
new peaks with chemical shifts close to those of complex 2, which is the region for 
Pt'-NH2 trans to N were present; and two new peaks were seen in the Pt"-NH2 
trans to 0 region, however these did not match the signals for compound 33. Three 
new peaks were also seen at -45 ppm which were assigned to Pt"-NH2 trans to 
01-12. This difference in the photoproducts produced between irradiation with blue or 
UVA light could be due to pH effects. The pH was adjusted to 5 before the start of 
both reactions but was not changed again. The reaction is much faster with UV light 
and consequently the pH rise will be more rapid. The species seen upon blue light 
irradiation could be intermediates, and perhaps they are only visible because the pH 
is still relatively low. 
c) Trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] (3) 
The behaviour of trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] (3) upon irradiation was 
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very different to that of the cis isomer (1). Very little precipitate was observed and 
after 120 min UVA irradiation the majority of platinum remained in the +4 oxidation 
state. The new Pt1" peaks were originally thought to be isomers, but two of the Pt"" 
photoproducts were identified as the monoazide species trans [Pt(N3)(OH)3('5NH3)2] 
(37) and the tetrahydroxy compound trans-[Pt(OH)4(15NH3)21 (38). The identification 
of the monoazide complex by 2D HSQC NMR spectroscopy and ESI-MS, confirms 
that the azides do not leave the platinum centre together. 
The lack of Pt" photoproducts means reduction is not occurring readily. The azides 
are therefore not leaving as azide radicals after each donating an electron to Pt'v but 
more likely as free azide (N3-). The azide anion (N3-) is also photoactive and can 
form N2 upon irradiation. E551  Perhaps some of the azide ligands break down while 
still attached to platinum, the formation of nitrene species upon irradiation of metal 
azide complexes has been previously reported.[ 11-251  Nitrenes are highly reactive and 
would go on to react further until stable, this could help explain the unidentified Pt" 
NMR peaks (34-36, 39). However, it seems unlikely that azide would react in two 
completely different ways during the same experiment. Another possibility is the 
formation of dimers; loss of the azides to form tn- and tetra-hydroxy species means 
that there are now several oxygen ligands free to bridge the platinum centres. 
Platinum(II) oxygen bridged dimers are well known, 29'56 and Pt1"' dimers have also 
been reported. E49,501  The formation of dimers is believed to be the most likely 
explanation for the extra NMR peaks. 
Initially the reluctance of the trans isomer to reduce to Pt" upon irradiation was 
unexpected. However, the behaviour of complex 3 in the presence of nucleobases 
was found to be totally different (Chapter 6). 
d) Trans, trans, trans-[Pt(N3)2(OH)2(N}13)(py)] (4) 
The pattern of peaks observed in the 2D [1 H,15N] HSQC NMR spectra after 
irradiation of trans, trans, trans-[Pt(N3)2(OH)2(' 5NH3)(y)] (4) for 15 mm (Figure 
5.11 a) is remarkably similar to that produced upon irradiation of complex 3 (Figure 
5.5a). This suggests that the photoproducts are the same, except with pyridine in 
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place of an '5 NH3 ligand. As there is only one '5N-labelled ammonia in '5N-4 this 
result gives further evidence against the new plV  peaks being due to 
photoisomerisation. Peaks 66 and 68 (Figure 5.11 and Table 5.5) were identified as 
the 	monoazide (trans- [Pt(N3)(OH)3(15  NH3)(PY)D   and tetrahydroxy (trans- 
[Pt(OH)4('5NH3)(y)]) species, respectively. This was carried out in the same way as 
for complex 3. The two small Pt" peaks clearly visible after 60 min irradiation 
(Figure 5.11 b) are in the region for H315  N-Pt"  trans to N. [30]  
Unlike experiments with complex 3, continued irradiation of solutions of complex 4 
led to further changes in the Pt" peaks. After 120 mm, peaks 65, 66 and 68 were the 
only Pt" peaks present. An insoluble precipitate was produced which presumably 
accounts for the overall loss in signal intensity. There was much more precipitate 
than for complex 3, but not as much as for complexes 1 and 2. 
By 1D ['H] and 2D ['H,'H] COSY NMR spectroscopy, it has been confirmed  that 
pyridine is not released from platinum upon irradiation. The stability studies also 
showed that pyridine does not leave the Pt's" centre in water or cell culture media 
over long periods of time. 
5.4.2.2 UV-Visible Spectroscopy 
Compounds 1 - 12 and 14 were irradiated with UVA light, and the reactions 
followed by UV-visible spectroscopy. All the compounds were photoactive, and the 
overall trend was a decrease in the N3 - Pt LMCT band. However, after only 1 mm 
irradiation, the absorbance bands of the cis compounds (1, 2 and 12) did not 
decrease. For complexes 2 and 12 the peak intensity increased slightly (Figure 5.14 
and Figure 5.15), but continued irradiation for 5 min and beyond then led to the 
expected decrease of the LMCT band. It is not clear why the absorbance initially 
increased upon irradiation only for compounds with cis geometry, but NMR studies 
have shown the photoreactions of cis (1) and trans (3) complexes produce very 
different photoproducts (Sections 5.3.2.1 a and c). 
Complex 12 contains chloride ligands which when bound to Pt1V  also give LMCT 
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bands in the UV-visible spectrum. 571 These bands appear in roughly the same region 
as those of azide due to the similar placement of the two ligands in the 
spectrochemical series N3 Cl-J5 8' This helps explain the broad shape of the LMCT 
peak at 264 nm (Figure 5.15). 
The complexes with trans geometry (3 - 11) generally showed a relatively large 
decrease in the LMCT band after only 1 min irradiation. For the trans complexes 
which do not contain pyridine or picoline rings (3, 5 - 7, 11) a new peak appeared at 
slightly higher energy (ca. 250 nm) after 5 min irradiation. This new peak is probably 
present for complexes 4 and 8 - 10 as well, but is masked by the aromatic ring 
absorbances. This new peak can be assigned to Pt'"  monoazide species, in which one 
of the azide ligands has been replaced with a hydroxide group (e.g. trans, trans. 
trans- [Pt(N3)(OH)3(NH3)2]). The PtIV  monoazide compound is likely to be 
photoactive too, and indeed this new peak decreases upon further irradiation. Trans, 
trans, trans-[Pt(N3)(OH)3(NH3)2] (38) has also been identified as a photoproduct of 
complex 3 by NMR spectroscopy as has trans, trans, trans-[Pt(N3)(OH)3(NH3)(py)] 
(50) from complex 4. 
The electronic absorption spectrum of trans, cis-[Pt(bpy)(OAc)2(N3)2] (14) during 
irradiation was complicated by absorbance bands from the bipyridine ring. The 
reaction could not be followed by the disappearance of the N3 - Pt LMCT band. 
Instead, after an initial decrease of the peak assigned as the LMCT band (250 nm), 
another band with a similar 2max  began to increase. Presumably the decrease is due to 
loss of the azide ligands and consequently the N3 - Pt LMCT band, but the 
photoproduct(s) formed must also absorb strongly in this region. 
The photoproducts were identified as {Pt(bpy)(OH)2J and [{Pt(bpy)(j.i-OH)}2] with 
extinction coefficients at ca. 250 nm of 14,400 and 16,000, respectively. [4  The 
electronic spectrum of an irradiated solution of 14 (Figure 5.18) was remarkably 
similar to those of [Pt(bpy)(OH)2] and [{Pt(bpy)(ji-OH)}2], and these compounds are 
also the main species seen by ESI-MS. 
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An interesting feature of the photoreaction of trans, cis-[Pt(bpy)(OAc)2(N3)2] was the 
appearance of a broad peak at 370 nm, which increased with increasing irradiation 
time (Figure 5.16). The photochemical oxidative addition of chloride to 
[Pt"(bpy)C12] to produce [Pt"(bpy)C14] has been reported, [591  this reaction was also 
followed by UV-visible spectroscopy and a decrease of a broad absorbance at ca. 400 
nm was observed. This band can be assigned as a metal-to-ligand charge-transfer 
(MLCT) from the HOMO, which is the metal based d2 orbital, to the LUMO 
which is the ic' anti-bonding orbital on bipyridine. 39'401 This MLCT band would be 
expected to appear upon reduction of Pt" to Pt" as observed upon irradiation of 
trans, cis- [Pt(bpy)(OAc)2(N3)2]. 
Two photoproducts from the irradiation of trans, cis-[Pt(bpy)(OAc)2(N3)2] have been 
identified, but it is surprising that neither of them contained acetate. Perhaps further 
study of the photoreaction of complex 14 could help the overall understanding of the 
mechanism of photoactivation of Pt"' azide complexes. 
5.5 Conclusions 
All the Pt"  azide complexes synthesised (1 - 14) were found to be photoactive, as 
determined by observing the changes in the UV-visible spectra. These Pt"' diazide 
complexes also proved to be very stable in the absence of light under the various 
conditions tested. Trans, trans. trans-[Pt(N3)2(OH)2(NH3)2] (3) was even found to be 
stable to reduction by glutathione. 
1D 'H and 2D ['H,'5N] HSQC NMR spectroscopic studies of the photoreactions of 
cis, trans, cis-[Pt(N3)2(OH)2(l 5NH3)2] (1), cis, trans- [Pt(' 5N-en)(N3)2(OH)2] (2), 
trans, trans, trans- [Pt(N3)2(OH)2(' 5NH3)2] (3) and trans, trans, trans-
[Pt(N3)2(OH)2(15NH3)(py)] (4) have demonstrated the different behaviour of the cis 
(1, 2) and trans (3, 4) complexes upon irradiation (Figure 5.19). Pt"'  photoproducts 
with hydroxides substituted for the azide ligands were identified for complexes 3 and 
4. This means that the mechanism of photoactivation (at least for 3 and 4) does not 
involve the transfer of an electron from each azide ligand to reduce the platinum 
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irradiation can help to explain the increased cytotoxicity of the trans complexes 
(Appendix 2). 
Major Products 	Minor Products 
OH 
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Figure 5.19 Summary of the photoreactions of a) the cis complexes 1 and 2, and 
b) the trans complexes 3 and 4 in aqueous solution. 
Two of the major photoproducts from irradiation of trans, cis-[Pt(bpy)(OAc)2(N3)2] 
(14) were also identified, both of which were Pt11 complexes (Figure 5.20). This 
indicates the major photoreaction of complex 14 is reduction. 
Figure 5.20 Photoproducts produced upon irradiation of trans, cis-
[Pt(bpy)(OAc)2(N3)2] (14) with UV light (365 nm). 
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6.1 Introduction 
The reactions of platinum(IV) azide complexes upon irradiation have been 
investigated by several techniques (Chapter 5). The interaction of these complexes 
with nucleobases and DNA is also of interest as DNA is generally accepted to be the 
main target of cisplatin." Once inside the cell, cisplatin hydrolyses to the mono- and 
di-aqua species, cis- [Pt(NH3)2Cl(OH2)] and cis-[Pt(NH3)2(OH2)2]2 , which form 
lethal cross-links on DNA. The N7 positions of two adjacent guanine bases are the 
preferred binding sites of c1sp1atin. 21 Besides GG intrastrand cross-links (70 %), the 
other major DNA adducts are intrastrand AG (but not GA) cross-links (15 %). Minor 
adducts include 1,3-intrastrand and interstrand cross-links involving two non-
neighbouring guanines. [2] 
The photoreactions of several Pt IV  azide complexes in the presence of the nucleotides 
5'-GMP and d(GpG), and 9-ethylguanine have been followed by 1D 'H and 2D 
['H,'5N] HSQC NMR spectroscopy. The preferential platination site for cis, trans-
[Pt(en)(N3)2(OH)2] has been determined by a transcription mapping study on plasmid 
DNA, and HPLC analysis of a platinated DNA duplex. 
6.2 Experimental 
6.2.1 Materials 
Complexes 1-4, and [PtC12('5NH3)(py)] were synthesised as previously described 
(Chapter 3). Silver nitrate, D20 and 1,4-dioxane were purchased from Aldrich, 5'-
GMP and reduced glutathione from Acros, HC104 from Fisons, 9-ethylguanine (9-
EtG), H202 and the sodium salt of d(GpG) from Sigma. 
6.2.2 Synthesis of trans-[Pt('5NH3)(py)(5'-GMP)2]2 
[Pt"C12(15NH3)Qy)] (3.4 mg, 0.009 mmol) was suspended in H2O (3 mL) and 
AgNO3 (3.2 mg, 0.018 mmol) added. After stirring for 24 h at 333 K, the insoluble 
AgCl was filtered off. An NMR sample was prepared using 0.54 mL of the above 
solution and 60 jL of D20, 5'-GMP (4 mol equiv, 2.8 mg) was added and the pH 
adjusted to 5 1 0.2. The 1D 'H and 2D [1H,15N] HSQC NMR spectra were acquired 
after 24 h (pH measured as 5.09), and then the sample was analysed by ESI-MS. 
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6.2.3 Photoreactions in the Presence of 5'-GMP, 9-Ethylguanine and d(GpG) 
Samples were prepared by dissolving the 5'-GMP or 9-ethylguanine in 90 % H20 I 
10 % D20 (0.6 mL) plus 2 p.L dioxane (1 %), and then adding this solution to 0.5 
mol equiv of the Pt'' azide complex. The sample was transferred to an NMR tube 
and the pH adjusted to 5 with HC104 (0.1 M) and NaOH (0.1 M). Samples with 
d(GpG) were made up in the same way, except a 3:2 molar ratio of PtIV  azide 
complex to dinucleotide was used. 
Details of the acquisition of NMR spectra, ESI-MS and pH adjustments are described 
in Chapter 2. UV irradiation (365 nm) was carried out with a UV lamp, while an 
argon:krypton laser was used for photoreactions at visible wavelengths (457.9 and 
647.1 nm); these light sources and the experimental set-up used for irradiations are 
described in detail in Chapter 2.3. 
6.2.4 Transcription Mapping of DNA Adducts 
A stock solution of cisplatin (5 x 10-4  M in 10 mM NaC104) was prepared at 298 K 
and used immediately. Plasmid pSP73KB [2455 base pairs (bp)] was isolated 
according to standard procedures and banded twice in CsC1/ethidium bromide 
equilibrium density gradients. Riboprobe Gemini System II for transcription 
mapping containing T7 RNA polymerase was purchased from Promega. 
Plasmid DNA was incubated with cisplatin in 10 mM NaC104 at 310 K in the dark 
for 24 h, or treated with a 0.5 molar equivalent of cis, trans-[Pt(en)(N3)2(OH)2] (2) in 
10 mM NaCI04 and irradiated (?. = 457.9 nm, 10 mW) for 3 h, while an identical 
sample was kept in the dark. These samples were then precipitated by ethanol and 
redissolved in the medium required for subsequent analysis. An aliquot of each 
sample was used to determine the value of rb (rb is defined as the number of 
molecules of the platinum compound bound per nucleotide residue) by flameless 
atomic absorption spectrophotometry (FAAS). 
Transcription of the (NdeI I HpaI) restriction fragment of pSP73KB DNA with 
DNA-dependent T7 RNA polymerase and electrophoretic analysis of transcripts 
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were performed according to the protocols recommended by Promega (Promega 
Protocols and Applications, 43-46 (1989/90) and previously described in detail). 3'41  
The incubations and irradiations were carried out by the author at the University of 
Edinburgh. Transcription mapping was conducted by Dr. Jana Kapárková and Prof. 
Viktor Brabec at the Academy of Sciences of the Czech Republic, Brno. 
6.2.5 HPLC Analysis of DNA Adducts 
The oligodeoxyribonucleotide duplex containing 40 bp, 
5 '-CCCGGATTATACGGCTTAAACCAAATTGCTTAAATTGGCC/ 
5 '-GGCCAATTTAAGCAATTTGGTTTAAGCCGTATAATCCGGG 
was from East Port (Prague, Czech Republic); the single-stranded oligonucleotides 
constituting this duplex were purified by strong anion exchange chromatography 
(Pharmacia MonoQ column) on a Pharmacia FPLC system with 10 mM NaOH, 0.2 - 
0.8 M NaCl gradient. The duplex was formed by heating a mixture of the 
complementary single-stranded oligonucleotides at equal concentrations (related to 
the mononucleotide content) at 263 K for 5 min followed by incubation at 298 K for 
4 h. DNase I from bovine pancreas, nuclease P1 from Penicillium citrinum and 
alkaline phosphatase from calf intestine were also from Sigma-Aldrich. Acrylamide, 
(bis)acrylamide and urea were from Merck KgaA (Darmstadt, Germany). 
The oligonucleotide duplex was treated with 1.5 molar equivalents of cis, trans-
[Pt(en)(N3)2(OH)2] in 100 mM NaC104 and irradiated (2 = 457.9 nm, 30 mW) for 6 
h, while an identical sample was kept in the dark. These samples were then 
exhaustively dialyzed against 100 mM NaCI04 in the dark. Aliquots were used to 
determine the value of rb by FAAS. 
These analyses were performed using a Hitachi Series 4 liquid chromatograph 
equipped with a LCI-100 computing integrator and a Waters iBondapack C18 
column. The products were separated by reverse phase (RP) HPLC (isocratic elution 
with 0.1 M ammonium acetate, pH 5.0 in 4 % CH3CN at 1 ml/min flow rate). The 
following enzymatic digestion protocol was used in order to characterize the 
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platinated deoxyribooligonucleotides. The samples (50 .ig of the oligonucleotide) 
were incubated with 72 units of DNase I at 310 K. After 4 h nuclease P1(40 tg) was 
added, and the reaction was allowed to continue at 310 K for 18 h. Finally, alkaline 
phosphatase (39 units) was added and the incubation continued for an additional 4 h 
at 310 K. The digested samples containing constituent nucleosides were then heated 
for 2 min at 80 °C, centrifuged and the supernatant analyzed by RP-HPLC. Each 
analysis was performed four times and the data varied on average + 1 % from their 
mean. 
The incubations and irradiations were carried out by the author at the University of 
Edinburgh. HPLC analysis was conducted by Dr. Jana Kapárková and Prof. Viktor 
Brabec at the Academy of Sciences of the Czech Republic, Brno. 
6.3 Results 
The binding of 5'-GMP and d(GpG) to cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] (1) and 
cis, trans- [Pt('5N-en)(N3)2(OH)2] (2) upon irradiation with blue light (457.9 nm) has 
been shown previously. [5,121  These reactions were repeated with UV light (365 nm) to 
determine whether the photoproducts were the same. It was thought that the higher 
energy light would perhaps cause some fragmentation of the reactants or products. 
UV light (365 nm) has been used to activate the Pt IV  azide compounds in the cell 
cytotoxicity experiments (Appendix 2), therefore their chemical behaviour upon 
irradiation at 365 nm is important. 
OH 	 H2  OH 
H3N, N3 	 N,  	,N3 
Pt 
H3N\ 
OH 	 H2 OH 
1 2 
H3N OH N3 Q, OH  
Pt' 
N('  NH3 	 N( NH3  
OH 	 OH 
3 4 
Figure 6.1 Structures of PtW  azide compounds. 
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Reactions of PtIV  diazido-dihydroxy complexes can be followed by 'H NMR studies 
of the am(m)ine protons if the reactions are carried out in H20. However at neutral 
pH no 'H am(m)ine peaks are detected due to fast exchange of the NH protons with 
the solvent. With decreasing p1-I the signals appear, and so the pH is usually adjusted 
to 5. 
As explained above in order to observe the 'H am(m)ine peaks of Pt' diazido 
dihydroxy complexes it is necessary to adjust the pH to 5. However, when these 
complexes were irradiated on their own in solution the pH was found to increase 
(Section 5.3.2). The increase in pH with longer irradiation times was more 
pronounced for complex 1 than for 3 or 4 (Chapter 5, Figure 5.1). When these 
reactions are carried out in the presence of 5'-GMP, the pH increase followed a 
similar trend for complexes 3 and 4, compared to the complexes alone. However the 
pH increase for complex 1 was significantly less than for irradiation of 1 on its own 
(Figure 6.2). This is perhaps due to buffering effects caused by the phosphate group 
of 5'-GMP (pKa 6.25)J91 Adjustment of the pH to 5 after irradiation, but before 
acquiring NMR spectra was carried out for all experiments unless otherwise stated. 
Time of Irradiation (mm) 
Figure 6.2 The increase in pH (from 5 + 0.2) after each irradiation determined for 
cis, trans, cis- [Pt(N3)2(OH)2(' 5NH3)2] (1), trans, trans, trans- [Pt(N3)2(OH)2(' 5NH3)2] 
(3) and trans, trans, trans-[Pt(N3)2(OH)2(' 5NH3)(py)] (4) in the presence of 2 mol 
equiv 5'-GMP. 
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Figure 6.3 Structures and atom numbering schemes for a) 5'-GMP and b) 9-
ethylguanine. 
6.3. 1.1 Cis, trans, cis-[Pt(N3)2(OH)2(' 5NH3)2] (1) 
A 3 mM sample of cis, trans. cis-{Pt(N3)2(OH)2('5NH3)2] (1) was irradiated with 
UVA light in the presence of 2 molar equivalents of 5'-GMP. 11) ['H] and 21) 
['I-1,'5N] HSQC NMR spectra were acquired after 0, 1, 5, 15, 30 and 60 min of 
irradiation with the pH readjusted to 5 each time. 
After 1 mm, four new ['H,'5N] NMR cross-peaks assignable to Pt" species were 
visible (70-73), including one which corresponded to cis-[Pt('5NH3)2(5'-GMP- 
2+ 	 [61  N7)2] (70) (Table 6.1). After 5 mm another new peak for a Pt" complex (74) 
appeared (Table 6. 1), which has been assigned as trans- [Pt('5NH3)2(5'-GMP-N7)2]2 
(Figure 6.4). The chemical shifts of 74 agree well with the literature values, [36]  and 
are almost identical to those of the major product formed on photoreaction of trans, 
trans, trans- [Pt(N3)2(OH)2('5NH3)2] with 5'-GMP. This product was confirmed as 
trans-[Pt(' 5NH3)2(5 '-GMP-N7)2]2 (Section 6.3.1.2). 
The three other peaks (71-73) are as yet unassigned. However, peaks 71 and 72 grew 
in intensity at the same rate and so are likely to be due to inequivalent 15NH3's within 
the same molecule. Perhaps one of the bound 5'-GMP components has undergone a 
modification caused by the light, however no reaction was seen when a 6 mM sample 
of 5'-GMP in 90 % H20 I 10 % D20 was irradiated at 365 nm for 4 h. The reaction 
was monitored by 'H NMR spectroscopy and the spectrum was identical before and 
after irradiation. 
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Figure 	6.4 	2D [1H,15N] 	HSQC NMR spectra 	of 	cis, 	trans. 	cis- 
[Pt(N3)2(OH)2(15  NH3)21   (3 MM) and 5 '-GMP (6 mM) after irradiation with UV light 
for a) 5 min and b) 30 mm. * 195Pt satellites. 
Table 6.1 'II and '5N NMR chemical shifts of Pt" photoproducts after UV irradiation 
of cis, trans, cis-[Pt(N3)2(OH)2(' 5NH3)2] 
Peaks' 6('H) I ppm 6('5N) I ppm Assignments 
70 4.45 -67.47 cis- [Pt(' 5NH3)2(5 '-GMP-N7 2]2  
71 4.11 -68.68 Pt" photoproduct 
72 4.07 -67.95 Pt" photoproduct 
73 4.17 -64.92 Pt" photoproduct 
74 4.13 -60.55 trans-[Pt(' 5NH3)2(5 '-GMP-N7)2]2 
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6.3.1.2 Trans, trans, trans-[Pt(N3)2(OH)2('5NH3)2] (3) 
A 3 mM sample of trans, trans, trans- [Pt(N3)2(OH)2('5N113)2] (3) was irradiated with 
UVA light in the presence of 2 molar equivalents of 5'-GMP. 1D [1H] and 2D 
['H,15N] HSQC NMR spectra were acquired after 0, 1, 5, 15, 30 and 60 min of 
irradiation with the pH readjusted to 5 each time. 71 As described in section 6.3, the 
pH rises upon irradiation. 
The NMR spectra showed that about 7 % of complex 3 had undergone 
photoreduction and photosubstitution after only one minute of irradiation. The Pt" 
product had 6('H,15N) chemical shifts of 4.14, -60.51 ppm, which are characteristic 
of the bis-GMP adduct trans- [Pt('5NH3)2(5'-GMP-N7)2]2 (74) (Figure 6.5)J361 After 
1 h,> 75 % of complex 3 had been converted into 74 as the major product (Figure 
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Figure 6.5 2D [1H,15N] HSQC NMR spectra recorded during reaction of trans, 
trans, trans- [Pt(N3)2(OH)2('5NH3)2] with 2 mol equiv of 5'-GMP after a) 0 min,b) 1 
mm c) 30 mm, and d) 120 min irradiation. The pH was adjusted to 5 ± 0.2 after every 
irradiation. * 195Pt satellites. 
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Trans [Pt(lsNH3)2(5.GMPN7)J2* (74) 
I 	 —I 
Trans-[Pt(15NH3)2(5-GMP-N7)12 (74) 
40 
2011  	\ 	-..... 	 Free 5-GMP 
0 	. 	_
(3) 
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Time (mm) 
Figure 6.6 The decrease in concentration of trans, trans, trans-
[Pt(N3)2(OH)2('5NH3)2] (-) and free 5'-GMP (-) with time of irradiation based on 
the integrals of the corresponding peaks in the 2D [1H,'5N] and 1D ['H] NMR 
spectra, respectively. The formation of the product trans- [Pt(' 5NH3)2(5 '-GMP-
N7)2]2+  (74) was followed using both the 1D (-) and 2D (-) spectra. 
Table 6.2 'H and 15N NMR chemical shifts of Pt" photoproducts from irradiation of 
trans, trans, trans-[Pt(N3)2(OH)2(' 5NH3)2]. 
Peaksa 6(1 H) / ppm 5N) / 
PPM 
Assignments 
74 4.14 -60.51 trans-[Pt(' 5NH3)2(5 '-GMP-N7)2]2 
75 4.10 -63.23 trans-{Pt(' 5NH3)2(OH2)2]2 
76 3.94 -62.65 Pt" photoproduct 
77 3.97 -65.30 Pt11 photoproduct 
78 4.04 -61.42 trans-[Pt('5NH3)2(9-EtG)2]2 
a) See Figure 6.5 for peak labels 
The formation of 74 can be followed by measuring the intensity of the 2D ['H, 15N] 
cross peak or the new H8 peak in the ID ['H] spectra. These results are plotted in 
Figure 6.6 and the rates correlate well. A correction for 195Pt satellites (which are 
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(8.79 ppm) in complex 74. This low-field shift of the 118 signal is characteristic of Pt 
binding to the N7 position of 5'-GMP. 81  
H8 Pt- H8 
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 ppm 
(1H) 
Figure 6.7 'H NMR spectra of trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (3 mM) and 
5'-GMP (6 mM) after UVA irradiation for various times. The H8 regions of free and 
platinum-bound 5'-GMP are boxed. Spectra are offset for clarity. 
Binding of Pt" to N7 was further confirmed by a 1H NMR pH titration over the range 
pH 1 - 11 (Figure 6.8). The 118 chemical shift change associated with the protonation 
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of N7 of 5'-GMP (pKa ca. 2.5)' was absent for the product (74)J' 03  
A his adduct trans- [Pt('5NH3)z(9-ethylguanine-N7)2] (78; Table 6.2) appeared as a 
product from the photoreaction of complex 3 with 9-ethylguanine after only 1 mm 
of irradiation. ESI-MS gave a peak at mlz 295.3 assignable to [Pt('5NH3)2(9- 
ethylguanme-N7)2
]2+ (caic. mlz 294.7). 
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8.8 




8.2 	 NI PF<a 
81 	I 	I 	I I 	I 	 I 	I 	I 
0 2 4 6 8 	10 12 
pH 
Figure 6.8 Variation with pH of the H8 NMR chemical shift of the major product 
from irradiation of trans, trans, trans-[Pt(N3)2(OH)2('5NH3)2] in the presence of 5'-
GMP (74 trans- [Pt('5NH3)2(5'-GMP-N7)2]), in comparison with free 5'-GMP. The 
large increase in chemical shift below pH 4 for free 5'-GMP is absent for 74 
indicating coordination of Pt to N7. 
Interestingly (in view of the deeper tissue penetration of red light), irradiation of 
complex 3 (3 mM) and 5'-GMP (6 mM) with red light (?. = 647.1 n -n., P = 18 mW) 
also gave rise to a detectable amount of trans-{Pt( 15  NH3)2(5,  -GMP-N7)2]2+ (ca. 2/o 
after 90 mm; Figure 6.9)." 
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8(1H) 
Figure 6.9 2D [11-1,15N] NMR spectrum of trans, trans, trans- {Pt(N3)2(OH)2('5NH3)2] 
after irradiation with red light (X = 647.1 nm, 18 mW, 90 mm) pH 5 * 195Pt satellites. 
6.3.1.3 Trans, trans, trans- [Pt(N3)2(OH)2('5NH3)Qy)] (4) 
Trans, trans, trans-[Pt(N3)2(OH)2('5NH3)(py)J (3 mM) was irradiated with UV light 
in the presence of 2 mol equiv of 5'-GMP. The reaction was followed by 1D ['H] and 
2D ['H,'5N] HSQC NMR spectroscopy, spectra were recorded after 0, 1, 5, 15, 30 
and 75 min irradiation, with the pH adjusted to 5. 
Initially, by comparison with the photoreaction of complex 3 and 5'-GMP, it was 
assumed that peak 79 was assignable to the bis-GMP adduct trans-[Pt(15NH3)(py)(5'-
GMP-N7)2I2 (Figure 6.10). 
To confirm this, trans- [Pt('5NH3)(py)(5'-GMP-N7)2]2 was synthesised from trans-
[Pt(15NH3)(py)C12] and analysed by 1D ['H] and 2D ['H,'5N] HSQC NMR 
spectroscopy and mass spectrometry (Figure 6.11). The only peak present after 24 h 
was 83 (Table 6.3, Figure 6.11); a new 5'-GMP H8 signal had appeared which was 
shifted to low field (8.86 ppm) compared to free 5'-GMP (8.12 ppm) (Table 6.4). 
This is characteristic of platinum binding to the N7 position of 5'-GMP. By mass 
spectrometry this product was confirmed to be trans- [Pt('5NH3)(py)(5'-GMP-N7)2]2 
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Table 6.3 'H and '5N NMR chemical shifts (ppm), coupling constants (Hz) and 
assignments of Pt" and Pt'" pyridine complexes. 





4 5.65 -46.00 282.3 49.5 t,t,t-[Pt''(N3)2(OH)2('5NH3)(py)] 
79 4.15 -66.37 - - t-[Pt"('5NH3)(py)(N3)(5'-GMP)J 
80 4.42 -65.63 - - t-[Pt"(' 5NH3)(py)(5 '-GMP)2] 
81 4.57 -63.77 - - Pt" photoproducts 
82 4.35 -68.80 - - Pt" photoproducts 
83 4.42 -65.25 - - t-[Pt"(15NH3)(y)(5'-GMP)2] 
84 4.15 -67.72 - - t-[Pt11('5NH3)(y)Cl(5'-GMP)j1 
50 5.56 -45.62 298 50 t-[Pt"(N3)(OH)3(15NH3)(py)] 
51 5.94 -47.10 290 48 Pt'' photoproducts 
a) See Figures 6.10 and 6.11 a for peak labels 
Figure 6.10 2D [11-1,15N] HSQC NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2('5N113)(py)J in the presence of 2 mol equiv of 5'-GMP after a) 1 mm, 
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Figure 6.11 NMR and ESI-MS of synthesised trans-[Pt('5NH3)(py)(5'-GMP-
N7)2]2 . a) 1D ['H] and 2D ['H,'5N] HSQC NMR spectra and b) ESI-MS, calculated 
mlz for {[Pt('5NH3)(py)(5'-GMP-N7)2]2 - 2H + 2 Na} 531.06 
Table 6.4 'H NMR chemical shifts of pyridine and H8 5'-GMP resonances. 
Peaksa  ('H) / ppm Assignments 
5'GMP H8  py-H0 py-H pyHm 
4 8.72 8.25 7.78 - i,t,t-[Pt(N3)2(OH)2(15NH3)(py)] 
79 8.68 7.94 7.47 8.67 t-[Pt"('5NH3)(py)(N3)(5'-GMP)f' 
80183b 8.57 7.87 7.36 8.86 7[Pt7('5NH3)(y)(5'-GMP)212 
84 8.63 7.91 7.41 8.74 t-[Pt"('5NH3)(py)Cl(5'-GMP)f 
See Figures 6.10 and 6.11 a for peak labels 
Peak 80 was observed after irradiation of 4 and 5'-GMP. Peak 83 was obtained 
from synthesised trans-{Pt"(' 5NH3)(py)(5 '-GMP)2]2 . Therefore these peaks are both 
assigned as trans- [Pt"('5NH3)(y)(5'-GMP)2]2 . 
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Interestingly this experiment showed that the main photoproduct 79 is not the bis-
GMP adduct. The chemical shifts of peak 80 (Table 6.3) agree very well with those 
of the synthesised trans- [Pt('5NH3)(y)(5'-GMP-N7)2]2 (83) and so species 80 is 
assigned as the bis-GMP adduct. 
Peak 79 is believed to be the monoazide species trans- [Pt'1(15NH3)(py)(N3)(5'-GMP-
N7)] for the following reasons. 
A peak for trans-[Pt11(15NH3)(py)(N3)(5'-GMP-N7)I was detected in the mass 
spectrum of irradiated samples of 4 containing 5 '-GMP. 
Peak 79 decreased in intensity upon further irradiation (Figure 6.12) which 
would be expected if azide was still bound to platinum. 
The chemical shifts of trans-[Pt"(15NH3)(py)Cl(5'-GMP)] (84) are known 
(Table 6.3). Due to the similar electronic properties of azide and chloride 
trans-[Pt11('5NH3)(py)(N3)(5'-GMP-N7)] would be expected to have similar 
'H and 15N chemical shifts. Indeed the chemical shifts of 79 and 84 compare 
well. 
The main Pt '  photoproduct in the presence of 5'-GMP is the monoazide 
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Figure 6.12 The decrease in concentration of complex 4 and formation of complexes 
79 and 80 upon irradiation with UVA light based on the integrals of peaks in the 2D 
['H,15N] HSQC NMR spectra. 
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Peaks 81 and 82 are unassigned, but at least one, if not both, are assignable to species 
which contain 5'-GMP. One other new H8 peak (8.84 ppm) can be seen in the 'H 
NMR spectra (Figure 6.13), however it is possible that yet another H8 peak could be 
masked by the pyridine resonances. There was no evidence for pyridine release 
during the irradiation of complex 4 in the presence of 5'-GMP. 
Figure 6.13 'H NMR spectra for the reaction of trans, trans, trans-
[Pt(N3)2(OH)2(15NH3)(y)] in the presence of 2 mol equiv 5'-GMP after irradiation 
for a) 1 mm, b) 15 min,c) 30 mm, and d) 75 mm. The H8 peaks of 5'-GMP are 
boxed and highlighted with filled circles (.). 
The reaction between complex 4 and 5'-GMP was repeated using red light (647.1 
nm, 15 mW). Peaks corresponding to trans-[Pt(15NH3)(py)(N3)(5'-GMP)] (79) and 
trans- [Pt(' 5NH3)(py)(5'-GMP)2]2 (80) appeared after 2.5 h irradiation (Figure 6.14). 
This is remarkable considering the low power and the weak absorbance of 4 at this 
wavelength (E647 = 3 M'cm') 
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Figure 6.14 2D [11-1,15N] HSQC NMR spectra of trans, trans, trans-
{Pt(N3)2(OH)2(15NH3)(py)] (3 mM) in the presence of 2 mol equiv 5'-GMP after 150 
min irradiation with red light (647.1 run, 15 mW). * '95Pt satellites. 
6.3.2 Photoreactions of Pt" Azide Complexes with d(GpG) 
0 
H—' X'LNHNH2 
HO 	I 	i 
J  ipi  H H (fANH H H 
I 	N 	N 	NH2 
OH H 
Figure 6.15 Structure of d(GpG). 
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6.3.2.1 Cis, trans, cis-[Pt(N3)2(OH)2(15  NH3)21   (1) 
A solution of cis, trans, cis-[Pt(N3)2(OH)2('5N1-13)2J (0.75 mM) and the sodium salt of 
d(GpG) (0.5 mM) was irradiated with UVA light. 1D ['H] and 2D ['H,'5N] NMR 
spectra were acquired after 0, 3, 6, 11, 16, 26, 36, 46 and 56 min with the pH 
readjusted to 5. 
-70 
E 60  
0. 
CL  
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Figure 6.16 2D ['H,'5N] HSQC NMR spectrum of cis, trans, cis-
[Pt(N3)2(OH)2('5NH3)2] (0.75 mM) and d(GpG) (0.5 mM) after 11 min of UV 
irradiation.'95Pt satellites are indicated by *• 
Figure 6.16 shows a peak for cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2] and two small 
peaks which correspond to cis- [Pt(1 5NH3)2)2(d(GpG)-N7( 1 ),N7(2))]2 6('H, '5N) 
(4.45, -68.30 / 4.38, -68.10) (85) after 11 min irradiation. [121  These new Pt" peaks 
first appear after 11 mm, but do not significantly increase in intensity upon further 
irradiation. The concentration of the Pta' starting material does, however, continue to 
decrease. 
6.3.2.2 Cis, trans-[Pt(' 5N-en)(N3)2(OH)2] 
A solution of cis, trans-[Pt(' 5N-en)(N3)2(OH)2] (0.75 mM) and d(GpG) (0.5 mM) 
was irradiated with UV light. NMR spectra were acquired after 0, 1, 3, 6, 11, 16, 26, 
36 and 46 mm. The pH was readjusted to 5 after each irradiation and before NMR 
analysis. 
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H8 peaks 	H8 peaks 
[Pt(15en15)d(GpG)] d(GpG) 
8.8 8.6 8.4 8.2 8.0 7.8 7.6 7.4 ppm 
Figure 6.17 ['H] NMR spectra of the 118 region of cis, trans-[Pt(' 5N-en)(N 3)2(OH)2] 
(0.75 mM) and d(GpG) (0.5 mM) after irradiation with UV light for various lengths 
of time. 
Figure 6.17 shows peaks assignable to the H8 of free d(GpG) (8.02, 7.78 ppm) and 
for Pt"-bound (8.48, 8.17 ppm). This low-field shift of about 0.4 ppm of 118 is 
characteristic of Pt binding to N7 of d(GpG).'31  
The 2D ['H,15N] HSQC NMR spectrum of complex 2 in the presence of d(GpG) 
(Figure 6.18a) after 26 min irradiation contained a new set of cross-peaks (86, 5.64, - 
31.22 ppm) which consists of four resonances of equal intensity and is separated into 
two pairs associated with distinct '5N chemical shifts 5.58, 5.62 / -31.47 ppm and 
5.66, 5.71 / -31.10 ppm. This is the region where Pt"(15  NH2)   trans to N peaks are 
expected, 141 and the shifts agree well with those reported for [Pt(en)(d(GpG)-
N7,N7)]2 (86).'' These peaks first appear after 3 min of irradiation, and continue to 
increase in intensity until about 30 mm (Figure 6.18b). Only 2 other new peaks (6.30, 
-8.15 and 6.27, -16.68) were seen during the course of the reaction. These were 
relatively small and are most likely to be Pt's' substitution photoproducts (Figure 
6.18a). 
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Figure 6.18 Photoreaction of cis, trans- [Pt('5N-en)(N3)2(OH)2] and d(GpG). a) 2D 
['H,'5N] HSQC NMR spectrum of cis, trans-[Pt('5N-en)(N3)2(OH)2] and d(GpG) 
after irradiation for 26 mm. b) Progress of the reaction based on peak integrals for 
both 1D 'H and 2D [1H,15N] spectra. If the reaction had gone to completion and 
platinum was bound to all the d(GpG) present, the amount of [Pt(15N-en)(d(GpG)-
N7(l),N7(2))]2 formed would be 67 %, as indicated by the dotted line. 
6.3.3 Transcription Mapping of DNA Adducts 
Transcription mapping studies on a 212 base pair (bp) fragment of pSP73KB plasmid 
DNA treated with cis, trans-[Pt(en)(N3)2(OH)2] and irradiated, were carried out to 
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vitro RNA synthesis by RNA polymerases on DNA templates which contain several 
types of bifunctional adducts of platinum complexes, can be prematurely terminated 
at the level or in the proximity of the adducts. 3'4'17"81 Importantly, monofunctional 
DNA adducts of several platinum complexes, such as [PtC1(dien)]Cl or 
[PtCl(NH3)3]Cl are unable to terminate RNA synthesis. 
Cutting of pSP73KB DNA by NdeI and HpaI restriction endonucleases yielded a 
212-bp fragment (a substantial part of its nucleotide sequence is shown in Figure 
6.19a). 3'41 This fragment contained a T7 RNA polymerase promotor in the upper 
strand close to its 3' end. The experiments were carried out using this linear DNA 
fragment, treated with cis, trans-[Pt(en)(N3)2(OH)2] at ri = 0.5 (ri is defined as the 
molar ratio of free platinum complex to nucleotide phosphates at the onset of 
incubation with DNA) and cisplatin at rb = 0.01, for RNA synthesis by T7 RNA 
polymerase. 
Two samples of plasmid DNA were treated with cis, trans-[Pt(en)(N3)2(OH)2], one 
was irradiated while the other was kept in the dark. Both samples were precipitated 
with ethanol, dissolved in 10 mM Tris.HCI plus 0.1 M EDTA (pH 7.2) and then the 
platinum content estimated by FAAS. The non-irradiated sample contained no 
platinum, whereas the irradiated sample was modified at a level of rb = 0.01. RNA 
synthesis on the template modified by cis, trans-[Pt(en)(N3)2(OH)2] / irradiation and 
by cisplatin yielded fragments of defined sizes (Figure 6.19b), which indicates that 
RNA synthesis on these templates was prematurely terminated. The major stop sites 
produced by the irradiated template (Figure 6.19b, lane "Irradiated") were similar to 
those produced by cisplatin (Figure 6.19, lane "Cisplatin"), however no stop sites 
were produced by the template treated with cis, trans-[Pt(en)(N3)2(OH)2] which was 
not irradiated. The stop sites produced by the irradiated sample and those modified 
by cisplatin appeared at guanines mainly contained in GG sequences (i.e. at the sites 
which are preferential DNA binding sites of cisplatin. [2,19] 
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Figure 6.19 Inhibition of RNA synthesis by T7 RNA polymerase on the NdeL/HpaI 
fragment of pSP73KB plasmid modified by cis, trans-{Pt(en)(N3)2(OH)2] and 
cisplatin. a) Schematic diagram showing the portion of the nucleotide sequence used 
to monitor inhibition of RNA synthesis by cis, trans-[Pt(en)(N3)2(OH)2] and 
cisplatin. The arrow indicates the start of the T7 RNA polymerase. (.), major stop 
signals (from 6.19b, lane Irradiated). The numbers correspond to the nucleotide 
numbering in the sequence map of pSP73KB plasmid. b) Autoradiogram of 6% 
polyacrylamide / 8 M urea sequencing gel. Lanes: Control - nonmodified template; 
Dark - the template modified by cis, trans-[Pt(en)(N3)2(OH)21  and not irradiated; 
Cisplatin - the template modified by cisplatin; Irradiated - the template modified by 
cis, trans- [Pt(en)(N3)2(OH)21 and irradiated. 
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6.3.4 HPLC Analysis of DNA Adducts 
A 40-bp deoxyribooligonucleotide duplex (with a random nucleotide sequence) was 
treated with cis, trans-[Pt(en)(N3)2(OH)2] and irradiated, an identical sample was 
kept in the dark. Both samples treated with cis, trans-[Pt(en)(N3)2(OH)2] were 
exhaustively dialyzed against 100 mM NaC104 in the dark and the content of 
platinum in these samples was estimated by FAAS. The nonirradiated sample 
contained no platinum, whereas the irradiated sample was modified at a level of rb = 
0.07. Both samples treated with cis, trans-[Pt(en)(N3)2(OH)2] and the control 
(nonmodified) sample were enzymatically digested to mononucleosides. RP-HPLC 
analysis of enzymatic digests of oligonucleotide duplexes was performed by 
recording the optical density at 260 nm. 
Well-resolved mononucleoside peaks were observed in the profiles, which reflected 
the proper proportions Of the single mononucleosides in the non-modified duplex 
when integrated and normalized by their extinction coefficients. Digestion of the 
duplex which was treated with cis, trans-[Pt(en)(N3)2(OH)2], but not irradiated 
produced the mononucleoside peaks whose integrated area remained unaffected (not 
shown). In contrast, digestion of the platinated sample which was irradiated resulted 
mainly in the decrease of the integrated area of the deoxyriboguanosine peak, and to 
a markedly smaller extent also in the decrease of the deoxyriboadenosine peak 
(Figure 6.20). The peaks for deoxyribocytidine and thymidine were not affected. It 
was verified by FAAS that no product containing platinum co-eluted with the peaks. 
The platinated products were not retained by the column under the conditions used, 
so they could not be identified and quantified. The integrated area of the 
deoxyriboguanosine peak decreased by 58% and that of the deoxyriboadenosine peak 
by 2%. 
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Figure 6.20 Reverse phase Cl 8 HPLC separation of the products of the enzymatic 
digest of the 40-bp oligonucleotide duplex. a) Control (nonmodified) and b) modified 
by cis, trans-[Pt(en)(N3)2(OH)2J and irradiated. 
6.4 Discussion 
6.4.1 Photoreactions of Pt" Azide Complexes with 5'-GMP and 9-Ethylguanine 
The target for cisplatin and other related platinum anticancer drugs is DNA, [20]  the 
preferred binding site is the N7 position of guanine bases. The interaction of several 
Pt '  azide complexes with 5'-GMP and / or 9-EtG upon irradiation was investigated. 
When the platinum complexes are 15N-labelled this reaction can be followed by 2D 
['H,'5N] HSQC NMR spectroscopy. 
6.4.1.1 Cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2] (1) 
The chemical shifts of the new Pt" peaks produced on irradiation at 365 nm of 
aqueous solutions of cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2] (1) and 5'-GNP, are all in 
the region for H3N-Pt trans to nitrogen.'41 The main Pt" product can be assigned as 
5 	 2+ 	 6] czs-[Pt(1  NH3)2(5 -GMP)2] (70) from literature values. Interestingly a peak for the 
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trans isomer trans- [Pt('5NH3)2(5'-GMP)2]2 (74) also appeared after 5 mm. 
Photo i somerisation could have occurred when the complex was in the Pt"  or Pt IV 
oxidation state, or during the reduction step. Photoisomerisation of platinum 
compounds has been reported previously. [21,221 
No cross-peaks due to photoproducts such as cis-[Pt(15NH3)2(OH/OH2)2]2 or cis- 
[Pt(' 5NH3)2(OH/0H2)(5 '-GMP)]2 	appeared, 	although they are possible 
intermediates. Their absence indicates that platinum binding to 5'-GMP is rapid upon 
loss of the azide ligand(s). 
These results compare well with those of a similar reaction carried out with blue light 
(457.9 nm). 5 '2' The same five peaks (70 - 74) are observed even though the pH was 
adjusted to 5 before irradiation but not changed again after. During irradiation with 
UVA light, the pH was readjusted to 5 after each irradiation (0, 1, 5, 15, 30, 60 and 
120 mm). The reaction with blue light is much slower, as would be expected due to 
the much lower absorbance at 457.9 nm (18 M'cm'), compared to 365 nm (298 M 
'cm'). 
6.4.1.2 Trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2J (3) 
No reaction was observed between trans, trans, trans- [Pt(N3)2(OH)2('5NH3)2] and 5'-
GMP in the dark (Chapter 5, Section 5.3.1.3), but after irradiation for only one 
minute, 7 % of the starting material underwent photoreduction and photo substitution 
to produce trans- [Pt('5NH3)2(5'-GMP-N7)2]2 (74; Figure 6.5))171  This is remarkable 
as only a very small amount of reduction was seen after 60 min irradiation of trans, 
trans, trans- [Pt(N3)2(OH)2('5NH3)2] in the absence of nucleotides (Chapter 5, Section 
5.3.2.1c). After 1 h, > 75 % of trans, trans, trans- [Pt(N3)2(OH)2(15NH3)2] was bound 
to 5'-GMP as the trans bis-G adduct (Figure 6.6). 
To confirm that platinum was bound to 5'-GMP in the N7 position a 'H NMR pH 
titration over the range pH 1 -11 was carried out. Free 5'-GMP binds two protons at 
the phosphate group and one at the N7 position (Figure 6.3).' The pKa values of 5'-
GMP are listed in Table 6.5. 
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Table 6.5 PKa values of 5'-GMPJ9' 
Deprotonation PKa 
-P(0)-(OH)2 0.3 ± 0.2 
N7 H 2.48 ± 0.04 
-P(0)(0)(OH) 6.25 ± 0.02 
Ni H 9.49 ± 0.02 
Protonation of Ni and N7 of free 5'-GMP cause the H8 'H NMR signal to shift to 
lower field, whereas phosphate protonation causes a shift to higher field (Figure 
6.8).[101 Figure 6.8 shows that the H8 shift associated with N7 protonation is absent 
for photoproduct 74 indicating that platinum is bound to 5'-GMP in the N7 
position. [71  
Figure 6.6 plots the decay of the 5'-GMP and complex 3 peaks, and the formation of 
trans-[Pt('5NH3)2(5'-GMP-N7)2]2 upon irradiation. After 120 min there is no trans, 
trans, trans- {Pt(N3)2(OH)2('5NH3)2] left but there is still some free 5'-GMP, and -'74 
% has been converted into trans-[Pt('5NH3)2(5'-GMP-N7)2]2 . The other 26 % of 
Pt- '5NH3 is contained in 3 other platinum(II) complexes (75, 76 and 77) which have 
peaks close to those of 74 (Figure 6.5). Cross-peak 75 has been assigned as trans-
[Pt(' 5NH3)2(OH2)2]2 from literature values. [6]  
Irradiated solutions of complex 3 and 5'-GMP, as well as 15N-labeiled NMR samples, 
were analysed by ESI-MS in the hope of detecting a peak for 74 (trans-
[Pt(15NH3)2(5'-GMP-N7)2]2 ). However this complex was never observed, which. 
could perhaps be due to the charge on the phosphate groups interfering; this charge 
depends on the pH. When complex 3 was irradiated in the presence of 9-
ethylguanine (9-EtG) (Figure 6.3), ['H, '5N] HSQC NMR spectroscopy showed the 
major product was a Pt" complex (4.04, -61.42 ppm). Upon analysis by mass 
spectrometry, a peak for [Pt('5NH3)2(9-EtG)2]2 with the appropriate isotope pattern 
was seen. This result helps to confirm that the major product upon irradiation of 
complex 3 and 5 '-GMP is the his trans GMP adduct 74, and shows that when there 
are no phosphate groups present, the product can be detected easily by mass 
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spectrometry. 
After observing the efficiency of the photoreaction of complex 3 and 5'-GMP using 
UVA light, it was repeated with red light (2. = 647.1 nm). The reason for attempting 
this reaction is because of the greater depth of penetration into tissue of light with a 
longer wavelength. 231 After 90 min irradiation (647.1 nm, P = 18 mW), a peak for 74 
was present. This is remarkable considering the relatively low power, and the weak 
absorbance at 647.1 nm (s = 8 M'cm). 
The formation of a major product (74) on irradiation of complex 3 in the presence of 
5'-GMP, and absence of the range of side-reactions seen on irradiation of compound 
complex 3 alone, suggest that 5'-GMP can rapidly trap reactive intermediates 
produced during the photoexcitation process. [7]  
These reactions of 3 with guanine derivatives are remarkable for two reasons. First, 
platination occurs very rapidly in comparison to reactions of transplatin, [241  and 
second bis-guanine adducts are readily formed, whereas the progression from mono-
to bis-adducts is rarely observed for reactions of transplatin. The lack of ability of 
transpiatin to form bis-G adducts is thought to be responsible for its lack of 
anticancer activity. 251  
6.4.1.3 Trans, trans, trans- [Pt(N3)2(OH)2('5NH3)(py)] (4) 
The photoreaction of trans, trans, trans- [Pt(N3)2(OH)2(5NH3)(py)] gave a similar 
pattern of Pta' peaks in the 2D ['H,'5N] HSQC spectrum, to those seen upon 
irradiation of trans, trans, trans- [Pt(N3)2(OH)2(5NH3)2] (3) (Chapter 5). For this 
reason it was thought that the two compounds acted in a similar way when irradiated. 
Although this assumption appears to be true for the compounds alone in solution, a 
different scenario arises when irradiation takes place in the presence of 5'-GMP. 
The photoreaction of complex 4 in the presence of 2 mol equiv of 5'-GMP gave 
unexpected results. The main Pt" photoproduct was not trans- [Pt"('5NH3)(py)(5'-
GMP)2]2 , as for complex 3 for which the main photoproduct was trans- 
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{Pt('5NH3)2(5'-GMP)2]2 (74), although this complex did appear after only 5 mm 
irradiation. The main photoproduct is assigned as the Pt" monoazide compound 
trans- [Pt11 ( 15 	 + NH3)(py)(N3)(5 -GMP)] (79) for reasons described in detail in Section 
6.3.1.2. This indicates that Pt's' is probably not reduced only by the azide ligands, 
which agrees with the previous results where complexes 3 and 4 were not 
significantly reduced when irradiated on their own. Previous work has shown that 5'-
GMP can reduce Pt" compounds to their Pt" counterparts, and the required electrons 
are believed to come from the sugar fragment. [26,271  In theory it should be possible to 
observe such changes by 'H NMR, however the region of the spectrum which 
contains the peaks for the 5'-GMP sugar ring contains many peaks and it is not 
possible to separate and identify them. 
Loss of the pyridine ring upon irradiation was originally thought to be the reason for 
the high in vitro phototoxicity of complex 4 (Appendix 2). However, NMR studies 
have shown that the pyridine ring is not released from the platinum centre in the 
presence or absence of nucleobases (Section 5.3.2.1 and Figure 6.13). This is 
interesting as it suggests that pyridine may not be readily released under cell testing 
conditions. 
So-called "non-classical" trans-platinum compounds (e.g. trans-[Pt(NH3)LCI 2] 
where L = e.g. quinoline, pyridine, thiazole) have recently been found to be cytotoxic 
in vitro. 28' 291 These compounds interact with DNA in a different way to cisplatin, and 
their increased activity compared to transplatin is believed to be due to reduced 
reactivity towards biological thiols. 29'301 Unfortunately these complexes have proved 
inactive in vivo, possibly because of their insolubility, [311  and work is now underway 
to produce water soluble analogues. [32]  Complex 4 contains a planar ligand and has 
trans geometry, but also has the added advantage of being extremely water soluble 
(>50 mM). This could help to explain the increased activity of complex 4. However 
there is not yet any clear evidence that DNA is indeed the main (or only) target for 
photoactivated PtT"-azide complexes. 
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6.4.2 Photoreactions of Pta' Azide Complexes with d(GpG) 
Cis-[Pt't(NH3)2{d(GpG)}} accounts for 60 - 65 % of all cisplatin adducts. [2] 
Diguanine platinum complexes have therefore been used as simple models of the 
local structures of an intrastrand cross-link of two adjacent guanines in DNA. NMR 
and X-ray studies have both shown that platinum is bound to the N7 position of 
guanine. [33,341 
Binding of cis, trans, cis-[Pt(N3)2(OH)2('5NH3)2] and cis, trans-[Pt(' 5N-
en)(N3)2(OH)2J to d(GpG) upon irradiation with blue light (457.9 nm) has previously 
been shown. 5"21 These reactions were repeated during this work using UVA light 
(365 nm). 
6.4.2.1 Cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] (1) 
The reaction of cis, trans, cis-[Pt(N3)2(OH)2(15NH3)2] with d(GpG) upon irradiation 
resulted in two new NMR peaks which corresponded to the N7-bound product 
[Pt('5NH3)2(d(GpG)-N7,N7)] (85).' These peaks first appeared after 11 mm, but did 
not increase upon further irradiation and were not very intense. 
A similar experiment has previously been carried out with blue light (457.9 nm) [51 
and all the d(GpG) was bound to platinum after only 0.77 h. The remaining cis, 
trans, cis-[Pt(N3)2(OH)2(15NH3)2] continued to decrease in concentration and the 
formation of a yellow precipitate was observed. A peak for NH4 also appeared and 
increased in intensity with irradiation. Neither a yellow precipitate nor a NH4 peak 
was observed during the reaction with UVA light. 
The main difference between the reactions with blue and UVA light was the pH. The 
pH was adjusted to 5 before irradiation with 457.9 nm light, but was not adjusted 
again, whereas the pH was readjusted to 5 after each irradiation with UV light. It 
seems that changing the pH alters the course of the reaction with d(GpG) in a way 
that is not seen for the analogous reaction with 5'-GMP. The pKa of the phosphate 
group in d(GpG) is low (ca. 	whereas the 5'-GMP phosphate group has a pKa 
between 6 and 7[91  Therefore perhaps the buffer effect of 5'-GMP is playing a role. 
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6.4.2.2 Cis, trans-[Pt('5N-en)(N3)2(OH)2] (2) 
Irradiation of 2 in the presence of d(GpG) quickly gave rise to new cross-peaks 
assignable to Pt1" isomers/substitution products and to the Pt" species [Pt('5N-
en)d(GpG)-N7,N7] (86) (Figure 6.18a), an intrastrand GG cross-link of the type 
formed by cisplatin on DNA. [21  The 'H NMR spectra in Figure 6.17 confirm that 
binding occurs to N7 of G. Overall the photoreaction can be represented as: 
H2 OH 
N,I N3  d(GpG) 
C 1 t 




pt" " + 3N2 
N1 'G2 
H2 
It is notable that platination of DNA can occur more rapidly via this photoactivation 
pathway than by the usual chemical activation of cisplatin, which is determined by 
slow rate-limiting hydrolysis steps. [35,36] 
There is no significant increase in the intensity of peak 86 after 30 min of 
irradiation, although the intensity of complex 2 further decreases. 
This experiment has been previously carried out using blue light (457.9 nm, 10 
mW).t5121 The sample was irradiated directly in the NMR probe and the pH adjusted 
to 5 only at the start. The reaction with blue light was much slower, as expected due 
to the much lower absorbance of 2 at 457.9 nm ( = 8 Mcm') compared to 365 nm 
(c = 298 M'cm'). No intermediates appeared in the reaction with UVA light, the 
only new peaks were due to the product 86 and these peaks compared well with those 
produced upon irradiation with blue light. 
6.4.3 Transcription Mapping of DNA Adducts 
The profile of DNA platination of a 212-bp fragment of plasmid DNA was 
determined by transcription mapping of the DNA adducts. Platination was carried 
out by incubating the DNA fragment with complex 2 and then irradiating. RNA 
synthesis can be instigated on the fragment by T7 polymerase, but this synthesis is 
prematurely terminated by bifunctional platinum adducts. Importantly 
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monofunctional DNA adducts are unable to stop RNA synthesis. The aim of this 
experiment was to investigate the photoinduced platination of DNA by 2 and 
compare its base selectivity with that of cisplatin. Complex 2 was chosen for this 
study because of the efficiency of its reaction with d(GpG) (Section 6.3.2.2), and 
previous workers have shown that [Pt"(en)C12] forms adducts with DNA which are 
the same as those formed by cisplatin. 37'38' 
Platinum determination by FAAS showed that no platinum binding to DNA occurred 
in the dark, but platination levels of rb = 0.01 (one bound Pt per 100 nucleotides) 
were attained on irradiation. The major stop sites on the irradiated fragment were 
similar to those produced by cisplatin, and appeared at guanine residues mainly 
contained in GG sequences (Figure 6.19b). These results demonstrate the high 
specificity of 2 for G and the preferential formation of predominantly GG intrastrand 
cross-links is evident. These results were confirmed by HPLC analysis 
RNA 
Plasmid DNA 	Polymerase 	 Platinated 
Fragment Promotor Fragment 
T7' 	
H2 OH 	 T7 
N,,1N3 457.9nm 	
I212 bp 212 bp 	+ 	
N'IN3 30mW,3h  
H2 OH 
Figure 6.21 Transcription mapping study of a 212-bp fragment of plasmid DNA 
platinated by cis, trans-[Pt(en)(N3)2(OH)2] and irradiated. 
6.4.4 HPLC Analysis of DNA Adducts 
HPLC analysis of enzymatic digests of a synthetic 40-bp oligonucleotide duplex, 
irradiated in the presence of complex 2 suggested that the major binding sites involve 
bifunctional GG adducts which is in agreement with the transcription mapping 
results. 
The rb of the irradiated sample was 0.07, at this rb 5.6 or 11.2 guanines would be 
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platinated depending on whether the adducts were monofunctional of bifunctional, 
respectively. The 40-bp duplex used in these analyses contained 17 guanine residues. 
Thus, the decrease of the deoxyriboguanosine peak corresponds to the loss of 
9.9 guanine residues. The peaks corresponding to other nucleosides were 
unchanged (only deoxyriboadenosine peak decreased by 2%), which implies that 
guanine residues were preferentially platinated by complex 2 after irradiation and 
mainly in a bifunctional manner. This confirms the transcription mapping results 
where the platinum adducts were found at consecutive GG bases. 
6.5 Conclusions 
One of the main mechanisms of photoactivation of Pta' azide complexes reported in 
the literature, [19,41]  involves the concerted release of the azide ligands in the form of 
two azide radicals. Two electrons are transferred to the platinum centre (one from 
each azide ligand) which results in a reduction from Pt" to Pt". The reluctance of the 
trans compounds (3 and 4) to photoreduce when irradiated on their own (Chapter 5) 
hinted that this was not the mechanism of photoactivation (at least for trans 
complexes). The assignment of the main photoproduct from irradiation of 4 plus 5'-
GMP as the monoazide complex trans- [Pt(N3)(5'-GMP)('5NH3)(py)J, indicates the 
formation of azide radicals is definitely not the only mechanism by which azides are 
lost from this compound. More detailed experiments are required to fully define the 
photoactivation pathway, which may be different for complex 4 compared to the 
other Pt"" azide complexes, and may help to explain its high phototoxicity (Appendix 
2). 
The transcription mapping study and HPLC studies on complex 2 have shown a 
similar profile of nucleotide platination on duplex DNA (high specificity for G and 
the formation of predominantly GG intrastrand cross-links), as cisplatin. 
Overall the platinum(IV) diazido compounds investigated (1-4) have shown a 
remarkable affinity for G bases, whether in the form of nucleotides, nucleosides, 
duplex DNA or plasmid DNA, but most importantly these reactions have been 
observed only upon irradiation, and not in the dark. 
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Chapter 7 Mull iphoton Excitation 
7.1 Introduction 
Multiphoton processes were predicted theoretically in 1931 by Maria G6ppert-
Mayer, 11 however it was not until 30 years later that the first experimental evidence 
was reported. In 1961 the two-photon excitation (TPE) of a CaF2:Eu2 crystal was 
demonstrated by Kaiser and Garrett using a ruby laser. 21  
TPE relies on two photons being almost simultaneously (ca. 106  s) absorbed by an 
atom or molecule, this produces an excitation equivalent to the absorption of a single 
photon of about twice the energy (Figure 7.1). The intermediate state after absorption 
of the first photon is referred to as the "virtual state", it need not correspond to any 
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Figure 7.1 Two-photon excitation. a) UV-visible spectrum showing the wavelength 
of excitation by TPE and OPE. b) Energy level diagram showing that the absorbance 
of two photons from the red region (700 nm) can excite an atom or molecule to the 
same state as one photon from the blue region (350 nm). 
This theory can also be applied to the absorption of three [3-51  or more photons. [6-81 
Research into multiphoton excitation is a rapidly expanding area due to the recent 
availability of commercial pulsed femtosecond lasers, and also because of the 
discovery of practical applications, such as 3D data storage, 19-121  fluorescence 
microscopy, [13-151  and photodynamic therapy (PDT). [16-18] 
PDT is a cancer treatment which involves the activation of a photosensitizing drug 
with light, the mechanism of action is described in more detail in Chapter 1. One of 
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the main problems associated with PDT is the wavelength of absorbance of most of 
the drugs; this is the same problem as that encountered with Pt"'-azide compounds. A 
great deal of work has been done in an attempt to extend the wavelength of 
absorption of photosensitizers.r""'I For this reason, attention has turned to the 
activation of PDT drugs by two-photon excitation. 6'18' 
An important property of a molecule undergoing TPE is its two-photon cross-
section."'"' The one-photon cross-section of a molecule is another way of 
expressing the extinction coefficient; it is not really related to molecular dimensions, 
rather it is the strength of the optical transitions and selection rules which are most 
important. It is expressed as a cross-section because it is easy to imagine a relative 
capture area. Two-photon cross-sections are similar, but are expressed in units of 
cm4s (i.e. the product of two areas and time) because two photons have to be 
"captured simultaneously". It can also be described as a quantitative measure of the 
probability of a two-photon absorption. t15]  It is possible (although by no means 
simple) to measure two-photon cross-sections. 231  
TPE depends on two photons interacting with a molecule almost simultaneously, and 
so has a quadratic dependence on the light intensity. Conventional one-photon 
excitation (OPE) has a linear dependence on light intensity. TPE probabilities are 
extremely small and focusing the beam increases the local intensity at the focus 
point. This can be achieved by placing an objective lens in the path of the beam and 
ensuring the focal point is within the sample. Away from the focus TPE probability 
drops off rapidly. 
Pulsed lasers are used to further increase the likelihood of two-photons 
simultaneously interacting with a molecule; this means the "average" power can still 
be kept relatively low. In the following sections, a mode-locked Ti:Sapphire laser is 
used to induce two-photon excitation. The term "mode-locked" is used to describe a 
laser operating with only a certain set of frequencies (modes) propagating in the laser 
cavity. The phase between these modes is locked, so that there is destructive 
interference between the propagating frequencies everywhere in the cavity, except at 
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one point where the waves add constructivelyJ24' This results in a single short pulse 
of light travelling in the cavity, with the repetition rate dictated by the distance 
between the two cavity end mirrors and the speed of light. Femtosecond Ti:Sapphire 
lasers require a relatively large number of intracavity frequencies to achieve 1 50-fs 
pulses, therefore the pulses have a significantly large spectral bandwidth. The 
Ti: Sapphire laser is capable of TPE in the wavelength range 700 - 1000 nm. 
The main advantage of using TPE for the photoactivation of drugs is clearly the 
accessibility of longer wavelengths. Most porphyrins currently used in PDT are 
excited between 620 and 690 nm, where the maximum tissue penetration depth is Ca. 
1 cm. 5' In comparison, a 10-fold increase in the depth of penetration can be 
achieved by near infrared (NIR) light (750 - 1400 nm).'71 NIR light also minimizes 
the effects of laser-induced hyperthermia as it has reduced absorption in tissues. The 
small excitation volumes, which can potentially be confined to the order of ca. 1 jim3  
are also an advantage. The point of activation can be controlled in three dimensions 
and the problem of absorption all along the beam associated with OPE is overcome. 
One of the main problems associated with Pt''-azide compounds is their wavelength 
of absorbance. The intense ligand-to-metal charge transfer (LMCT) bands (N3 - Pt) 
are centred in the UV region generally between 250 and 300 nm, at these 
wavelengths there is virtually no tissue penetration. E261  Attempts to shift this LMCT 
band and improve absorption in the visible region by synthetic means are discussed 
in Chapter 3. However, another approach is to use multiphoton excitation, this would 
enable the use of red or NIR light to activate the compounds. 
7.2 Experimental 
The platinum compounds cis, trans-[Pt(en)(N3)2(OH)2], trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2}, cis, trans- [Pt(' 5N-en)(N3)2(OH)2], trans, trans, trans-
{Pt(N3)2(OH)2(15  NH3)(py)]  and trans, trans, trans- [Pt(N3)2(OH)2(1 5NH3)2] were 
synthesised as described in Chapter 3. Cis, trans-{Pt(en)12(OAc)2] was prepared by 
Dr. Phillipe Muller using the literature method. [271  Azobenzene (99 %), d6-benzene, 
d6-DMSO, DMSO and D20 were purchased from Aldrich, and 5'-GMP was 
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purchased from Acros. Azo-dye 1 was supplied by DyStar UK Ltd. and was used 
without further purification (86 % azo-dye, 14 % NaCl and water). 
Irradiations with the argon-krypton laser were carried out as described in Chapter 4. 
NMR spectra were recorded on a Bruker DMX500 spectrometer and UV-visible 
spectra were recorded on a Cary 300 Perkin-Elmer photospectrometer. This 
equipment is described in detail in Chapter 2. A UV lamp was employed for one-
photon excitations in the ultraviolet region (365 nm) (Chapter 2). The UV quartz 
cuvettes used were Hellma cells supplied by Aldrich and were either standard (3.5 
mL) or ultra micro (100 tL). 
Two-photon excitation was performed with a 10 W Verdi and Mira Ti: Sapphire laser 
(Coherent) producing pulses of Ca. 150 fs at 76 MHz, with a full-width half-
maximum (FWHM) at 740 nm of 5.6 nm. The pulse width and spectrum were 
measured with an autocorrelator (Mini, APE) and spectrometer (Wavescan, APE). 
The laser spectrum was continuously monitored to ensure pulse stability. The laser 
power was varied with neutral density filters and measured with a power meter 
(Fieldmaster with LM1O head, Coherent). The laser was focused with a x4,  NA = 
0.1, objective lens. For the samples which were irradiated in NMR tubes, the 
alignment was checked by observing the two-photon fluorescence of a solution of 
fluorescein in an identical tube, this tube was then replaced with that containing the 
sample. By approximating the square of the illuminating point spread function as a 
3D Gaussian volume, [15]  the estimated focal volume was ca. 30 pL. 
For two-photon excitation at wavelengths below 700 nm an optical parametric 
oscillator (OPO) (APE, Berlin) that was synchronously pumped by a modelocked 
femtosecond Ti:Sapphire laser was used. It was operated in the ring-cavity 
configuration, which has a single resonant OPO and intracavity SHG (second 
harmonic generation), and covers the range 525-680 nm, which fills the gap between 
the Ti-Sapphire output (700-1000nm) and its frequency doubled signal (350 - 500 
nm). 
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The Ti-sapphire laser and optical parametric oscillater were operated by Dr. Stephen 
Magennis who helped set-up all multiphoton experiments, and also carried out the 
kinetic calculations in Section 7.3.2.1. Sample preparation, NMR analysis and all 
other work was carried out by the author. 
7.3 Results 
7.3.1 Cis, trans-IPt(en)(N3)2(OH)21 
Initially, the OPE of cis, trans- [Pt(en)(N3)2(OH)2] using the Ti: Sapphire laser (457 
nm, 1.5 mW) was investigated. The reaction was followed by observing the change 
in absorbance at 330 nm (Figure 7.2a). Irradiations were also carried out with the 
Argon-Krypton laser (457.9 nm, 40 mW) for comparison (Table 7.1). Similar rates of 
reaction were seen with both lasers (Figure 7.2b). Controls were placed beside the 
irradiating samples during excitation, but kept in the dark and then treated 
identically. 
TPE using the same set-up did not result in any photoactivation. Many different 














240 mm 	mad 
-33O min hrrad 
0.50 
310 320 	330 	340 0 	50 	100 	150 	200 	250 	300 	350 
Wavelength (nm) Time (mm) 
Figure 7.2 One-photon excitation of cis, trans-[Pt(en)(N3)2(OH)2]. a) Change in 
absorbance at 330 nm upon irradiation of a 1 mM sample in 1120 (Ar-Kr laser 457.9 
nm, 40 mW). b) A comparison of the rate of reaction using two different lasers, Ar-
Kr laser (457.9 nm, 40 mW) and Ti-Sapphire laser (457 nm, 1.5 mW). 
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Table 7.1 Experimental conditions for one- and two-photon excitation of cis, trans-
[Pt(en)(N3)2(OH)2]. 
? Power Solvent Irrad. Conc. Time Vol. Analysis Laser 
(nm) (W)  Vessel (MM) (h) (mL)  
457.9 0.04 H20 Cuvette 1 Various 3 UV-vis Ar-Kr 
(3.5mL)  1-Photon 
457 0.0015 H20 Cuvette 1 2, 4, 5.5 3 UV-vis Ti-sapphire 
(3.5mL)  1 -Photon 
914 0.75 H20 Cuvette 1 2 3 UV-vis Ti-sapphire 
(3.5mL)  2-Photon 
800 1.4 H20 Cuvette 1 1 3 UV-vis Ti-sapphire 
(3.5mL)  2-Photon 
800 1.4 H20 Cuvette 1 3.5 1 UV-vis Ti-sapphire 
(3.5mL)  2-Photon 
800 1.4 H20 Cuvette 1 1,2 1 UV-vis Ti-sapphire 
(3.5mL)  2-Photon 
750 1.4 H20 Cuvette 1 1.5, 3.5 1 UV-vis Ti-sapphire 
(3.5mL)  2-Photon 
760 1 D20 Cuvette 3 5 0.1 NMR Ti-sapphire 
(1 00.iL)  2-photon 
760 1 D20 Cuvette 0.07 3 0.1 NMR Ti-sapphire 
(1 00tL)  2-photon 
720 0.7 D20 Cuvette 3 4.5 0.1 NMR Ti-sapphire 
(1 00.iL)  2-photon 
7.3.2 Azo-Dye 
Photoisornerisation of the azo-dye 1 (Figure 7.3) from trans to cis can easily be 
followed by NMR spectroscopy. The 'H NMR spectrum of the trans isomer (Figure 
7.4a) consists of two singlets, each of relative intensity 1, at 8.67 and 8.40 ppm (Hi 
and H4, respectively), two doublets, each of intensity 1, at 8.31 and 8.16 ppm (115 
and H7, respectively, 2J= 1.7 Hz), a doublet of intensity 2 at 8.01 ppm (H3' and H5', 
1J= 8.7 Hz), and a doublet of intensity 2 at 7.61 ppm (112' and H6'). The cis isomer 
(Figure 7.4b) also consists of two singlets, each of relative intensity 1, at 7.47 and 
8.26 ppm (Hi and H4, respectively), two doublets each of intensity 1 at 8.16 and 
8.03 ppm (H5 and H7, respectively, 2J = 1.7 Hz) a doublet of intensity 2 at 7.24 ppm 
(H3' and 1-15', 'J= 8.7 Hz), and a doublet of intensity 2 at 7.16 ppm (H2' and H6'). 
Two-photon excitation (740 nm, 0.75 W) of a d6-DMSO solution of 1 in an NMR 
tube (14 mM, 0.6 mL) led to the appearance of cis isomer peaks in the NMR 
spectrum. This result was achieved after only 90 min irradiation; it was assumed to 
be due to TPE as 1 has no measurable absorbance at 740 nm (Figure 7.5). The effect 
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Figure 7.4 'Fl NMR spectra of azo-dye 1 in d6-DMSO (14 mM) a) before irradiation 
(100 % trans) and b) at the photostationary state (54 % trans : 46 % cis). The peaks 
are assigned according to the numbered structure in Figure 7.3 with c or t denoting 
the cis and trans forms respectively. 
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Figure 7.5 Electronic absorption spectrum of azo-dye 1 in DMSO (7 x 10 M) 
before irradiation (solid line) and after one-photon irradiation at 457 nm to the 
photostationary state (dashed line). 
The effects of varying volume and concentration were determined together. A 50 [tL, 
69 mM sample in d6-DMSO in an NMR tube was irradiated at 880 nm for 1.5 h, and 
compared to a 600 .iL, 10 mM sample treated identically. A significantly larger 
proportion of the smaller more concentrated sample was converted to the cis isomer 
(13 % cf. 22 %). Whether mixing was essential was determined by irradiating (740 
nm, 0.55 W) two identical samples (150 jtL, 14 mM) for 5 min but only stirring one. 
The stirred sample was found to contain 6.0 % of the cis isomer, whereas the static 
sample only had 4.0 % cis. This experiment was repeated with a lower power (285 
mW) and again the stirred sample had a larger proportion of the cis isomer (1.2 % cf. 
0.60 %). Stirring appears to accelerate the reaction but is not essential. As expected 
the excitation wavelength was found to have a large effect on the level of 
photoisomerisation. Irradiation at 740 nm (1 W) produced a much larger amount of 
the cis isomer than irradiation at 880 (1 W) for the same length of time (Figure 7.6). 
The conditions used for TPE of 1 described hereafter were as follows. 
Small volume :!~ 150 LL 
High concentration ~! 14 mM 
Stirred in an NMR tube (with magnetic stirrer bars 2 mm) 
2=740nm 
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Figure 7.6 Dependence of the two-photon wavelength on the rate of 
photoisomerisation. 'H NMR spectra of 1 in d6-DMSO after irradiation at a) 740 nm 
and b) 880 nm for 15, 45, 90 mm. The boxed areas highlight some of the emerging 
cis isomer peaks. c) Comparison of the percentage of cis isomer produced at the two 
different wavelengths. 
7.3.2.1 Rate of Reaction 
The photostationary state (PSS) is the point where the forward (ki(hv)) and backward 
(/c,(hv, A)) reaction rates are equal, and further irradiation does not change the 
cis:trans ratio. It can be expressed according to equation 1. 
ki(hv) 
trans 	cis 	 (1) 
k 1 (hv, A) 
The rate constants k,(hv) and /ci(hv) are rate constants for the photoisomerisation 
process, the combined process of photoexcitation (absorption) followed by excited 
state isomerization. The integrated rate law for approach to the PSS is given by 
equation 2, 
[cis](t) = [cis](PSS) - [[cis](PSS) - [cis](0)] exp(—kt) 	(2) 
where [cis](t), [cis](0) and [cis](PSS) are the concentrations of the cis form present at 
time t, at time 0, and at the PSS, respectively, and the rate constant k is the sum of 
the rate constants for the forward and reverse reactions, k, (hv) and k.1 (hv, A). 
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Seven samples (150 tL, 14.2 mM) were irradiated at 740 nm (1.1 W) for various 
lengths of time (1, 5, 10, 20, 52, 85 and 116 mm). As analysis of the samples by 
NMR spectroscopy required the addition of 450 tL of d6-DMSO, it was not possible 
to irradiate, analyse, then continue irradiation, so each point was measured starting 
from 0 h with a fresh sample. The time course results were plotted (Figure 7.7) [281
and fitted to the rate law (Equation 2), giving values of [cis](PSS) = 54 % and k = 
7.594 x 10" s. The value of k_,(A) has been previously determined 291 by 
monitoring the reversion of the PSS to the thermal equilibrium (100 % trans), it was 
found to be 2.4 x 10-6 s 1 and so makes a negligible contribution to k. Since there 
was no evidence of any additional thermal effects during irradiation, which is most 
likely due to the lack of one-photon absorption at the excitation wavelength, k is the 
sum of the photochemical rate constants only. The equilibrium constant at the PSS, 
ki (hv) / k_,(hv) is 0.54 / 0.46, and so the photochemical rate constants are ki (hv) = 4.1 
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Figure 7.7 Time course of two-photon photoisomerisation upon irradiation at 740 
nm (1.1 W) as determined by 'H NMR spectroscopy. The solid curve is the fitted 
integrated rate law (Equation 2). 
7.3.2.2 Two-Photon or One-Photon Excitation? 
Confirmation that the observed photoisomerization was definitely due to the 
absorption of two photons (not OPE at 740 nm) was provided in two ways. [2'1 The 
first method involved irradiating two identical samples (100 tL, 22 mM) under the 
same conditions (740 nm, 1.2 W), except that for one the Ti:Sapphire laser was 
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operated in continuous-wave mode (i.e. one-photon mode). For this sample no 
conversion to the cis isomer was seen whereas 3.5 % cis isomer was seen for the 
sample irradiated by the laser while mode-locked. 
The second method involved monitoring the initial rate of photoisomerisation as a 
function of the laser power. For two-photon processes the initial rate has a nonlinear 
dependence upon the power, and plotting a logarithmic graph of the results will give 
a straight line with a gradient of two. E151  The initial rate of photoisomerisation was 
measured at 7 different powers on 14 mM (150 .iL) samples. The results were 
plotted as described above (Figure 7.8) and fitting a straight line gave a gradient of 
1.7 ± 0.1. However, using only the data for low power excitation (up to ca. 400 mW), 
the slope of the In—In plot is 2. Samples were irradiated in an NMR tube for 1.5 - 50 
min to give < 5 % conversion in each case (typically 2 - 4 %). The low conversion 
ensured that initial rate conditions were applicable. The relative conversion was then 
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Figure 7.8 Dependence of the initial rate of cis isomer formation on the average laser 
power at 740 nm, as monitored by 111 NMR spectroscopy. For a 160 fs pulse, at a 
repetition rate of 76 MHz, an average power of 100 mW corresponds to an 
instantaneous peak power of 10 kW. The solid line shows the best straight line fit to 
the data (R = 0.99). 
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7.3.3 Pt1" Complexes 
7.3.3.1 Trans, trans, trans- [Pt(N3)2(OH)2(NH3)2] 
Activation of trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] by two-photon irradiation was 
attempted in both UV cuvettes and NMR tubes. No reaction was seen for TPE of 
samples contained in cuvettes. 
Irradiations in NMR tubes were carried out using the set-up and conditions optimised 
for azo-dye 1 (i.e. small volume, high concentration and stirring). The Pt"  compound 
was labelled with '5N-ammonia to enable the reaction to be followed by 1D ['H] and 
2D ['H,'5N] HSQC NMR spectroscopy. A 14 mM (100 jiL) sample in 90 % H20 / 10 
% DO was irradiated at 720 nm (0.2 W) for 6 h, 395 L H20, 55 tL D20 and 2 iL 
dioxane were added before analysis. New Pt" peaks were observed after the pH was 
adjusted to 5. This reaction was repeated with 2 molar equivalents of 5'-GMP added, 
the power was increased to 400 mW and the sample irradiated for 5.5 h. Analysis by 
NMR spectroscopy showed 3 new Pt" peaks, 10 % of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2] had been reduced and bound to 5'-GMP. 
7.3.3.2 Cis, trans- [Pt(en)12(OAc)2] 
TPE of cis, trans-[Pt(en)12(OAc)2] (Figure 7.9a) was followed by both UV-visible 
and NMR spectroscopy. A sample (0.4 mM, 0.5 mL) in methanol was irradiated in a 
cuvette at 796 nm (650 mW). The absorbance band centred at 400 nm (Figure 7.9b) 
decreased indicating that a reaction had taken place. The spectra were measured after 
2 h and 3.5 h. A dark control was treated identically and placed beside the irradiated 
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Figure 7.9 Two-photon excitation of cis, trans-[Pt(en)12(OAc)21.  a) Structure of cis, 
trans-[Pt(en)12(OA02] b) UV-visible spectrum in methanol, the LMCT (I - Pt) band 
at 	400 nm decreases upon irradiation. c) NMR spectra in d6-DMSO, a decrease of 
the CH2, CH3 and NH2 peaks can be seen after irradiation, new peaks in the CH3 and 
NH2 region are also visible. 
Cis, trans-[Pt(en)12(OAc)2} in d6-DMSO (4.7 mM, 150 p.L) was irradiated at 790 nm 
(0.7 W) in an NMR tube for 134 min whilst stirring. A dark control was placed 
beside the sample being irradiated. Figure 7.9 shows new peaks have appeared in the 
irradiated sample; these peaks are in the same position as those produced by OPE 
(results not shown). 
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To determine whether the observed photoreactions were definitely a result of TPE, 
two identical samples were irradiated (720 nm, 0.75 W, 3 h) one with the laser in 
continuous-wave mode (OPE) and the other with the laser mode-locked (TPE). Upon 
analysis by 1D ['H] NMR spectroscopy it was found that both samples had 
undergone a reaction and produced new species in the same amounts. A dark control 
was also set-up but this sample contained no new peaks after 3 h. This means that the 
photoreactions observed so far for the platinum complexes are probably more likely 
to be a result of one-photon absorption at longer wavelengths. 
7.3.4 Three-Photon Excitation 
7.3.4.1 Trans, trans, trans- [Pt(N 3)2(OH)2(py)(' 'NH,)] 
Three-photon excitation of trans, trans, trans- [Pt(N3)2(OH)2('5NH3)(py)] (8.4 mM) 
in the presence of 2 molar equivalents of 5'-GMP was attempted with the OPO laser. 
Irradiation of 150 pL at 900 nm (0.7 W) was carried out for 7 h, the sample was 
made up to 0.6 mL with a 90 % H20 / 10 % D20 solution containing 2 pL dioxane (1 
%) and analysed by 1D ['H] and 2D ['H,'5N] HSQC NMR spectroscopy. No new 
peaks were seen indicating that no photoreaction has taken place. 
7.3.4.2 Trans, trans, trans-[Pt(N3)2(OH)2( ' 5NH3)2] 
The above reaction was repeated with trans, trans, trans- [Pt(N3)2(OH)2(' 5NH3)2] (9.9 
mM) and 2 molar equivalents of 5'-GMP, but again no photoactivation was observed. 
7.3.4.3 Cis, trans-[Pt('5N-en)(N3)2(OH)2] 
Three-photon excitation of cis, trans-[Pt(' 5N-en)(N3)2(OH)2] (3 mM) and 5'-GMP (6 
mM) was also attempted as described above but again was unsuccessful. 
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Figure 7.10 Experimental set-up for two-photon excitation of a sample in an NMR 
tube, using the Ti:Sapphire laser. 
7.4.1 Cis, trans-IPt(en)(N3)2(OH)21 
Cis, trans-[Pt(en)(N3)2(OH)2] was chosen over cis, trans, cis-[Pt(N3)2(OH)2(NH3)21 
for these studies due to its slightly higher extinction coefficient (Cmax = 14,300 cf. 
13,700 M'cm'). The first experiment involved the OPE of cis, trans-
[Pt(en)(N3)2(OH)2J with the Ti:Sapphire laser. The rate of reaction was compared 
with that achieved using the argon:krypton laser. 
There was a large difference in the powers used, and a possible reason why roughly 
the same effect can be seen is that the Ar:Kr laser is equipped with a fibre optic. This 
is used to deliver the light into the sample, and may mean the beam is not as focussed 
as that of the Ti:Sapphire laser and therefore power is being lost 
All two-photon irradiations of cis, trans-{Pt(en)(N3)2(OH)21 were unsuccessful. 
Many different experimental conditions were tried (Table 7. 1), and samples were 
analysed by both UV-visible and NMR spectroscopy. The 2-photon cross sections 
for these types of complexes are not known. However if they are low, smaller sample 
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volumes would be needed to observe the photochemistry. Also 2-photon absorption 
may not occur at double the one-photon wavelength, although a range of 
wavelengths was tried. 
7.4.2 Azo-Dye 
As TPE of various cis, trans-[Pt(en)(N3)2(OH)2] samples had failed, attention was 
turned to a new system. The trans-to-cis photoisomerisation of azo molecules is a 
well known reaction [30]  which involves the conversion of the thermally stable trans 
structure to the cis form. Initially the excitation of azo-dye 1 was intended as a quick 
check on whether the experimental set-up was adequate, however due to some 
interesting results a more in-depth study was carried out. 
The photosimerisation of 1 is reversible, and the back reaction occurs both 
photochemically and thermally (Equation l)." The photostationary state is reached 
when the forward and backward reaction rates are equal. Several studies on azo 
containing materials using non-resonant excitation have recently been reported, 32381  
however the nature of the photogenerated species, the identity of the excited states 
involved, and the efficiency of the photoinduced process were not established. The 
photoisomerisation of azo-dyes is easily followed by 'H NMR spectroscopy as 
demonstrated by Tait et. al J391 and this technique also enables the unambiguous 
identification of the photoproducts. 
Azo-dye 1 (Figure 7.3) was chosen for these studies for several reasons: 1) the one-
photon photochemistry had already been investigated, 2) it has a very high 
absorbance in the required wavelength range (Xmax 353 nm), and 3) the half-life (ty2) 
of the cis isomer is ca. 115 h. The NMR spectra were always recorded immediately 
after irradiation and a large ty2 means the amount of thermal reversion to the trans 
state is negligible. 
The structure of 1 (Figure 7.3) consists of an azo unit with a substituted phenyl group 
attached to one azo nitrogen, and a substituted naphthyl group on the other azo 
nitrogen. R is a methyl group, and R' is a typical "reactive" group to enable the 
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attachment of the dye to textile fibres. These substituents are not expected to 
significantly alter the photochemical properties of the parent dye molecule, and they 
do not interfere with the signals of interest in the 11-I NMR spectrum. 
TPE was generally carried out at 740 nm where there is no measurable absorbance, 
however there is a significant one-photon absorbance at 370 nm due to intense i—ir 
transitions. Upon irradiation new peaks appear which can all be assigned to the cis 
isomer, indicating no other species are produced. The cis peaks are all shifted up-
field relative to those of the trans isomer. This is because the position of the rings in 
the trans structure means the protons encounter only a local deshielding within the 
ring plane; however in the cis structure the rings are much closer and so the protons 
are now subject to the additional shielding effect of the other aromatic ring (Figure 
7.1 
R 











Figure 7.11 Cis-trans isomerisation of azo-dye 1. a) Chemical structure diagram, b) 
space-fill model which shows the twisting of the phenyl ring in the cis structure. 
7.4.2.1 Rate of Reaction 
The rate of two-photon induced photoisomerisation was determined by measuring 
the amount of cis isomer after various irradiation times. The results were fitted to the 
integrated rate law (Equation 2) and compared to those obtained by one-photon 
irradiation (457 nm, 10 mW) (Table 7.2). 
231 
Chapter 7 Multiphoton Excitation 
Table 7.2 Data relating to the one- and two-photon induced isomerisation of azo-dye 
1. 
Parameter One-Photon Two-Photon 
457 nm 740 (370) nm 
[cis](PSS) 29% 54% 
k j(hv) 50 x 10 	s_I  4.1 x 10 	s 1  
k j(hv) 120 x 10-4S-1 3.5 x 10 s 1  
Cc/s I Cirans 1 0.3 
k 170 x 10-4S-1 7.59 x 10-4S-1 
From the absorbance at 370 and 457 nm, which are taken from the spectra in Figure 
7.5, the ratio of the one-photon molar absorption coefficients of the cis and trans 
isomers (Cj I Ci,.a,js) were calculated as 1 at 457 nm and 0.3 at 370 nm. If the trans 
isomer is 3.3 times more absorbent at 370 nm than the cis isomer, the forward 
reaction rate will also be increased by the same amount so ki (hv) will now be 167 x 
10 	s-1  and k 287 x 10 	The expected amount of cis isomer which would be 
produced by one-photon irradiation at 370 nm is therefore 58 %. This is very similar 
to the value of 54 % obtained by two-photon irradiation, which indicates the ratio of 
the two-photon cross sections of the two isomers is essentially equivalent to the C 
ratio. From these results it is clear the same photochemical mechanism is operating 
in the two different excitation regimes; this suggests that the same excited states are 
accessed by both OPE and TPE. 
7.4.2.2 Two-Photon or One-Photon Excitation? 
To ensure that the trans-cis photoisomerisations were due to the absorption of two-
photons, the laser was operated in continuous-wave mode at 740 nm. Although the 
average power was the same as for mode-locked operation, the laser was not pulsed, 
so the peak laser power was low. Therefore, "simultaneous" absorption of two 
photons was unlikely. The reaction was carried out as normal and NMR analysis 
showed no evidence of photoisomerisation. 
This result was confirmed by a power-rate study where the initial rate of reaction was 
measured as a function of power. The initial rate of a two-photon process has a 
quadratic dependence on the powerW  (initial rate cc power) and therefore the 
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logarithmic plot has a gradient of 2 (ln(initial rate) cc 21n(power)). 31'401 A In-in plot 
of the results (Figure 7.8) gave a slope of 1.7 ± 0. 1, however using the data for low 
power excitation (up to ca. 400 mW) the slope is 2 within error. The small deviation 
at higher laser powers is most likely due to competing processes, such as 
saturation. 231  
These results are significant as they have shown by the unambiguous identification 
of the photoproducts, and measurement of the kinetic parameters that the two-photon 
reaction closely mimics the one photon process. The photochemical reaction 
pathways are the same, and the efficiencies of photoisomerisation are similar. 1281 
As well as finding widespread use in synthetic dyes and pigments, 3t1 and 
photoresponsive biomolecular 4 and supramolecular systems, [42,43]  azo molecules 
are increasingly being used in phototonic-based materials. 441 In particular, polymers 
doped with azo dyes or containing azo units are promising materials for optical 
storage, [451  holography, [46]  optical switching 471 and non-linear optics. 481 The 
desirable properties of these materials arise predominantly from photoinduced 
motions resulting from photoisomerisation of the azo groups. The advantages of 
using TPE to induce these reactions are similar to those described for PDT. The 
longer wavelength allows an increased depth of penetration into materials, while the 
small focal volume can potentially give complete 3D control. 
7.4.3 Pt1"  Complexes 
Now that a successful method had been designed for TPE, attention was turned back 
to the platinum complexes. Irradiations were generally carried out in NMR tubes on 
small, concentrated samples (100 - 150 tL,> 14 mM). 
Photoactivation of a platinum compound was finally successful for trans, trans, 
trans- [Pt(N3)2(OH)2('5NH3)2]. Evidence of new Pt's' peaks were observed by 2D 
['H,15N] HSQC NMR spectroscopy, and by repeating the reaction in the presence of 
5'-GMP Pt 11  peaks were seen. Unfortunately, as this reaction was so slow, no time 
was available to check whether it was definitely TPE by operating the laser in 
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continuous wave mode. However, in Chapter 6 the photoactivation of this compound 
was achieved with red light (647.1 nm) and was shown to be relatively efficient (1.5 
% reduced and bound to 5 '-GMP, 19 mW, 90 mm) considering the low absorbance 
(E647 = 6 M'cm) at this wavelength. Therefore these results must be treated as 
preliminary until they can be confirmed as due to TPE. 
Photoactivation of a similar compound, cis, trans-[Pt(en)12(OAc)2], was also 
observed by both NMR and UV-visible spectroscopy. This reaction was faster and so 
it was possible to operate the laser in both the mode-locked (TPE) and continuous-
wave (OPE) state to confirm whether the photoproducts produced were due to TPE. 
Unfortunately the two different samples both showed evidence of new species in the 
same amounts, a control sample contained no new products. This means all the 
photoreactions of cis, trans-[Pt(en)12(OAc)2] so far are due to the absorption of one-
photon at 720 nm. 
These results are perhaps not surprising since cis, trans-[Pt(en)12(OAc)2] has a 
LMCT (I 4 Pt) band centred at 400 nm (Figure 7.9), which tails out into the red 
region. Reduction of trans, trans, trans-[Pt(N 3)2(OH)2(NH3)2] with red light has 
previously been demonstrated and this compound has its LMCT (N3 - Pt) band at 
286 nm. 
7.4.4 Three-Photon Excitation 
As two-photon excitation of platinum compounds was proving difficult to acheive, a 
few three-photon excitation experiments were attempted. The advantage of using 
three photons is that excitation directly into the LMCT (N3 - Pt) band is possible, a 
wavelength of 900 nm was used which corresponds to an absorbance at around 300 
nm. The extinction coefficients at 300 nm of the two compounds, trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(y)] and trans, trans, trans-[Pt(N3)2(OH)2(NH3)2J, are 15,000 
and 13,000 M' cm' respectively. 
The experiments were carried out in the same way as the two-photon excitations, but 
no photoreactions were observed. 
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7.5 Conclusions 
The reason for the failure to activate pt" compounds by two-photon excitation is not 
known. As the same experimental set-up was successfully used to irradiate azo-dye 1 
this is unlikely to be the problem. It is possible that absorbance at the two-photon 
wavelength (370 nm) was not high enough, TPE is also a much less efficient process 
than OPE. The two-photon cross-section could also be a problem for these small 
molecules, alterations of the structure are required to investigate this. However, the 
incorporation of aromatic chelating ligands, such as bipyridine and phenanthroline 
(Chapter 3), might help to increase the probability of capturing two photons 
simultaneously. 
New laser systems which are more powerful and efficient are constantly being 
developed. Indeed it is now possible to obtain lasers which can carry out TPE at low 
wavelengths (< 300 nm) with very high peak power. Therefore, the activation of 
platinum-azide compounds could still be achieved by two-photon excitation in the 
near future. 
Two-photon excitation of azo-dye 1 produced some exciting results. By the 
unambiguous identification of the photoproducts and measurement of the kinetic 
parameters, it was shown that the two-photon induced reaction closely mimics the 
one-photon process. This is significant as it demonstrates that TPE using commercial 
Ti:Sapphire lasers is a practical alternative to the conventional OPE of azo materials. 
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Appendix 1 Structures and Numbering of Platinum Azide Complexes. 
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Appendix 2 In Vitro Phototoxicity Data 
Complex IC50 Value (tM' 
HaCaT A2780 A2780cis 
Light Dark Light Dark Light Dark 
Complex 1 174.2 > 288.0' 133.3 > 288.0 204.8 > 288.0 
Complex 2 > 267.9 > 267.9 >267.9 > 267.9 >267.9 > 267.9 
Complex  154.1 >288.0 99.1 >288.0 163.9 >288.0 
Complex  6.1 >244.3 1.9 >244.3 16.9 >244.3 
Complex 5 60.3 > 276.8 39.9 > 276.8 128.7 > 276.8 
Complex  68.2 >266.5 58.4 >266.5 90.1 >266.5 
Complex  5.8 >241.0 5.4 187.0 16.1 >241.0 
Complex 8 55.3 > 236.2 51.0 > 236.2 59.8 > 236.2 
Cisplatin 144.0 173.3 151.3 152.0 261.0 229.0 
Transpiatin 250.0 >333.3 60.8 131.5 >333.3 >333.3 
Chlorpromazine 9.0 239.7 5.7 193.9 4.9 112.0 
IC50 Value: Concentration of complex that reduced neutral red dye uptake by 50%. 
> No IC50 value determined within concentration range used. 
All in vitro phototoxicity testing was carried out by Dr. Julie Woods and Dr. Karen 
Harper at the Photobiology Unit in Ninewells Hospital, Dundee. 
Phototoxicity testing was carried out on three different cell lines, HaCaT 
keratinocytes, A2780 cells and A2780cis cells. HaCaT keratinocytes are a human 
skin cell line, A2780 cells are a human ovarian carcinoma cell line and the A2780cis 
cells are a human ovarian carcinoma cell line which is resistant to cisplatin. 
For cell irradiation, 2 x 6ft Cosmolux RA Plus (Cosmedico), 15500/100W light 
sources were used, each filtered to attenuate UVB/UVC wavelengths. Immediately 
before use, the compounds were dissolved in warm Earle's Balanced Salt Solution 
(EBSS), sonicated and vortexed to assist dissolution. For experiments, cells were 
seeded at densities of 3 or 5 x 104  cells/cm2. After overnight incubation, washed cells 
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were incubated with test compounds in EBSS for 1 h at 310 K / 5%CO2. Cells were 
then irradiated with 5 J cm-2 glass filtered UVA (1.77 mW cm 2: Xmax 365 nm) for 50 
mm. Test compounds were removed and cells incubated with complete medium for 
24 h before assessing phototoxicity. Control plates were treated identically to the test 
plates and sham irradiated. 
Phototoxicity was monitored by measuring the uptake of neutral red dye into viable 
cells. Briefly, after irradiation cells were washed and then incubated with DMEM 
containing 5% FCS, 1% NEAA and 50 jig ml-1 neutral red dye for 3 h at 310 
K15%CO2. After this time, cells were rapidly washed with formaldehyde containing 
1 % (w/v) CaCl2, and solubilised in 50 % EtOH containing 1 % acetic acid. 
Absorbance was read at 540 nm against a solubilisation solution as blank. The IC50 
value was defined as the concentration of compound that inhibited dye uptake by 
50% and was calculated using non-linear regression (Graphpad Prism). Goodness of 
fit was determined from the R2 values of the curves and 95 % confidence intervals. 
Chlorpromazine, cisplatin and transplatin were used as references. Chlorpromazine is 
an antipsychotic drug which is a member of the phenothiazine family. 
Phenothiazines are known to have antimutagenic activity upon exposure to light. 
The cell test results showed that generally complexes with azides in the trans 
position were more phototoxic than the corresponding cis compounds. This is the 
reason that this work has focussed on developing new complexes with trans 
geometry. One complex has shown remarkable phototoxicity while remaining 
inactive in the dark, trans, trans, trans-[Pt(N3)2(OH)2(pyridine)(NH3)] (4). The 













Figure A2.1 Phototoxicity of trans, trans, trans-[Pt(N3)2(OH)2(py)(NH3)] (4) 
towards A2780 human ovarian cancer cells upon irradiation (365 nm) and in the 
dark. 
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Appendix 3 Stability Study Results 
 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 	ppm 
Figure A3.1 1D 'H and 2D ['H,'5N] HSQC NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2('5NH3)2] (3) (3 mM) in 90 % H20 / 10 % D20 were acquired after 
a,c)Oh and b,d) 154d. 
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a) 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm 
Figure A3.2 1D 'H NMR spectra of trans, trans, trans-[Pt(N 3)2(OH)2(NH3)(py)] (4) 
(3 mM) in 90 % H20 / 10 % D20 were acquired after a) 0 h and b) 154 d. 
a) 
Figure A3.3 1D 'H spectra of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(MeNH2)] (5) 
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8(1 H) 
Figure A3.4 1D 'H NMR spectra of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-pic)J 
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Figure A3.5 1D 'H and 2D [1 H,'5N] NMR spectra of cis, trans, cis-
[Pt(N3)2(OH)2(NH3)2] (1) (3 mM) in the presence of NaCl (100 MM) were acquired 
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6(1H) 
Figure A3.6 1D 'H and 2D ['H,'5N] NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)21 (3) (3 mM) in the presence of NaCl (100 mm) were acquired 
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Figure A3.7 1D 'H and 2D ['H,15N] NMR spectra of trans, trans, trans-
{Pt(N3)2(OH)2(NH3)21 (3) (3 mM) in the presence of 5 '-GMP (6 mM) were acquired 
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Figure A2.8 1D 'H NMR spectra of trans, trans, trans-{Pt(N3)2(OH)2(NH3 )(py)] (4) 
(3 mM) in 90 % EBSS / 10 % D20 were acquired after a) 0 hand b) 154 d. 
a) 
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 	ppm 
8(l H) 
Figure A3.9 1 D 'H spectra of trans, trans, trans-{Pt(N3)2(OH)2(NT43)(MeNH2)] (5) 
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Figure A3.10 1D 'H and 2D ['H,'5N] NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)21 (3) (3 mM) in the presence of reduced glutathione (6 MM) 
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Figure A3.12 1D 'H and 2D ['H,'5N] HSQC NMR spectra of trans, trans, trans-
[Pt(N3)2(OH)2('5NH3)2] (3) (3 mM) in 90 % H20 / 10 % D20 at 310 K were acquired 
after a, c) 0 h and b,d) 21 d. 
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